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Ontmoeting 
 
Wanneer je goed naar me kijkt 
Wanneer ik niet kan doen wat jij zegt 
Wanneer ik dingen zie die jij niet ziet 
Wil jij dan nog weten wie ik ben? 
 
Wanneer ik helemaal niet reageer 
Wanneer mijn woorden niet de jouwe zijn 
Wanneer mijn boosheid geen grenzen kent 
Wil jij dan nog bij me zijn? 
 
Wanneer ik jou uitleg geef met gebaren en mimiek 
Wanneer ik steeds dezelfde rituelen herhaal 
Wanneer ik in mijn hoekje zit te wiegen 
Weet jij dan wie ik ben? 
 
Wanneer ik jou mijn waardevolle spulletjes laat zien 
Wanneer ik al mijn agressie voor jou niet meer nodig heb 
Wanneer ik wil varen op jouw kompas 
Mag jij weten wie ik ben. 
 
(Onbekende auteur, gedicht gepubliceerd in: Sprekende ogen, wringende handen 
van Gea van Otterdijk-Smets) 
 
 
 
Aan Margo en alle andere Rett meisjes, omdat jullie zo bijzonder zijn. 
 
En aan mijn oma, omdat ik weet hoe trots je zou zijn geweest. 
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General introduction 
Rett syndrome (RTT) is a severe genetic neurodevelopmental disorder, affecting 
predominantly females (Rett, 1966; Hagberg et al., 1983; Kerr & Witt Engerström, 
2001; Smeets et al., 2012). The main focus of research in RTT has been to further 
the understanding of its genetic basis and the search for a possible cure. The aim of 
this thesis is to contribute to an improved clinical management of this syndrome. 
This chapter starts with a brief historical and clinical introduction in RTT, including 
the cascade of emerging features in the four recognised stages, the diagnostic crite-
ria, the genetic background and clinical management in particular. Finally, the re-
search questions and outline of this thesis are presented. 
History of Rett syndrome 
In 1954, Andreas Rett, a neuropaediatrician in Vienna, first recognized the charac-
teristic features of the syndrome that later came to bear his name. In his waiting 
room he noticed two girls, seated next to each other on the lap of their respective 
mothers, who displayed exactly the same behaviour. He recognized that these girls’ 
hand movements were different from the stereotypic behaviours among other 
disabled children. He and his nurse were able to recall and examine other girls in 
their care who demonstrated these same characteristics. His publication in the 
“Wiener Medizinische Wochenschrift” in 1966, however, remained largely unno-
ticed (Rett, 1966). It was Professor Hagberg who revealed this unique syndrome to 
the international medical world with his publication in 1983 titled “A progressive 
syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: 
Rett’s syndrome: Report of 35 cases” (Hagberg et al., 1983). In the years that fol-
lowed, information about RTT spread rapidly. Today we know that RTT is a neuro-
developmental disorder due to mutation in the gene encoding for the methyl-CpG 
binding protein 2 (MECP2), a finding first demonstrated by researchers from Profes-
sor Zoghbi’s laboratory at the Baylor College of Medicine in Houston, Texas (Amir et 
al., 1999). 
Rett syndrome 
RTT is one of the leading causes of severe intellectual disabilities (ID) in females, 
with an incidence ranging from 1/10,000 to 1/15,000 (Leonard et al., 1997; Bien-
venu et al., 2006). Typical RTT is characterized by seemingly normal postnatal de-
velopment, followed by stagnation in development and the loss of acquired motor 
and language skills, severe cognitive impairment, gait abnormalities and the re-
placement of purposeful hand use by typical hand stereotypies, the hallmark of the 
disorder (Hagberg, 1995; Hagberg et al., 2002; Neul et al., 2010). This period of 
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regression is than followed by a ‘‘wake-up’’ period, in which development reaches a 
plateau or shows quite slow improvement (Mount et al., 2001; Hagberg, 2002; Hag-
berg et al., 2002; Neul et al., 2010). This stage includes a wide variety of RTT-specific 
symptoms, such as scoliosis, seizures and autonomic abnormalities. It can last for a 
variable period, most often for decades, and is followed by late motor deterioration, 
mainly involving gross motor functions (Hagberg, 2002). This cascade of clinical 
symptoms was described in four stages: the early-onset stagnation, the rapid devel-
opmental regression, a pseudo-stationary stage and a late motor deterioration 
(Hagberg & Witt Engerström, 1986). The schematic representation in Figure 1 by 
Chahrour and Zoghbi provides an indication of a possible course of the RTT clinical 
phenotype. The lifespan is extremely variable and some individuals survive above 70 
years of age (Chahrour & Zoghbi, 2007). 
 
Figure 1 Onset and Progression of RTT Clinical Phenotypes (Chahrour & Zoghbi, 2007) 
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Diagnosis of RTT 
RTT is diagnosed clinically, based on internationally accepted diagnostic criteria that 
were developed and revised over the years. These clinical criteria are a useful tool 
for the clinicians who are involved in the first diagnostic work-up and for RTT re-
searchers (Hagberg et al., 2002; Neul et al., 2010). The recently revised diagnostic 
criteria for typical and atypical RTT are shown in Table 1. 
 
Table 1 Revised diagnostic criteria for RTT 2010 (Neul et al., 2010) 
Consider diagnosis when postnatal deceleration of head growth is observed 
Required for typical or classic RTT 
1. A period of regression followed by recovery or stabilization 
2. All main criteria and all exclusion criteria 
3. Supportive criteria are not required, although often present in typical RTT 
Required for atypical or variant RTT 
1. A period of regression followed by recovery or stabilization 
2. At least 2 out of the 4 main criteria 
3. 5 out of 11 supportive criteria 
Main Criteria 
1. Partial or complete loss of acquired purposeful hand skills 
2. Partial or complete loss of acquired spoken language 
3. Gait abnormalities: Impaired (dyspraxic) or absence of ability 
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and 
washing/rubbing automatisms 
Exclusion Criteria for typical RTT 
1. Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection 
that causes neurological problems 
2. Grossly abnormal psychomotor development in first 6 months of life 
Supportive Criteria for atypical RTT 
1. Breathing disturbances when awake 
2. Bruxism when awake  
3 Impaired sleep pattern  
4 Abnormal muscle tone 
5. Peripheral vasomotor disturbances 
6. Scoliosis/kyphosis 
7. Growth retardation 
8. Small cold hands and feet 
9. Inappropriate laughing/screaming spells 
10. Diminished response to pain 
11. Intense eye communication - “eye pointing”  
 
There is a wide variability in the rate of progression and clinical severity of the dis-
order. In addition to the typical form of RTT, accounting for three quarters of the 
cases (Hagberg, 2002), there is a number of recognisable atypical variants where-
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fore diagnostic criteria have been established (Hagberg & Gillberg, 1993; Hagberg et 
al., 2002; Neul et al., 2010). These atypical variants include an early seizure variant 
(Hanefeld, 1985), a preserved speech variant (Zappella, 1992) and a congenital vari-
ant (Ariani et al., 2008). Mutations in MECP2 have been found in the majority of the 
preserved speech variant cases (De Bona et al., 2000; Renieri et al., 2009). In the 
congenital and the early seizure variant, mutations in other genes have been identi-
fied. The congenital variant of RTT is related to mutations in FOXG1 (Ariani et al., 
2008; Mencarelli et al., 2010; Florian et al., 2011) and the early seizure variant is 
related to mutations in CDKL5 (Tao et al., 2004; Archer et al., 2006; Bahi-Buisson & 
Bienvenu, 2011). These disorders are now considered as separate entities, different 
from MECP2-related RTT. The incidence of MECP2 mutations in males is unknown, 
with conflicting results in previous studies (Moog et al., 2006; Kankirawatana et al., 
2006; Villard, 2007; Santos et al., 2009). Clinically it encompasses a wide spectrum 
of neurological disorders, ranging from mild ID to severe neonatal encephalopathy 
(Villard, 2007). 
MECP2 
RTT is considered a monogenic X-linked dominant disorder, since using a battery of 
modern mutation detection assays, causative mutations in MECP2 are detectable in 
at least 95% of the typical RTT cases (Amir et al., 1999; Percy, 2008; Neul et al., 
2008). Up until now, more than 500 different MECP2 mutations have been identi-
fied, with eight most common recurrent mutations accounting for approximately 
70% of the cases (http://mecp2.chw.edu.au/mecp2/). 
Since MECP2 mutations are neither necessary nor sufficient to make the diag-
nosis, diagnosis of RTT remains strongly based on clinical criteria (Neul et al., 2010). 
 
 
Figure 2 Schematic diagrams of the MECP2 gene and common recurrent mutations in RTT (Adapted from 
Bradbury et al., 2007) 
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MECP2 contains four functional domains: a methyl-CpG-binding domain (MBD), a 
transcriptional repression domain (TRD), two nuclear localization signals and the C-
terminal segment (CTS) (Matijevic et al., 2009). Figure 2 shows a schematic diagram 
of the gene, including the domains and the common recurrent mutations. The 
MeCP2 protein is ubiquitously present but particularly abundant in the brain (Amir 
et al., 1999). It is widely believed to be a transcriptional repressor that targets nu-
merous functional genes essential for normal central nervous system development 
and functioning (Nan et al., 1997; Chahrour & Zoghbi, 2007). However, the precise 
role of MECP2 mutations in producing the clinical RTT phenotype is still unclear 
(Berger-Sweeney, 2011). Even the concept of RTT as a pure neuronal disorder has 
been questioned, as a previously unrecognized role for the glial cells in the neuropa-
thology of RTT has recently been published (Zoghbi, 2009; Lioy et al., 2011). 
Genotype-phenotype correlations 
Since 1999, a major focus of research has been on identifying the genetic determi-
nants associated with the phenotypic variability in RTT (Amir et al., 2000; Cheadle et 
al., 2000; Huppke et al., 2000; Auranen et al., 2001; Hoffbuhr et al., 2001; Monros et 
al., 2001; Nielsen et al., 2001; Yamashita et al., 2001; Hoffbuhr et al., 2002; Huppke 
et al., 2002; Leonard et al., 2003; Smeets et al., 2003; Weaving et al., 2003; Schanen 
et al., 2004; Colvin et al., 2004; Charman et al., 2005; Fukuda et al., 2005; Kerr & 
Prescott, 2005; Leonard et al., 2005; Smeets et al., 2005; Bebbington et al., 2008; 
Neul et al., 2008; Smeets et al., 2009; Bebbington et al., 2010; Temudo et al., 2011). 
Genetic factors that were considered include the type and domain of mutation, 
common recurrent mutations, and the individual variability in X-chromosome inac-
tivation (XCI) patterns. These studies have yielded conflicting results. Females with 
the same MECP2 mutation varied significantly in phenotype and clinical severity 
could not always be explained by XCI patterns. The limited correlation between 
genotype and phenotype might be due to the variability in classification of muta-
tions, assessment tools, and structure of the data sets (Ham et al., 2005; Hite et al., 
2009; Grillo et al., 2012). Furthermore, other genetic and/or epigenetic mechanisms 
might modulate the clinical presentation (Ogier & Katz, 2008; Takahashi et al., 2008; 
Xinhua et al., 2008; Matijevic et al., 2009). 
Clinical management 
Currently no cure for RTT exists, although disease reversibility has been demon-
strated in animal models (Guy et al., 2007, Gadalla et al., 2012). Clinical manage-
ment of RTT is essentially symptomatic and supportive (Ellaway & Christodoulou, 
2001; Weaving et al., 2005; Williamson & Christodoulou, 2006; Smeets et al., 2012). 
Only interventions aimed at improving condition and quality of life of RTT females 
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are at the moment available. An individualised multidisciplinary team approach is 
advocated, aimed at optimising each patient’s abilities and predicting and treating 
symptoms and problems as they develop to improve the health, longevity and quali-
ty of life of the individuals and their families (Ellaway & Christodoulou, 2001; Wil-
liamson & Christodoulou, 2006; Julu et al., 2008; Smeets et al., 2012). It is clear that 
certain RTT features contribute more than others to the clinical severity and may 
demand complex management strategies. Autonomic features and nutritional prob-
lems are major reasons for seeking medical attention in RTT (Julu et al., 2008; Motil 
et al., 2012). Besides, parents express their concern about the lack of available in-
formation on clinical management of their adult RTT daughters. 
Autonomic dysfunction 
The brainstem features become prominent at the end of the regression stage and 
the beginning of stage three and remain present throughout life (Julu & Witt 
Engerström, 2005). Breathing abnormalities associated with non-epileptic vacant 
spells are the most distressing feature to the RTT females. Having a significant dele-
terious impact on the RTT female as well as on the quality of life of the families, 
breathing abnormalities are common reasons for seeking medical attention (Smeets 
et al., 2006; Julu et al., 2008; Ogier & Katz, 2008; Smeets et al., 2012). The primary 
pathophysiology is related to a defective control mechanism of carbon dioxide exha-
lation causing respiratory alkalosis or acidosis (Julu et al., 2008). Since it reflects the 
immaturity of the brainstem, detailed neurophysiology evaluating the brainstem 
functions in RTT is required (Julu & Witt Engerström, 2005). Three cardiorespiratory 
phenotypes are described, each demanding a specific approach (Julu, 2001; Julu et 
al., 2005; Julu et al., 2008; Julu et al., 2012). 
Nutrition 
Growth retardation and malnutrition often complicate the clinical course of females 
with RTT. The growth trajectory of RTT deviates from the typical pattern of growth 
failure in children with chronic illnesses or other central nervous system or chromo-
somal disorders (Motil et al., 2009). There is deceleration of linear growth during 
the first 2 years of life. Later on, height and/or weight for height often fall 2 SD be-
low normal (Schultz et al., 1993; Reilly & Cass, 2001; Motil et al., 2012). Although 
RTT females have a good appetite, the majority meets the criteria of moderate to 
severe malnutrition (Rice & Haas, 1988; Reilly & Cass, 2001; Motil et al., 2012). The 
pathophysiology of this malnutrition remains unclear. Both nutritional and non-
nutritional factors are thought to contribute. These factors include inadequate die-
tary intake, malabsorption, altered metabolic processes or increased metabolic rate 
(Motil et al., 1998; Reilly & Cass, 2001; Oddy et al., 2007; Motil et al., 2009; Platte et 
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al., 2011; Motil et al., 2012). To optimize clinical management of malnutrition, clari-
fication of the pathophysiology is of great importance. 
Ageing 
Owing to better life circumstances and major advances in medical care and technol-
ogy, the life expectancy of persons with childhood onset disorders and/or genetic 
syndromes has increased (Patja et al., 2000; Donckerwolcke & Van Zeben-Van der 
Aa, 2002; Maaskant et al., 2002; Fisher & Kettl, 2005; Tyler & Noritz, 2009; Haveman 
et al., 2010). Consequently, the number of adults with ID has increased substantially 
during the last decades and expectations are that it will continue to increase in the 
next years (Janicki & Breitenbrach, 2000; Bernard et al., 2002; Tyler & Noritz, 2009; 
Haveman et al., 2010). Therefore, clinicians are increasingly challenged by the need 
for care for adults with specific genetic syndromes (Donckerwolcke & Van Zeben-
Van der Aa, 2002; Tyler & Noritz, 2009; Vignoli et al., 2012). Compared to persons 
without ID, age-specific conditions occur more often and earlier in life (Maaskant et 
al., 1996; Van Schrojenstein Lantman-De Valk et al., 1997; Haveman et al., 2009). 
Nevertheless, studies on ageing in RTT are scarce, including a few cross-sectional 
studies and some longitudinal follow-up case studies (Nielsen et al., 2001; Jacobsen 
et al., 2001; Cass et al., 2003; Hagberg, 2005; Lotan et al., 2010; Vignoli et al., 2012). 
The clinical condition of RTT women appears to stabilize over time, and prolonged 
survival has recently been demonstrated (Freilinger et al., 2010; Kirby et al., 2010). 
Good knowledge of the clinical course of the syndrome at adult age including the 
specific healthcare problems is needed to provide for optimal care and support on 
the long term. 
Aim and outline of this thesis 
The aim of this thesis is to contribute to an improved clinical management of RTT. 
The main research questions in this context are: 
1. What is the role of the genotype in clinical management of the RTT female? 
The limited correlations between the RTT genotype and phenotype might be due to 
several reasons. In chapter 2 one possible reason, namely “the effect of subjectivity 
among clinicians and researchers completing the scoring lists” is investigated. Chap-
ter 3 presents a collaborative multicentre study evaluating the influence of the 
genotype on brainstem instability in RTT. 
2. Malnutrition in RTT: could altered metabolic processes be a cause? 
The pathophysiology of malnutrition in RTT remains unclear. Altered metabolic 
processes, due to the breathing irregularities present in RTT, are suspected. Meta-
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bolic investigations to test this hypothesis are described and discussed in chapter 4 
and appendix 1. 
3. What is the phenotype of adult RTT women? 
Given the need for good knowledge of the ageing process in RTT, two ageing studies 
were carried out. In chapter 5 and 6 these studies are presented, providing more 
insight into age-related features in RTT. The first study is a cross-sectional study and 
the second a longitudinal study. 
 
In chapter 7, is a general discussion reflecting upon the findings and their implica-
tion for clinical management of RTT with recommendation for future research. In 
appendix 2 the important role of autonomic dysfunction in RTT is discussed and a 
description of the autonomic assessment as performed at the RTT Expertise Centre 
is provided. 
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Abstract 
Rett syndrome (RTT; OMIM 312750) is an X-linked dominant neurodevelopmental 
disorder leading to cognitive and motor impairment, epilepsy, and autonomic dys-
function in females. Since the discovery that RTT is caused by mutations in MECP2, 
large retrospective genotype-phenotype correlation studies have been performed. 
A number of general genotype-phenotype relationships were confirmed and specific 
disorder profiles were described. Nevertheless, conflicting results are still under 
discussion, partly due to the variability in classification of mutations, assessment 
tools, and structure of the data sets. The aim of this study was to investigate rela-
tionships between genotype and specific clinical data collected by the same experi-
enced physician in a well-documented RTT cohort, and evaluate its prognostic value 
in counseling young parents with a newly diagnosed RTT girl regarding her future 
outcome. The Maastricht-Leuven Rett Syndrome Database is a register of 137 mo-
lecularly confirmed clinical RTT cases, containing both molecular and clinical data on 
examination and follow up by the same experienced physician. Although the gen-
eral genotype-phenotype relationships were confirmed, the clinical severity was still 
found to be very variable. We therefore recommend caution in using genotype-
phenotype data in the prognosis of outcome for children in Rett syndrome. Early 
diagnosis, early intervention, and preventive management are imperative for better 
outcomes and better quality of daily life for RTT females and their families.  
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Introduction 
Rett syndrome (RTT; OMIM 312750) is a unique X-linked dominant neurodevelop-
mental disorder leading to cognitive and motor impairments, epilepsy, and auto-
nomic dysfunctions in females (Hagberg et al., 1983; Williamson & Christodoulou, 
2006; Smeets et al., 2009). Clinical diagnosis is readily confirmed by finding a muta-
tion in the methyl-CpG-binding protein 2 gene (MECP2) located on the X-
chromosome (Amir et al., 1999). Since the discovery of MECP2, large retrospective 
genotype-phenotype correlation studies have been performed. A number of general 
genotype-phenotype relationships were confirmed and specific disorder profiles 
were described (Huppke et al., 2002; Leonard et al., 2003; Colvin et al., 2004; 
Schanen et al., 2004; Charman et al., 2005; Kerr & Prescott, 2005; Leonard et al., 
2005; Smeets et al., 2005; Bebbington et al., 2008; Neul et al., 2008; Smeets et al., 
2009; Bebbington et al., 2010). Nevertheless, conflicting results are still under dis-
cussion, partly due to the variability in classification of mutations, assessment tools 
and structure of the data sets (Ham et al., 2005). The aim of this study was to inves-
tigate relationships between genotype and specific clinical data collected by the 
same experienced physician in a well-documented RTT cohort, and to evaluate its 
prognostic value in counseling young parents with a newly diagnosed RTT girl re-
garding her future outcome. This study was performed in collaboration with the 
members of the ESRRA group (see Acknowledgments). 
Materials and methods 
The Maastricht-Leuven Rett syndrome database  
The Maastricht-Leuven Rett Syndrome (MLRS) database currently consists of 137 
molecularly confirmed RTT cases. It contains both molecular and clinical data on 
examination and follow-up by the second author, a physician already experienced in 
RTT. The RTT center of expertise was founded after the discovery of MECP2 muta-
tions as the genetic cause of RTT (Amir et al., 1999). Dutch and Belgian RTT females 
were referred to this center by general practitioners, pediatricians, and pediatric 
neurologists for diagnosis or second opinion of RTT. Complementary to the start of 
the center, the MLRS database was set up in 2000. For the database, diagnosis of 
RTT was based on the consensus diagnostic criteria for RTT (Hagberg et al., 2002), 
and confirmed by identifying a mutation in the MECP2 gene. Phenotypic data were 
collected through clinical evaluations including data on personal history, age at 
onset of stagnation, age at diagnosis, clinical type, and clinical severity of RTT 
(scored using the International Scoring System, ISS). The database lacks some older 
women with RTT, since in this age group clinical and genetic data were often in-
complete. 
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DNA analysis 
DNA analysis was performed by sequencing the coding and intron regions and by 
additional Multiplex Ligation-dependent Probe Amplification (MLPA) analysis of 
MECP2 to exclude for large deletions. Nomenclature according to the MECP2A iso-
form reference sequence AF158180 was used, numbering started at the A of the 
ATG translation initiation codon. X-chromosome inactivation (XCI) was studied only 
in 22 cases and has been published before (Smeets et al., 2003).  
Mutations were classified by location in the gene, including the methyl-CpG-
binding domain (MBD), the transcription repression domain (TRD) and the C-
terminal segment (CTS) of MECP2 (Table 1). The CTS hot spot region is an area be-
tween the base pairs (bp) at position 1030 and 1207 in MECP2 (Huppke et al., 2002). 
Furthermore, mutations were defined as recurrent when present in five or more 
females and analyzed separately as individual mutations. The p.R168X mutation is 
located in the inter-domain region between MBD and TRD. For analysis it is grouped 
as a mutation in the TRD domain, since this mutation leaves the MBD intact. Finally, 
since large deletions are not restricted to one domain they are excluded for geno-
type-phenotype analysis. 
 
Table 1 Mutation type and localization in MECP2 
Domain in MECP2 MBD (n) TRD (n) CTS (n) Others (n) Total 
 
 
 
 
 
 
 
 
 
 
 
 
p.D97E (1) p.P225R (1) p.S373X (1) Large deletions (8)  
p.L100V (1) p.R306C (12) Frameshifts (14)   
p.P101S (1) p.R255X (15)    
p.R106W (4) p.R270X (9)    
p.Q128P (1) p.R294X (12)    
p.R133C (10) p.R168X (15)    
p.R133H (2) Frameshifts (9)    
p.P152R (5)     
p.F157L (1)     
p.T158M (15)     
Total 41 73 15 8 137 
MBD: methyl-CpG-binding domain, TRD: transcription repression domain, CTS: C-terminal segment, n: 
number of patients (Nomenclature according to the MECP2A isoform reference sequence AF158180, 
numbering starting at the A of the ATG translation initiation codon) 
International scoring system 
Clinical severity was assessed using the International Scoring System (ISS, Table 2) 
(Kerr et al., 2001). Complete clinical and molecular data were available for the co-
hort of 137 RTT females, examined and re-examined between 1983 and January 
2009. Firstly, the ISS score was used to compare clinical severity in a quantitative 
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manner. The clinical scoring system consists of 20 items (features common in RTT, 
ranging from A to T), which were scored from 0 to 2; the lower the score, the better 
the clinical condition. The maximum score being 40, a score above 30 was consid-
ered as very severe, a score of 25-29 as severe, and a score of 10-24 as mild to less 
severe. A score <10 indicates the best clinical condition still recognizable as RTT. 
Secondly, the 20 items of the ISS were grouped into five functional domains: growth 
and development (A-E), musculoskeletal (F-H), movement (I-M), cortical (N-P), and 
autonomic features (Q-T). 
 
Table 2 ISS score (Adapted from Kerr et al., 2001) 
The Kerr scoring system 
A Head circumference during the first year 
 2 Already below the 3rd percentile at birth 
 1 Normal at birth but decelerating 
 0 Normal at birth with no deceleration 
B Early developmental progress (birth to 12 months) 
 2 No or virtually no progress 
 1 Suboptimal progress 
 0 Normal progress 
C Present head circumference (percentile/standard deviations sd)  
 2 Below 3rd percentile 
 1 3rd to10th percentile  
 0 Above 10th percentile  
D Weight (kg) 
 2 Below 3rd percentile  
 1 3rd to10th percentile  
 0 Above 10th percentile  
E Height (cm) 
 2 Below 3rd percentile  
 1 3rd to10th percentile  
 0 Above 10th percentile 
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The Kerr scoring system 
MUSCULOSKELETAL 
F Muscle tone (also describe) 
 2 Severe hypotonia, dystonia or hypertonia  
 1 Tone mildly abnormal  
 0 Normal 
G Spine posture 
 2 Severe scoliosis  
 1 Mild scoliosis 
 0 No deviation 
H Joint contractures 
 2 Severe contractures 
 1 Minor contractures  
 0 None 
MOVEMENT 
I Gross motor function 
 2 Cannot walk with support  
 1 Walking impaired 
 0 Walks normally 
J Hand stereotypy (patting, sqeezing, wringing, mouthing) 
 2 Dominating or constant 
 1 Mild or intermittent 
 0 None 
K Other involuntary movements (e.g. tremor, dystonia, chorea, athetosis) 
 2 Dominating or constant  
 1 Mild or intermittent 
 0 None 
L Voluntary hand use (e.g. self feeding) 
 2 None 
 1 Reduced or poor 
 0 Hand use normal 
M Oro-motor difficulty 
 2 Severe (e.g. feeding aversion; gagging, choking, tube/button fed) 
 1 Slight (e.g. delayed chewing, swallowing, on supplements) 
 0 None 
CORTICAL 
N Intellectual disability (= learning disability = retardation) 
 2 Apparent profound (infant level) 
 1 Any except profound 
 0 No impairment 
O Speech 
 2 Currently uses no real words with meaning 
 1 Currently uses some real words with meaning 
 0 Normal speech 
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The Kerr scoring system 
P Epilepsy 
 2 Uncontrolled or poorly controlled 
 1 Previous epileptic seizures or well-controlled with medication 
 0 Never 
AUTONOMIC FEATURES 
Q Disturbed awake breathing rhythm (e.g. hyperventilation, breath holding, panting) 
 2 Severe, with vacant spells & colour changes 
 1 Mild, without vacant spells & colour changes 
 0 Normal breathing pattern 
R Peripheral circulation of extremities 
 2 Cold or discoloured with atrophic changes 
 1 Cold or discoloured without atrophic changes 
 0 Normal colour and temperature of extremities 
S Mood disturbance 
 2 Prominent or disruptive agitation / crying spells 
 1 Abnormally prone to agitation  
 0 Normal 
T Sleep disturbance 
 2 Prominent / disruptive day sleeping or night waking  
 1 Present, not prominent  
 0 Normal sleep pattern 
Data analyses 
SPSS version 16.0 was used for analyzing the data. Comparisons of clinical data (age 
at onset of stagnation, diagnosis, and examination), overall severity score, domain 
scores, and the individual ISS item scores between the different domains of muta-
tions and the individual recurrent mutations were performed. The Mann-Whitney U 
test or Kruskal Wallis test (respectively, non-parametric test for two and more than 
two unrelated groups) were used when the data did not follow normal distribution 
(i.e., age at onset of stagnation, diagnosis and examination). Independent t-tests 
(means of two groups) or ANOVA (means of more than two groups) were used 
when the dependent variable was normally distributed (i.e., ISS). For ISS-total scores 
and ISS-domain scores, mean scores were computed. The age of examination dif-
fered between the respondents (range 2-49 years; mean: 14.9 years).  
Since it is plausible that age at examination did influence the ISS scores, mean 
total and mean domain scores were corrected for age at examination via ANCOVA. 
Hereby, based on clinical considerations and to avoid small numbers in subgroups, 
age at examinations was divided into three age groups: 0-9 years, 10-19 years and 
above 20 years of age. Chi-square tests were used to compare nominal data (ISS 
items). In these analyses, no correction for age at examination was performed due 
to the small sample size. However, it was analyzed by means of Chi-square tests if 
age at examination was statistically significantly related to the scores on the ISS-
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items, thus was a possible confounder. If this was the case, this was mentioned in 
the results. A p-value of ≤0.05 (two-sided testing) was used as threshold for statisti-
cal significance in all tests. 
Results 
Arranged by subject, explanatory remarks are made below. 
RTT cases 
Among the 137 females, 80% (n=109) were categorized as classic RTT and 20% 
(n=28) as variant RTT. The mean age at data collection was 14.9 years (range 2-49, 
sd=10.7). In the majority of the females, stagnation was noted at the age of 12 
months (mean 12.0, range 0-60, sd=8.2). The mean age at diagnosis was 7.8 years 
(range 0-46, sd=9.7). Half of the females were diagnosed between 2 and 4 years of 
age. 
Mean age at onset of stagnation. Mean age at onset was highest in females 
with a mutation in the MBD domain (13.6 months, sd=9.6) and almost equal in fe-
males with a mutation in the TRD or CTS domain (respectively, 11.5 months, sd=8.1 
and 11.6 months, sd=5.3). The differences in ranking were however not statistically 
significant (Kruskal Wallis test: p=0.42). Concerning the recurrent mutations, mean 
age at onset was substantially lower in females with a p.R168X mutation than fe-
males with a p.R306C mutation (7.3 months, sd=5.9 vs. 18.3 months, sd=14.7). The 
differences in ranking of all recurrent mutations were statistically significant (Krus-
kal Wallis test: p=0.01). 
Mean age at diagnosis. Mean age at diagnosis was highest in females with a 
mutation in the MBD and TRD domain, followed by females with a mutation in the 
CTS domain (respectively, 8.2 years, sd=10.2, 8.0 years, sd=10.5 and 6.9 years, 
sd=4.6). The differences in ranking were not statistically significant (Kruskal Wallis 
test: p=0.49). In recurrent mutations the age at diagnosis was between 5.4 years 
(sd=4.4) in females with a p.R294X mutation and 16.0 years (sd=16.1) in females 
with a p.R306C mutation. However, the differences in ranking of all recurrent muta-
tions were not statistically significant (Kruskal Wallis test: p=0.20). 
Mean age at examination. Mean age at examination was highest in females 
with a mutation in the MBD domain, followed by females with a mutation in the CTS 
and TRD domain (respectively, 16.4 years, sd=11.9, 14.7 years, sd=7.7 and 13.7 
years, sd=10.6). The differences in ranking were not statistically significant (Kruskal 
Wallis test: p=0.42). In recurrent mutations, the mean age at examination was be-
tween 8.6 years (sd=8.9) in females with a p.R270X mutation and 22.1 years 
(sd=11.0) in females with a p.R133C mutation. The differences in ranking were how-
ever not statistically significant (Kruskal Wallis test: p=0.09). 
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MECP2 mutations 
Of all the MECP2 mutations 79% were recurrent: p.R133C, p.P152R, p.T158M, 
p.R168X, p.R255X, p.R270X, p.R294X, p.R306C, and the CTS mutations (Table 1). 
Frameshift mutations clustered in both the TRD and the CTS region. Frameshift 
mutations in the TRD domain were the result of small deletions, insertions, and 
duplications. They were located in the center of the TRD with a mean frameshift 
extension of 15 new amino acids before termination of translation. Frameshift mu-
tations in CTS were all deletions, except for one due to a deletion and insertion. CTS 
deletions were all located in and around the hotspot region with a mean deletion of 
40 nucleotides (range 32-44), nearly all leading to a frameshift within 10 amino 
acids. One deletion only was leading to a frameshift with an exceptionally long ex-
tension (c.1157_1189del33, p.Leu386GInfsX91). All large deletions span over a re-
gion encompassing exon 3 and exon 4. The exact breakpoints were not investigated. 
In addition, one female showed a complex rearrangement in MECP2. She presented 
both loss of a part of exon 4 upstream to the hot spot region and a duplication of 
the 3’UTR end up to half of the IRAK2 gene. Preferential skewing was present in 5 of 
the 22 RTT cases that were studied (XCI with ratios <20 or >80%), regarding two 
females the results were not conclusive. However, skewing could not be related to 
the clinical severity. 
ISS score 
Table 3 shows the mean scores, range, and standard deviation (sd) or standard error 
(SE) of the ISS scoring list, including the total score, functional domains and individ-
ual items for all the RTT females and the MECP2 mutations with the lowest and 
highest scores. 
 
Table 3 Mean scores, range and standard deviation (sd) or standard error (SE) of the ISS scoring list, 
including the total score*, score on functional domains* and individual items for all the RTT females and 
the MECP2 mutations with the lowest and highest scores 
ISS MECP2 mutation Mean score Range sd SE 
Total ISS score 
 Lowest score 
 Highest score 
 
p.R133C 
p.P152R 
19.4 
13.7 
25.2 
4-34 
9-28 
15-34 
6.7 
 
 
2.01 
2.75 
Domain Growth and development (ABCDE) 
 Lowest score 
 Highest score 
 
p.R133C 
p.P152R 
3.76 
1.8 
5.5 
0-9 
0-6 
4-7 
2.5 
 
 
0.74 
1.02 
Item A 
 Lowest score 
 Highest score 
 
p.R294X 
p.R270X 
0.47 
0.17 
0.89 
0-2 
0-1 
0-2 
0.56 
0.39 
0.60 
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ISS MECP2 mutation Mean score Range sd SE 
Item B 
 Lowest score 
 Highest score 
 
p.R133C 
p.R168X 
0.64 
0.20 
1.0 
0-2 
0-1 
0-2 
0.57 
0.42 
0.54 
 
Item C 
 Lowest score 
 Highest score 
 
CTS 
p.P152R 
0.98 
0.40 
1.6 
0-2 
0-2 
1-2 
0.83 
0.74 
0.55 
 
Item D 
 Lowest score 
 Highest score 
 
p.R133C 
p.R255X 
p.R270X 
0.78 
0.50 
1.0 
1.0 
0-2 
0-2 
0-2 
0-2 
0.77 
0.71 
0.93 
0.71 
 
Item E 
 Lowest score 
 Highest score 
 
p.R294X 
p.P152R 
0.93 
0.50 
1.4 
0-2 
0-1 
1-2 
0.74 
0.52 
0.55 
 
Domain Musculoskeletal (FGH) 
 Lowest score 
 Highest score 
 
p.R306C 
p.R168X 
2.78 
1.3 
3.9 
0-6 
0-5 
0-6 
1.9 
 
 
0.48 
0.42 
Item F 
 Lowest score 
 Highest score 
 
p.R306C 
p.R168X 
1.09 
0.67 
1.4 
0-2 
0-1 
0-2 
0.72 
0.49 
0.83 
 
Item G 
 Lowest score 
 Highest score 
 
p.R306C 
p.P152R 
1.12 
0.83 
1.6 
0-2 
0-2 
0-2 
0.84 
0.72 
0.89 
 
Item H 
 Lowest score 
 Highest score 
 
CTS 
p.R168X 
0.54 
0.13 
0.93 
0-2 
0-1 
0-2 
0.72 
0.35 
0.96 
 
Domain Movement (IJKLM) 
 Lowest score 
 Highest score 
 
p.R306C 
p.P152R 
5.28 
3.5 
7.1 
0-10 
1-8 
4-9 
2.2 
 
 
0.61 
0.92 
Item I 
 Lowest score 
 Highest score 
 
p.R306C 
p.R270X 
1.12 
0.58 
1.7 
0-2 
0-2 
1-2 
0.87 
0.79 
0.50 
 
Item J 
 Lowest score 
 Highest score 
 
p.R294X 
p.R270X 
1.57 
1.2 
1.9 
0-2 
0-2 
1-2 
0.57 
0.58 
0.33 
 
Item K 
 Lowest score 
 Highest score 
 
p.R255X 
p.P152R 
0.50 
0.27 
1.0 
0-2 
0-1 
0-2 
0.68 
0.46 
0.71 
 
Item L 
 Lowest score 
 
 Highest score 
 
p.R306C 
p.R294X 
p.R255X 
1.41 
1.1 
1.1 
1.7 
0-2 
0-2 
0-2 
0-2 
0.66 
0.79 
0.79 
0.59 
 
Item M 
 Lowest score 
 Highest score 
 
p.R133C 
p.P152R 
0.67 
0.30 
1.2 
0-2 
0-1 
0-2 
0.67 
0.48 
1.1 
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ISS MECP2 mutation Mean score Range sd SE 
Domain Cortical (NOP) 
 Lowest score 
 Highest score 
 
CTS 
p.P152R 
4.37 
3.8 
5.1 
2-6 
2-6 
4-6 
1.1 
 
 
0.27 
0.47 
Item N 
 Lowest score 
 Highest score 
 
CTS 
p.P152R 
1.73 
1.4 
2.0 
1-2 
1-2 
2-2 
0.45 
0.51 
0 
 
Item O 
 Lowest score 
 Highest score 
 
p.R306C 
p.P168X 
1.85 
1.7 
2.0 
0-2 
0-2 
2-2 
0.38 
0.65 
0 
 
Item P 
 Lowest score 
 Highest score 
 
p.R270X 
p.P152R 
0.81 
0.56 
1.2 
0-2 
0-2 
0-2 
0.74 
0.73 
0.84 
 
Domain Autonomic features (QRST) 
 Lowest score 
 Highest score 
 
p.R270X 
p.P152R 
3.28 
2.7 
4.2 
0-8 
0-4 
1-7 
1.7 
 
 
0.59 
0.78 
Item Q 
 Lowest score 
 Highest score 
 
p.R133C 
p.T158M 
1.1 
0.60 
1.3 
0-2 
0-1 
1-2 
0.67 
0.52 
0.49 
 
Item R 
 Lowest score 
 Highest score 
 
p.R306C 
p.P152R 
0.97 
0.67 
1.2 
0-2 
0-2 
0-2 
0.66 
0.65 
0.84 
 
Item S 
 Lowest score 
 Highest score 
 
p.R270X 
p.R294X 
p.P152R 
0.57 
0.33 
1.0 
1.0 
0-2 
0-1 
0-2 
0-2 
0.68 
0.50 
0.85 
1.0 
 
Item T 
 Lowest score 
 Highest score 
 
p.R133C 
p.R306C 
0.65 
0.40 
1.1 
0-2 
0-2 
0-2 
0.73 
0.70 
0.72 
 
* Corrected for age at examination 
 
Total ISS score 
The mean severity score on the ISS scoring list was 19.4 points (range 4-34, sd=6.7). 
Mild to less severe RTT (ISS score 10-24) was present in 66%, severe RTT (ISS score 
25-29) in 21%, the best clinical condition still recognizable as RTT (ISS score <10) in 
7% and very severe RTT (ISS score ≥30) in 5% of the RTT females. 
Total ISS score was lowest in females with a CTS mutation (15.9, SE=1.69) in 
contrast to females with a mutation in the MBD (18.9, SE=1.03) or TRD domain 
(20.5, SE=0.77). This appeared to be statistically significant, which was mainly based 
on the differences between the CTS and TRD domain (ANCOVA with Bonferroni 
correction: p=0.05). As can be seen in Figure 1, the mean severity scores of the 
recurrent mutations show a wide range of scores. The lowest score was seen in 
females with a p.R133C mutation and the highest score in females with a p.P152R 
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mutation (13.7, SE=2.01 versus 25.2, SE=2.75). The overall differences were statisti-
cally significant (ANCOVA with Bonferroni correction: p<0.01). 
 
Figure 1 Total ISS score in recurrent MECP2 mutations (corrected for age at examination) 
 
ISS functional domains 
Growth and development (ISS items A-E). The mean score on the growth and devel-
opment domain was 3.76 (range 0-9, sd=2.5). Females with a mutation in the CTS 
domain scored the lowest with a mean of 2.5 (SE=0.64), followed by females with a 
mutation in the MBD and TRD domain (respectively, 3.6, SE=0.39 and 4.1, SE=0.29); 
these differences were just not statistically significant (ANCOVA with Bonferroni 
correction: p=0.08). Concerning recurrent mutations, females with a p.R133C muta-
tion scored lower than females with a p.P152R mutation (1.8, SE=0.74 vs. 5.5, 
SE=1.02). The overall differences were statistically significant (ANCOVA with Bonfer-
roni correction: p<0.001). 
Head circumference at birth (item A) was normal in 97% of the females, without 
deceleration during the first year in 58% of the females and with deceleration dur-
ing the first year in 39% of the females. The remaining 3% of the females had al-
ready a head circumference below the 3rd centile at birth. Statistically significant 
differences were only seen between females with a p.R294X and a p.R270X muta-
tion; 83% of the females with a p.R294X mutation had a normal head circumference 
during the first year of life, in contrast to 22% of the females with a p.R270X muta-
tion (Chi-square test: p=0.01). Age at examination did not seem to be a confounder, 
since the scores on this item did not differ significantly between the different age 
groups (Chi-square test: p=0.31). 
Early developmental progress during the first year of life (item B) was reported 
normal in 41%, suboptimal in 55% and (virtually) no progress in 4% of the females. 
Statistically significant differences were only seen between females with a p.R133C 
and a p.R168X mutation; in 80% of the females with a p.R133C mutation normal 
progress was reported in contrast to 13% of the females with a p.R168X mutation 
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(Chi-square test: p=0.02). Age at examination did not seem to be a confounder, 
since the scores on this item did not differ significantly between the different age 
groups (Chi-square test: p=0.25). 
Present head circumference (item C) was nearly equally distributed, whereas 
36% of the females had a head circumference above the 10th centile, 31% between 
the 3rd and 10th centile and 33% below the 3rd centile. Comparing the different 
domains, 73% of the females with a CTS mutation had a head circumference above 
the 10th centile, in contrast to 29% of the females with a mutation in the TRD do-
main and 32% of the females with a mutation in the MBD domain (Chi-square test: 
p=0.03). These differences were also found comparing females with a CTS mutation 
and females with a p.P152R mutation, all of whom had a head circumference below 
the 10th centile (Chi-square test: p=0.05). Age at examination did not seem to be a 
confounder, since the scores on this item did not differ significantly between the 
different age groups (Chi-square test: p=0.50). 
Weight (item D) was above the 10th centile in 43% of the females, between the 
3rd and 10th centile in 37% and below the 3rd centile in 20% of the females. Geno-
type-phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.21). However, age at examination 
could be a confounder, since the scores on this item did differ significantly between 
the different age groups (Chi-square test: p<0.001). The majority of the youngest 
females scored zero on this item, in contrast to around two thirds of the females 
older than 10 years of age who scored one or two on this item. 
Height (item E) was above the 10th centile in 31% of the females, between the 
3rd and 10th centile in 45% and below the 3rd centile in 24% of the females. Geno-
type-phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.20). However, age at examination 
could be a confounder, since the scores on this item did differ significantly between 
the different age groups (Chi-square test: p<0.001). The majority of the youngest 
females scored zero on this item, in contrast to 83% of the females older than 10 
years of age who scored one or two on this item. 
Musculoskeletal (ISS items F-H). The mean score on the musculoskeletal domain 
was 2.78 (range 0-6, sd=1.9). Concerning location of the mutation, differences in 
mean scores were small and not statistically significant (MBD: 2.5, SE=0.26, TRD: 
2.9, SE=0.20, and CTS: 2.4, SE=0.43; ANCOVA with Bonferroni correction: p=0.35). 
Comparing recurrent mutations, females with a p.R306C mutation scored 
significantly lower than females with a p.R168X mutation (1.3, SE=0.48 versus 3.9, 
SE=0.42; ANCOVA with Bonferroni correction p<0.01).  
A normal muscle tone (item F) was seen in just 22% of the females, severely ab-
normal tone was reported in 31% and mildly abnormal in 47% of the females. Geno-
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type-phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.19). Furthermore, age at examination 
did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi-square test: p=0.06). 
Scoliosis (item G) was present in 70% of the females, with mild scoliosis in 29% 
and severe scoliosis in 41%. Genotype-phenotype analysis concerning this item 
showed that females did not differ significantly from each other comparing the 
different scores (0-1-2) and the different groups of mutations (Chi-square test: 
p>0.37). However, age at examination could be a confounder, since the scores on 
this item did differ significantly between the different age groups (Chi-square test: 
p<0.001). The majority of the youngest females scored zero on this item, in contrast 
to around 10% of the females older than 10 years of age. 
Joint contractures (item H) were seen in 43% of the females. Minor contrac-
tures were reported in 29% and severe contractures in 14% of the females. Geno-
type-phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.09). However, age at examination 
could be a confounder, since the scores on this item did differ significantly between 
the different age groups (Chi-square test: p<0.001). 80% of the youngest females 
scored zero on this item, in contrast to around 41% of the females older than 10 
years of age. 
Movement (ISS items I-M). The mean score on the movement domain was 5.28 
(range 0-10, sd=2.2). Concerning location of the gene, the females did not differ 
statistically significant (MBD: 5.3, SE=0.35, TRD: 5.5, SE=0.26, and CTS: 4.4, SE=0.57; 
ANCOVA and Bonferroni correction: p=0.27). However, comparing the recurrent 
mutations, the lowest score was seen in females with a p.R306C mutation and the 
highest score in females with a p.P152R mutation. These differences were statisti-
cally significant (3.5, SE=0.61 vs. 7.1, SE=0.92; ANCOVA with Bonferroni correction 
p=0.001 and pairwise comparison p<0.05). 
One third of the females could walk normally (item I) and 24% were ambulant 
but had some impairment. Of the 61 non-walkers (44%), nine girls were younger 
than 5 years. Genotype-phenotype analysis concerning this item showed that fe-
males did not differ significantly from each other comparing the different scores (0-
1-2) and the different groups of mutations (Chi-square test: p>0.10). Age at exami-
nation did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi-square test: p=0.99). 
Hand stereotypy (item J) was reported in 96% of the females, being mild or in-
termittent in 36% of the females and dominating or constant in 61% of the females. 
Genotype-phenotype analysis concerning this item showed that females did not 
differ significantly from each other comparing the different scores (0-1-2) and the 
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different groups of mutations (Chi-square test: p>0.17). Furthermore, age at exami-
nation did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi-square test: p=0.39). 
Involuntary movements (item K) were present in 40% of the females, being mild 
or intermittent in 30% of the females and dominating or constant in 10%. Genotype-
phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.27). Furthermore, age at examination 
did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi-square test: p=0.38). 
Half of the females could not use their hands voluntarily (item L) and 41% had a 
poor or reduced hand use. Normal hand use was seen in 9% of the females. Com-
paring the different domains, 80% of the females with a CTS mutation had a poor or 
reduced hand use, in contrast to 30% of the females with a mutation in the TRD 
domain and 44% of the females with a mutation in the MBD domain (Chi-square 
test: p< 0.01). However, normal hand use was reported in 14% of the females with a 
mutation in the TRD domain and none of the females with a CTS mutation. Concern-
ing recurrent mutations, one third of the females with a p.R306C or p.R294X muta-
tion could not use their hands voluntarily compared to 80% of the females with a 
p.R255X mutation (Chi-square test: p=0.01). Age at examination did not seem to be 
a confounder, since the scores on this item did not differ significantly between the 
different age groups (Chi- square test: p=0.83). 
Oro-motor difficulties (item M) were reported in 56% of the females, being se-
vere in 10% of the females. In females with a p.R133C mutation oro-motor difficul-
ties were only reported in 30%, being severe in none of the females. This in contrast 
to females with a p.P152R mutation, among whom 60% were reported having oro-
motor difficulties, all being severe. These differences were statistically significant 
(Chi-square test: p=0.01). Age at examination did not seem to be a confounder, 
since the scores on this item did not differ significantly between the different age 
groups (Chi-square test: p=0.27). 
Cortical (ISS items N-P). The mean score on the cortical domain was 4.37 (range 
2-6, sd=1.1). Concerning location of the gene the females did not differ statistically 
significant (MBD: 4.4, SE=0.17, TRD: 4.4, SE=0.13, and CTS: 3.8, SE=0.27; ANCOVA 
and Bonferroni correction: p=0.10). Comparing recurrent mutations, the lowest 
score was seen in females with a CTS mutation and the highest score in females 
with a p.P152R mutation (5.1, SE=0.47). The range in scores were remarkably differ-
ent in females with a p.P152R mutation with a range of 4-6 points, in contrast to 2-6 
points in the total RTT group and in females with a CTS mutation. However, the 
scores between the different mutations did not vary statistically significant (AN-
COVA with Bonferroni correction: p=0.07) and also pairwise comparisons did not 
result in statistically significant differences. 
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All females were intellectually disabled (item N), whereas 73% functioned on an 
infantile (profound) level of development and 27% scored any level except pro-
found. Comparing the different domains, 40% of the females with a CTS mutation 
functioned on an infantile level, in contrast to 79% of the females with a mutation in 
the TRD domain and 73% of the females with a mutation in the MBD domain (Chi-
square test: p<0.01). These results were confirmed comparing females with a CTS 
mutation and females with a p.P152R mutation, of whom 100% functioned on an 
infantile level (Chi-square test: p=0.03). Age at examination did not seem to be a 
confounder, since the scores on this item did not differ significantly between the 
different age groups (Chi-square test: p=0.84). 
Eighty-six percent of the females could not speak (item O), 13% used some 
meaningful words or two-word sentences at the time of examination and 1% had a 
normal speech. Genotype-phenotype analysis concerning this item showed that 
females did not differ significantly from each other comparing the different scores 
(0-1-2) and the different groups of mutations (Chi-square test: p>0.27). Age at ex-
amination did not seem to be a confounder, since the scores on this item did not 
differ significantly between the different age groups (Chi-square test: p=0.27). 
A history of epilepsy (item P) was present in 61% of the females at some time of 
their life, whereas epilepsy was well-controlled in 42% and uncontrolled or poorly 
controlled by medication in 18% of the females. None of the females in this cohort 
developed epilepsy before the age of 4, except for a 2-year-old girl. Genotype-
phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.25). Age at examination did not seem 
to be a confounder, since the scores on this item did not differ significantly between 
the different age groups (Chi-square test: p=0.10). 
Autonomic functions (ISS items Q-T). The mean score on the autonomic domain 
was 3.28 (range 0-8, sd=1.7). The location of the mutation did not relate to mean 
scores on this ISS domain (MBD: 3.0, SE=0.27, TRD: 3.5, SE=0.20, and CTS: 2.7, 
SE=0.44; ANCOVA with Bonferroni correction: p=0.21). Also concerning recurrent 
mutations, the scores between the different mutations did not vary significantly 
(ANCOVA with Bonferroni correction: p=0.47). The lowest score was seen in females 
with a p.R270X mutation (2.7, SE=0.59) and the highest score in females with a 
p.P152R mutation (4.2, SE=0.78). The range in scores varied widely; in females with 
a p.R270X mutation with a range of 0-4 points, in contrast to 0-8 points in the total 
RTT group and 1-7 in females with a p.P152R mutation. 
Breathing problems (item Q) were present in 81% of the females, of whom 25% 
had severe breathing problems with vacant spells and cyanosis. Genotype-
phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.26). Furthermore, age at examination 
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did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi-square test: p=0.18). 
Poor peripheral circulation (item R) with cold or discolored extremities without 
atrophic changes were present in 56% of the females, 22% had atrophic changes, 
and another 22% had normal color and temperature of the extremities. Genotype-
phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.16). However, age at examination 
could be a confounder, since the scores on this item did differ significantly between 
the different age groups (Chi-square test: p=0.004). Only 8% of the youngest fe-
males scored two on this item, in contrast to around 15% of the females older than 
20 years of age who scored zero on this item. 
Mood disturbances (item S) were reported in approximately half of the females, 
of whom 12% had prominent or disruptive agitation/ crying spells. Genotype-
phenotype analysis concerning this item showed that females did not differ 
significantly from each other comparing the different scores (0-1-2) and the differ-
ent groups of mutations (Chi-square test: p>0.06). Furthermore, age at examination 
did not seem to be a confounder, since the scores on this item did not differ 
significantly between the different age groups (Chi- square test: p=0.88). 
Sleep disturbances (item T) were present in half of the females, being promi-
nent in 16% of the females. Genotype-phenotype analysis concerning this item 
showed that females did not differ significantly from each other comparing the 
different scores (0-1-2) and the different groups of mutations (Chi-square test: 
p>0.21). Furthermore, age at examination did not seem to be a confounder, since 
the scores on this item did not differ significantly between the different age groups 
(Chi-square test: p=0.25). 
Lowest and highest scores. In Table 3 the lowest and highest scores concerning 
the recurrent MECP2 mutations are reported separately. The following mutations 
frequently scored the lowest score on the total, domain, and/or individual ISS score: 
p.R133C, CTS, p.R294X, and p.R306C. Females with a p.R133C mutation had the 
lowest total score. Females with a p.R133C or a CTS mutation had low scores in 
almost all domains. Females with a p.R294X had low scores on four individual items 
belonging to different domains of the ISS scoring list. Females with a p.R306C muta-
tion had low scores on several domains and items, but especially concerning the 
musculoskeletal and movement domain. In contrast to these mutations, the follow-
ing mutations frequently scored the highest score on the total, domain, and/or 
individual ISS score: p.P152R and p.R168X. Females with a p.P152R mutation had 
the highest total score and high scores in almost all domains. Females with a 
p.R168X had high scores on several domains and items, but especially concerning 
the musculoskeletal domain. At last, females with a p.R270X mutation scored high 
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on the domains growth and development and movement, but low on the autonom-
ic features domain. 
Discussion 
At present, conflicting results in genotype-phenotype studies are still under discus-
sion, partly due to the variability in classification of mutations, assessment tools, 
and structure of data sets. The aim of this study was to investigate relationships 
between genotype and specific clinical data in a well-documented RTT cohort of 137 
RTT females and evaluate its prognostic value in counseling young parents with a 
newly diagnosed RTT girl regarding her future outcome. In this study all RTT females 
were seen by the same experienced physician and had a MECP2 mutation. 
Clinical severity was defined using the ISS scoring list. Concerning location of the 
MECP2 mutation, an overall mild phenotype was confirmed in females with a muta-
tion in the CTS domain (Huppke et al., 2002; Colvin et al., 2004; Smeets et al., 2005; 
Neul et al., 2008; Smeets et al., 2009; Bebbington et al., 2010). In line with previous 
reports, these females were more likely to have a normal head circumference with 
more preserved cognitive functions, and hand skills were more likely to be retained 
(De Bona et al., 2000; Zappella et al., 2001; Huppke et al., 2002; Hoffbuhr et al., 
2002; Smeets et al., 2005; Bebbington et al., 2010). Scoring the frequency of muta-
tions regarding the lowest and highest scores on the total, domain, and individual 
items of the ISS scoring list, milder and severe phenotypes concerning recurrent 
mutations can be distinguished. In this way a milder phenotype was confirmed in 
females with a p.R133C, p.R294X, and p.R306C mutation and a severe phenotype in 
females with a p.R168X mutation (Leonard et al., 2003; Colvin et al., 2004; Schanen 
et al., 2004; Kerr & Prescott, 2005; Smeets et al., 2005; Neul et al., 2008; Bebbington 
et al., 2008; Smeets et al., 2009; Bebbington et al., 2010). In our study, females with 
a p.R133C mutation tend to have a late onset of stagnation (Bebbington et al., 2008) 
and less severe oro-motor difficulties. In females with a p.R294X mutation head 
circumference was less likely to decline during the first year of life. Hand skills were 
more likely to be retained both in females with a p.R294X and p.R306C mutation, as 
has already been reported by Bebbington and colleagues (Bebbington et al., 2008). 
Furthermore, females with a p.R306C mutation were less likely to have problems on 
the musculoskeletal and movement domain, which is in line with the already pub-
lished better walking ability in these females (Schanen et al., 2004). This is in con-
trast to females with a p.P152R mutation, who are more likely to have problems in 
the movement domain. Moreover, none of these females had a normal head cir-
cumference, all functioned on an infantile level of development and oro-motor 
difficulties tend to be more severe. Concerning females with a p.R168X mutation, 
our study confirms that they have an early onset of stagnation and are more likely 
to have problems in the musculoskeletal domain (Neul et al., 2008). At last, females 
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with a p.R270X mutation showed a contrasting phenotype. These females tend to 
have more severe problems in both the movement and growth and development 
domain, in contrast to less severe problems in the autonomic features domain. 
Overall, general genotype-phenotype relationships were confirmed. The 
strength of our study was the use of a well-defined group of RTT girls, by whom 
clinical data were collected by the same experienced physician in Rett syndrome. 
Only due to these strict inclusion criteria, our study is hampered by the small sam-
ple size. Both these factors could explain why we did not confirm a late onset of 
regression in females with a CTS, p.R294X, and p.R306C mutation, and a better hand 
use in females with a p.R133C mutation (Huppke et al., 2002; Smeets et al., 2005; 
Neul et al., 2008; Bebbington et al., 2010). On the other hand, we report in our 
study on females with a p.R133C mutation who tend to have less severe oro-motor 
difficulties and females with a p.R294X mutation whose head circumference was 
less likely to decline during the first year of life. Concerning gross motor function, 
we did not confirm a better walking ability in females with a CTS mutation (Neul et 
al., 2008; Bebbington et al., 2010). Besides above mentioned factors, this could also 
be explained by two other factors. First of all, in the ISS score no difference is made 
between females who lost their walking ability and those who never acquired walk-
ing. In our study normal gait was reported if a RTT female was able to walk inde-
pendently without any support. Furthermore, despite the fact that age did not seem 
to be a confounder analyzing the scores between the different age groups, only 9 of 
the 61 non-walkers were younger than 5 years of age. Concerning weight, females 
with a CTS mutation were reported to be more likely to have a normal weight 
(Bebbington et al., 2010). Since in our study the youngest females scored remarka-
bly lower than the females older than 10 years of age, age at examination could be 
a possible confounder. This is in accordance with previous studies, in which weight 
for height falls below the 5th centile at a later age (Schultz et al., 1993; Reilly & Cass, 
2001). Furthermore, we do not confirm the higher prevalence of scoliosis in females 
with a CTS mutation, as has been reported by others (Smeets et al., 2005). This can 
be explained by the age dependent factor as well as overall high prevalence scores 
in the total RTT population (Kerr et al., 2003; Halbach et al., 2008). The high preva-
lence scores could also explain why we did not confirm a better communication 
ability in females with a CTS, p.R133C and p.R306C mutation (Leonard et al., 2003; 
Schanen et al., 2004; Neul et al., 2008; Bebbington et al., 2010). Furthermore, the 
contrasting phenotype in females with a p.R270X mutation is in difference to oth-
ers, who report a p.R270X mutation causing an overall severe phenotype (Colvin et 
al., 2004; Charman et al., 2005; Leonard et al., 2005; Bebbington et al., 2008; 
Smeets et al., 2009). This most likely could be explained by the limited attention for 
autonomic features in previous studies. However, since the autonomic features are 
of great influence on the health status of RTT females and their families, one should 
pay special attention to this subject in the counseling of parents (Halbach et al., 
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2008; Julu et al., 2008). Furthermore, one should realize that scoring systems and 
‘‘bed- side’’ clinical evaluation are insufficient to determine the contribution of 
autonomic dysfunction to the clinical severity in individual cases. At last, in our 
study females with a p.P152R mutation had a severe phenotype, which has only 
been published before by Kondo & Yamagata (2002). This could be explained by the 
low prevalence of this mutation. 
The aim of this study was to investigate relationships between genotype and 
specific clinical data, and evaluate its prognostic value in counseling young parents 
with a newly diagnosed RTT girl regarding her future outcome. Despite the fact that 
all clinical data were collected by the same experienced physician, every mutation is 
still associated with a wide range of severity scores. This should be kept in mind 
when counseling parents. We suggest that the range of scores for the individual ISS 
items may be found to be helpful in advising the parents of a newly diagnosed Rett 
girl. In addition, we share the general opinion of others that XCI may still affect 
clinical severity; however XCI status is unlikely to be useful as a prognosticator for 
individual cases, with the exception of those with extreme skewing (Archer et al., 
2007). 
In conclusion, general genotype-phenotype relationships were confirmed. De-
spite the fact that all RTT females were seen by the same experienced physician, the 
clinical severity was still found to be very variable. Due to this variability, these rela-
tionships have limited prognostic value in counseling young parents with a newly 
diagnosed RTT girl regarding her future outcome. We therefore recommend caution 
in using genotype-phenotype data in the prognosis of outcome for children in Rett 
syndrome. Early diagnosis, early intervention, and preventive management 
measures are imperative for good outcomes and better quality of daily life for RTT 
females and their families. 
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Abstract 
Objective Many studies have attempted to establish the genotype-phenotype corre-
lation in Rett syndrome (RTT). Cardio-respiratory measurements provide robust 
objective data, to correlate with each of the different clinical phenotypes. It has 
important implications for the management and treatment of this syndrome. The 
aim of this study was to correlate the genotype with the quantitative cardiorespira-
tory data obtained by neurophysiological measurement combined with a clinical 
severity score.  
Methods This international multicenter study was conducted in four European 
countries from 1999 to 2012. The study cohort consisted of a group of 132 well-
defined RTT females aged between two and 43 years with extended clinical, mo-
lecular and neurophysiological assessments. Diagnosis of RTT was based on the 
consensus criteria for RTT and molecular confirmation. Genotype-phenotype anal-
yses of clinical features and cardiorespiratory data were performed after grouping 
mutations by the same type and localization or having the same putative biological 
effect on the MeCP2 protein, and subsequently on eight single recurrent mutations. 
Results A less severe phenotype was seen in females with CTS, p.R133C and 
p.R294X mutations. Autonomic disturbances were present in all females, and not 
restricted to nor influenced by one specific group or any single recurrent mutation. 
Interpretation The objective information from non-invasive neurophysiological 
evaluation of the disturbed central autonomic control is of greater importance in 
helping to organize the lifelong care for females with RTT. Further research is need-
ed to provide insights into the pathogenesis of autonomic dysfunction, and to de-
velop evidence-based management in RTT.  
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Introduction 
Rett syndrome (RTT) is a neurodevelopmental disorder affecting almost exclusively 
females. It is caused by mutations in the gene encoding the methyl CpG binding 
protein 2 (MECP2) (Hagberg et al., 1983; Amir et al., 1999). A unique pattern of 
neurological and behavioral symptoms appears over time (Julu et al., 2008). Most 
prominent are the abnormal breathing patterns, which is a consequence of devel-
opmental brainstem immaturity in this syndrome. Abnormal breathing is the most 
distressing and underestimated feature in many RTT females. It is a major determi-
nant of the quality of daily life of the female and her family, and has an important 
secondary socio-economic impact on the community (Julu & Witt Engerström, 2005; 
Smeets et al., 2006; Julu et al., 2008). Neurophysiological research has established 
three cardiorespiratory phenotypes in RTT (forceful, feeble and apneustic breath-
ers), and their clinical relevance (Julu & Witt Engerström, 2005; Smeets et al., 2006; 
Julu et al., 2008; Halbach et al., 2011; Julu et al., 2012).  
Many genotype-phenotype correlation studies have been published (Huppke et 
al., 2002; Leonard et al., 2003; Colvin et al., 2004; Schanen et al., 2004; Charman et 
al., 2005; Kerr & Prescott, 2005; Leonard et al., 2005; Smeets et al., 2005; Bebbing-
ton et al., 2008; Neul et al., 2008; Smeets et al., 2009; Bebbington et al., 2010; Hal-
bach et al., 2012; Bebbington et al., 2012). Some have specific but many have incon-
clusive results. These studies are based on clinical scoring lists and/or question-
naires and lack objective measurement of the clinical phenotype. Cardiorespiratory 
variables can be measured objectively in different clinical phenotypes, providing 
robust quantitative data for research. We believe that this has important implica-
tions for life long management and future treatment in RTT (Julu et al., 2008).  
The aim of this collaborative multicenter study is to correlate the RTT genotype 
with the quantitative cardiorespiratory data obtained by neurophysiological meas-
urement combined with a clinical severity score.  
Methods 
Ethical approval was obtained from the Medical Ethical Committee at the Maas-
tricht University Medical Center. 
Study design and participants 
This was an international multicenter study conducted in four European countries 
from 1999 to 2012. The six participating centers were: Tuscany Rett Center, Versilia 
Hospital (Lucca, Italy), Medical Genetic Unit, Ferrara University Hospital (Ferrara, 
Italy), the National Swedish Rett Center (Frösön, Sweden), the Rett Expertise Center, 
Maastricht University Medical Center (Maastricht, the Netherlands), Neurodegen-
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eration and Neuroinflamation at Imperial college (London, United Kingdom), and 
Institute of Neurological Sciences, Southern General Hospital (Glasgow, United 
Kingdom). 
The study cohort consisted of a group of 132 well-defined RTT females with ex-
tended clinical, molecular and neurophysiological assessment. These females were 
referred to one of the participating centers. Neurophysiological assessment was 
performed in Italy and Sweden, each examining 66 RTT females. Diagnosis of RTT 
was based on the consensus criteria for RTT (Hagberg et al., 2002; Neul et al., 2010). 
Only females with molecular confirmation were included. Males with MECP2 related 
disorders were excluded from this study.  
Molecular analysis of MECP2 
DNA analysis of MECP2 was performed by sequencing the coding exons and imme-
diately adjacent intronic regions. Additional Multiplex Ligation-dependent Probe 
Amplification analysis of MECP2 was done to identify large genomic rearrange-
ments. Nomenclature was according to the MECP2A isoform reference sequence 
NM_004992.3. Numbering started at the A of the ATG translation initiation codon. 
Mutations were classified by type and localization in the gene (Table 1). As to 
mutation type, they were classified as missense (single amino acid substitutions) 
and truncating mutations (nonsense mutations, frame shift mutations and large 
deletions/duplications). The following domains were included for mutation localiza-
tion: the N-Terminal domain (NT domain), the methyl-CpG- binding domain (MBD), 
the transcription repression domain (TRD) and the C-terminal segment (CTS).  
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Table 1 Mutation type and localization in MECP2 
  Domain → 
 
Type  
of mutation ↓ 
NT (n) MBD (n) TRD (n) CTS (n) Total 
Truncating p.M5fsX (1) p.D90fsX (1) p.R168X (12) p.T327fsX (1) 85 
(Nonsense, p.R9fsX (9) p.R111fsX (1) p.G237fsX (1) p.K347fsX (1)  
Frame shift,  p.N126fsX (1) p.G238fsX (1) p.A358fsX (1)  
Large Deletion)  p.Q128X (1) p.R255X (9) p.P362fsX (1)  
  p.Y141X (2) p.G269fsX (2) p.A378fsX (1)  
  p.K144fsX (2) p.R270X (11) p.L386fsX (11)  
   p.R294X (10) p.P388fsX (1) 
p.P389fsX (2) 
 
    p.S401fsX (1)  
    p.R453X (1)  
Missense  p.R106W (5) p.P225A (1)  47 
  p.R133C (14) p.P225R (1)   
  p.S134C (1) p.P302L (1)   
  p.K135G (1) p.R306C (8)   
  p.P152R (5)    
  p.D156E (2)    
  p.T158M (8)    
Total 10 44 57 21 132 
NT: N-Terminal segment, MBD: methyl-CpG-binding domain, TRD: transcription repression domain, CTS: 
C-terminal segment, n: number of patients (Nomenclature according to the MECP2A isoform reference 
sequence NM_004992.3) 
ISS scoring list 
In order to evaluate the clinical severity of the common features in RTT, a modified 
version of the International Scoring System was used (ISS, Table 2) (Kerr et al., 
2001). The clinical scoring system originally consisted of 20 items (ranging from A to 
T), which were scored from zero to two; the lower the score, the better the clinical 
condition. Based on the high prevalence of gastro-intestinal and bladder problems 
in females with RTT, an additional item concerning these problems was added in the 
adapted ISS (item U) (Giesbers et al., 2012). These 21 items were grouped into five 
functional domains: Growth and Development (A-E), Musculoskeletal (F-H), Move-
ment (I-L), Cortical (M-O), and Autonomic features (P-U). The oro-motor disturb-
ances were included in the Autonomic domain, according to Julu and Witt 
Engerström (2005).  
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Table 2 Modified version of the ISS scoring list ( Adapted from Kerr et al., 2001) 
International Scoring System 
GROWTH AND DEVELOPMENT 
A Head circumference during the first year 
 2 Already below the 3rd percentile at birth 
 1 Normal at birth but decelerating 
 0 Normal at birth with no deceleration 
B Early developmental progress (birth to 12 months) 
 2 No or virtually no progress 
 1 Suboptimal progress 
 0 Normal progress 
C Present head circumference - (percentile/standard deviations sd)  
 2 Below 3rd percentile 
 1 3rd to10th percentile  
 0 Above 10th percentile  
D Weight (kg) 
 2 Below 3rd percentile  
 1 3rd to10th percentile  
 0 Above 10th percentile  
E Height (cm) 
 2 Below 3rd percentile  
 1 3rd to10th percentile  
 0 Above 10th percentile 
MUSCULOSKELETAL 
F Muscle tone (also describe) 
 2 Severe hypotonia, dystonia or hypertonia  
 1 Tone mildly abnormal  
 0 Normal 
G Spine posture 
 2 Severe scoliosis  
 1 Mild scoliosis 
 0 No deviation 
H Joint contractures 
 2 Severe contractures 
 1 Minor contractures  
 0 None 
MOVEMENT 
I Gross motor function 
 2 Cannot walk with support  
 1 Walking impaired 
 0 Walks normally 
J Hand stereotypy (patting, squeezing, wringing, mouthing) 
 2 Dominating or constant 
 1 Mild or intermittent 
 0 None 
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International Scoring System 
K Other involuntary movements (e.g. tremor, dystonia, chorea, athetosis) 
 2 Dominating or constant  
 1 Mild or intermittent 
 0 None 
L Voluntary hand use (e.g. self-feeding) 
 2 None 
 1 Reduced or poor 
 0 Hand use normal 
CORTICAL 
M Intellectual disability (= learning disability, retardation) 
 2 Apparent profound (infant level) 
 1 Any except profound 
 0 No impairment 
N Speech 
 2 Currently uses no real words with meaning 
 1 Currently uses some real words with meaning 
 0 Normal speech 
O Epilepsy 
 2 Uncontrolled or poorly controlled 
 1 Previous epileptic seizures or well-controlled with medication 
 0 Never 
AUTONOMIC FEATURES 
P Oro-motor difficulty 
 2 Severe (eg. feeding aversion; gagging, choking, tube/button fed) 
 1 Slight (eg. delayed chewing, swallowing, on supplements) 
 0 None  
Q Disturbed awake breathing rhythm (e.g. hyperventilation, breath holding, panting) 
 2 Severe, with vacant spells & color changes 
 1 Mild, without vacant spells & color changes 
 0 Normal breathing pattern 
R Peripheral circulation of extremities 
 2 Cold or discolored with atrophic changes 
 1 Cold or discolored without atrophic changes 
 0 Normal color and temperature of extremities 
S Mood disturbance 
 2 Prominent or disruptive agitation / crying spells 
 1 Abnormally prone to agitation  
 0 Normal 
T Sleep disturbance 
 2 Prominent / disruptive day sleeping or night waking  
 1 Present, not prominent  
 0 Normal sleep pattern  
U Gastro-intestinal and bladder 
 2 Reflux oesophagitis, severe constipation or neurogenic bladder dysfunction 
 1 Gastrointestinal dysmotility without secondary complications  
 0 No signs of gastrointestinal dysmotility or difficulties to empty bowel or bladder 
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Neurophysiological assessment 
Autonomic monitoring of brainstem function was carried out using the Neuro-
ScopeTM (Medifit Instruments Ltd, London UK). This is a cortico-bulbar neurophysio-
logical method for monitoring brainstem autonomic functions and cortical activity 
simultaneously in real-time and synchronizing the various autonomic signs. The 
cardiovascular and respiratory vital signs we quantified and recorded are: cardiac 
vagal tone (CVT), heart rate (HR) and the rate and rhythms of the breathing move-
ments. Transcutaneous partial pressures of oxygen (pO2) and carbon dioxide (pCO2) 
representing blood gases were recorded continuously and synchronized with auto-
nomic function. Cortical activity was monitored using electroencephalography (EEG) 
and synchronized with autonomic function. A continuous video record time-locked 
with the physiological data was kept for behavioral analysis.  
Data analysis 
Data was collected from all centers into a unified, anonymous database. Clinician 
experts in RTT made the ISS scoring list. Baseline brainstem functions were meas-
ured during normal breathing without agitation, with normal blood gases (pCO2 and 
pO2) and in the absence of epileptiform activity on EEG. 
The genotype-phenotype analyses were performed after grouping together all 
mutations of similar types, localizations or putative biological effect on the MeCP2 
protein. Consequently, mutations were then subdivided into the following five 
groups: 1) truncating mutations in the NT and MBD domain, causing loss of function 
or disruption of the two functional domains MBD and TRD; 2) missense mutations in 
the MBD domain, giving rise to a modified or non-functional MBD; 3) truncating 
mutations in the Interdomain and TRD, causing a loss of functional TRD; 4) missense 
mutations in TRD giving rise to a modified or non-functional TRD; 5) small trunca-
tions in the CTS leading to protein with an altered C-terminus. A further separate 
genotype-phenotype analysis was performed on eight recurrent mutations, defined 
as mutations present in at least 5% of the RTT females in this cohort (Table 3).  
We used descriptive statistics to analyses mutation types, ISS scores, and cardi-
orespiratory data including Valsalva’s manoeuvre type of breathing (Valsalva 
breathing). Linear regression analysis was used to analyze the relationships among 
ISS scores (total and functional domain scores), CVT, HR, and mutation groups or 
recurrent mutations. Checks for the normality assumption were done employing Q-
Q plots. If the normality assumption was in doubt, the analyses were done by ordi-
nal logistic regression. Relationships among cardiorespiratory phenotypes, Valsalva 
breathing (present or absent) and mutation groups or recurrent mutations, were 
examined using nominal logistic regression. The mutation groups and the recurrent 
mutations were used as predictor variables through dummy coding in the regression 
analyses. Since age may be a confounding factor for the ISS scores and HR, this vari-
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able was included as an extra predictor for these outcomes. First a statistical test 
was done to check whether there was a relation between mutation groups or recur-
rent mutations and the outcome in question. If present, it was re-examined in a 
pairwise fashion to determine which groups differed from each other with respect 
to the outcome variable. The level of statistical significance for all tests was set to a 
probability value of ≤ 0.05, and all analyses were carried out using SPSS18. 
 
Table 3 Recurrent mutations including number and percentage of RTT females 
Recurrent mutation Number of RTT females Percentage of RTT females 
p.R133C 14 11% 
p.T158M 8 6% 
p.R168X 12 9% 
p.R255X 9 7% 
p.R270X 11 8% 
p.R294X 10 8% 
p.R306C 8 6% 
C-terminal deletions 21 16% 
Total 93 70% 
Results 
The age of the RTT females ranged between two and 43 years (mean age: 12.46 
years, sd=9.36). According to the clinical criteria, 74% (n=98) of the females were 
typical RTT and 26% (n=34) atypical RTT.  
Mutation analysis 
MECP2 mutations were classified by mutation type, localization and putative pro-
tein function, as shown in Table 1. Truncating mutations were present in 64% (n=85) 
and missense mutations in 36% (n=47). 43% had a mutation affecting the TRD 
(n=57), whereas 41% (n=54) had a mutation affecting the MBD. The mutations local-
ized in the MBD were predominantly missense mutations (82%), while those affect-
ing in the TRD were mostly truncating (81%). Half of the truncating mutations, af-
fecting both the MBD and TRD, were due to a large deletion of both exon 3 and 
most of the coding part of exon 4. 16% (n=21) displayed a truncating mutation in 
the CTS leading to an extensive replacement of the C-terminus, which is likely to 
have an unfavorable effect on the natural protein function due to its putative effect 
on protein structure. 
Table 3 shows the recurrent mutations included in this study, together compris-
ing 70% of the pathogenic mutations in this cohort.  
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ISS scoring list 
The mean severity score on the ISS scoring list was 20.7 points (range 2-36, 
sd=7.59). Separating the scores into the functional domains, the mean scores were: 
Growth and Development, 3.79 points (range 0-8, sd=2.42); Musculoskeletal, 2.54 
points (range 0-6, sd=1.84); Movement, 4.76 points (range 1-8, sd=1.59); Cortical, 
4.10 points (range 1-6, sd=1.37); Autonomic, 5.53 points (range 0-12, sd=2.59) re-
spectively.  
Cardiorespiratory status of the RTT cohort 
49% were diagnosed as feeble breathers (n=65), 41% as forceful (n=54), and 10% as 
apneustic (n=13). Valsalva breathing was present in 62% (n=82), and occurred in all 
three cardiorespiratory phenotypes. We assessed both sympathetic and parasympa-
thetic functions of the autonomic nervous system by measuring HR and CVT of 
these females. HR varied between 66 and 172 beats/min (mean rate=99.2, sd=17.4). 
Mean CVT was 4.50 (range 0.9-13.9, sd=2.53). 
Genotype-phenotype analysis 
Clinical severity 
Total ISS score 
The total ISS score did differ significantly between the different mutation groups 
(F(df1=4, df2=126)=3.02, p=0.02). Females with a CTS mutation scored significantly 
lower than females with a mutation in the NT domain or nonsense mutation in the 
MBD (t=2.53, p=0.01), and with a nonsense or missense mutation in the TRD (re-
spectively t=3.22, p<0.01 and t=2.31, p=0.02).  
The total ISS score also differed significantly between the different recurrent 
mutations (F(df1=7, df2=83)=4.47, p<0.001). Females with a p.R133C, p.R294X or 
CTS mutation scored significantly lower than females with a p.T158M (t=2.32-2.57, 
p=0.01-0.02), p.R168X (t=2.70-2.92, p<0.01), p.R255X (t=3.54-3.70, p<0.001-0.01), 
p.R270X (t=2.55-2.79, p=0.01), or p.R306C mutation (t=2.05-2.35, p=0.02-0.04). 
Growth and Development domain 
The ISS score in the Growth and Development domain did differ significantly be-
tween the different mutation groups (F(df1=4,df2=126)=3.22, p=0.02). Females with 
a CTS mutation scored significantly lower than females with a mutation in the NT 
domain or nonsense mutation in the MBD (t=3.00, p<0.01), missense mutation in 
the MBD (t=2.53, p=0.01), and nonsense or missense mutation in the TRD (respec-
tively t=2.92, p<0.01 and t=2.76, p<0.01). 
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The ISS score also differed significantly between the different recurrent mutations 
(F(df1=7, df2=83)=4.57, p<0.001). Females with a p.R294X or CTS mutation scored 
significantly lower than females with a p.T158M (t=3.08, p<0.01 and t=2.89, p<0.01 
respectively); p.R168X (t=2.31, p=0.02 and t=2.03, p=0.05 respectively), p.R255X 
(t=3.88, p<0.001 and t=3.84, p<0.001 respectively), p.R270X (t=3.10, p<0.01 and 
t=2.93, p<0.01 respectively) or p.R306C mutation (t=3.00, p<0.01 and t=2.78, p<0.01 
respectively). Also females with a p.R133C mutation scored significantly lower than 
females with a p.T158M mutation (t=2.00, p=0.05) or p.R255X mutation (t=2.84, 
p=0.01).  
Musculoskeletal domain  
The ISS score in the Musculoskeletal domain did not differ significantly among the 
different mutation groups (F(df=4)=9.42, p=0.051), but did differ significantly among 
the different recurrent mutations (F(df=7)=15.00, p=0.04). Females with a p.R133C 
or p.R294X mutation scored significantly lower than females with a p.T158M 
(F(df=1)=12.23, p<0.001 and F(df=1)=9.39, p<0.01 respectively), p.R168X 
(F(df=1)=13.44, p<0.001 and F(df=1)=10.00, p<0.01 respectively), p.R255X 
(F(df=1)=14.83, p<0.001 and F(df=1)=11.47, p=0.001 respectively), p.R270X 
(F(df=1)=9.19, p<0.01 and F(df=1)=6.64, p=0.01 respectively) or p.R306C mutation 
(F(df=1)=5.86, p=0.02 and F(df=1)=4.11, p=0.04 respectively). Also females with a 
CTS mutation scored significantly lower than females with a p.T158M (F(df=1)=5.84, 
p=0.02), p.R168X (F(df=1)=6.38, p=0.01) or p.R255X mutation (F(df=1)=7.89, 
p=0.01). 
Movement domain 
The ISS score in the Movement domain did not differ significantly among the differ-
ent mutation groups (F(df1=4,df2=126)=1.27, p=0.29) or recurrent mutations 
(F(df1=7,df2=83)=1.55, p=0.16).  
Cortical domain  
The ISS score in the Cortical domain did not differ significantly among the different 
mutation groups (F(df1=1,df2=5)=12.78, p=0.21) or recurrent mutations 
(F(df1=1,df2=8)=14.83, p=0.34).  
Autonomic domain  
The ISS score in the Autonomic domain did not differ significantly among the differ-
ent mutation groups (F(df1=4,df2=126)=2.11, p=0.08) or recurrent mutations 
(F(df1=7,df2=83)=1.93, p=0.08).  
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Autonomic assessment 
Cardiorespiratory phenotype 
There was no significant correlation between cardiorespiratory phenotype and 
groups of mutations (χ2(df=8)=4.77, p=0.78). Excluding the apneustic breathers for 
the analysis did not change these results (χ2(df=4)=3.37, p=0.50). 
Also no significant correlation was seen among the cardiorespiratory pheno-
types and recurrent mutations (χ2(df=14)=13.42, p=0.49). Excluding the apneustic 
breathers for this analysis also did not change these results (χ2(df=7)=8.91, p=0.26).  
Valsalva manoeuvre type of breathing 
There was no significant correlation among the presence and absence of Valsalva 
breathing and the groups of mutations (χ2(df=4)=2.50, p=0.64) or recurrent muta-
tions (χ2(df=7)=10.81, p=0.15). 
Cardiac Vagal Tone (CVT) 
There was no significant correlation between CVT and the groups of mutations 
(F(df1=4, df2=126)=2.40, p=0.06) or recurrent mutations (F(df1=7, df2=83)=1.17, 
p=0.33).  
Heart rate (HR) 
There was no significant correlation between HR and the groups of mutations 
(F(df1=4, df2=126)=0.29, p=0.88) or recurrent mutations (F(df1=7, df2=83)=0.31, 
p=0.95).  
Discussion 
This multicenter study was the result of an international collaborative network set 
up to create a database with sufficient numbers of robust clinical, molecular and 
neurophysiological data for further analyses. The grouping of the mutations in 
MECP2 was based on the putative biological effects of these mutations on the 
MeCP2 protein as explained in our Methods. Despite the minor methodological 
differences, the clinical severity and general genotype-phenotype results were simi-
lar to those in previous studies. We used a modified version of the internationally 
accepted clinical scoring system (Kerr et al., 2001) to quantify the effects of RTT on 
growth, development and other bodily dysfunctions in our genotype-phenotype 
analyses. The ISS provided us with a form of quantifiable clinical severity of the 
various bodily dysfunctions in this RTT cohort, which indeed is comparable with 
previous research (Bebbington et al., 2008; Halbach et al., 2012). We have elucidat-
ed a less severe clinical phenotype in females with CTS, p.R133C or p.R294X muta-
tions (Huppke et al., 2002; Leonard et al., 2003; Colvin et al., 2004; Charman et al., 
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2005; Kerr & Prescott, 2005; Leonard et al., 2005; Smeets et al., 2005; Bebbington et 
al., 2008; Neul et al., 2008; Smeets et al., 2009; Bebbington et al., 2010; Halbach et 
al., 2012; Bebbington et al., 2012). However, clinical severity varies even within one 
specific type or group of mutations (Halbach et al., 2012). It means genotypes have 
very limited use for clinical management in RTT.  
The main reason for conducting this study was to evaluate the influence of 
MECP2 mutation on brainstem instability, which includes breathing dysrhythmia, so 
characteristic of RTT. Breathing dysrhythmia is a major reason for seeking medical 
attention and for secondary referral of persons with RTT (Julu & Witt Engerström, 
2005; Smeets et al., 2006; Julu et al., 2008). Cardiorespiratory data must be ob-
tained using objective and quantitative neurophysiological measurements of brain-
stem functions, because clinical management of brainstem autonomic dysfunction 
in RTT is a profound challenge. Each cardiorespiratory phenotype requires a unique 
and specific clinical approach (Julu et al., 2008). In this cohort of RTT females, up to 
49% were feeble breathers, 41% were forceful breathers and 10% were apneustic 
breathers. There is some but little difference in the distribution of the three cardi-
orespiratory phenotypes in this cohort compared with that previously reported (Julu 
& Witt Engerström, 2005). This cohort of RTT confirms that Valsalva breathing is a 
common complication of breathing dysrhythmia in RTT, affecting all three cardi-
orespiratory phenotypes as previously reported (Julu & Witt Engerström, 2005). The 
wildcat excitatory effects of Valsalva’s manoeuvres on the autonomic nervous sys-
tem in general and other brainstem functions can cause clinical deterioration in RTT 
(Julu & Witt Engerström, 2005). Detailed correlation analyses of the cardiorespirato-
ry data showed that the cardiorespiratory phenotypes in RTT are not influenced by 
genetic mutations. This provides further proof that cardiorespiratory phenotypes 
are more important for clinical management in RTT than the genetic mutations. 
The baseline brainstem functions were severely affected in all RTT females simi-
lar to the results in previous studies (Julu et al., 1997; Julu et al., 2001; Julu & Witt 
Engerström, 2005). The mean CVT in this cohort was lower than the normal mean 
value in young adults (Julu, 1992). Since CVT is the only central inhibitory output to 
the heart, it is very important in brainstem cardiorespiratory integration (Guyenet 
et al., 1996). Its role in rapid cardiovascular responses is very important and it is a 
major contributor to integrative inhibition within the cardiovascular system (Guy-
enet et al., 1996). The HR values in this cohort were within the normal limits for the 
age group. It implies that the resting sympathetic tone is within normal limits (Julu 
et al., 1997), and not exaggerated above normal as previously thought (Naidu et al., 
1987). This normal but unrestrained sympathetic tone due to little or no parasym-
pathetic negative feedback is the cause of a type of sympatho-vagal imbalance 
unique to RTT. This may contribute to the increased sudden deaths of up to 26% of 
females with RTT, compared with only 2.3% in the general population of the same 
age range (Kerr et al., 1997; Hagberg et al., 2001). The discussion above and the 
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high ISS score in the Autonomic domain both reflect the great impact of brainstem 
dysfunction on the clinical severity in RTT. We provide here sufficient reasons for 
carers of persons with RTT to seek medical attention starting early in childhood. This 
is because ‘‘bedside’’ clinical evaluation including ISS scoring cannot determine the 
contributions of autonomic dysfunction to the clinical severity in individual cases 
(Halbach et al., 2012). In persons with RTT, objective quantitative clinical and neu-
rophysiological assessment must be done early after diagnosis or promptly follow-
ing the onset of brainstem autonomic symptoms. This is necessary in order to plan a 
better and effective clinical management strategy for the RTT person (Julu et al., 
2005; Julu et al., 2008). 
In conclusion, this is the first study to use objective and robust data of cardi-
orespiratory variables in the investigation of genotype-phenotype correlation in 
RTT. All females with RTT had dysautonomia, and this was not restricted to nor 
influenced by one specific group or single recurrent mutation. The clinical variability 
within a specific genetic mutation or within a similar group of mutations makes 
genotype-phenotype correlations impossible and renders the genetic mutations of 
limited use in clinical management of RTT. The robust and objective information 
obtained from non-invasive neurophysiological evaluation of the brainstem auto-
nomic functions is of much greater importance and it helps to organize the lifelong 
care for persons with RTT. Although considerable progress is being made in under-
standing the mechanisms of autonomic dysfunction in RTT (Weese-Mayer et al., 
2006; Rohdin et al., 2007; Julu et al., 2008; Katz et al., 2009), further research is 
needed for a better understanding of the pathogenesis of autonomic dysfunctions 
in this syndrome. This will facilitate future development of evidence-based man-
agement strategies in RTT. 
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Abstract  
Despite their good appetite, many females with Rett syndrome (RTT) meet the crite-
ria for moderate to severe malnutrition. Although feeding difficulties may play a 
part in this, other constitutional factors such as altered metabolic processes are 
suspected. Irregular breathing is a common clinical feature, leading to chronic res-
piratory alkalosis or acidosis. We assumed that these changes in intracellular pH 
cause disturbances in the metabolic equilibrium, with important nutritional conse-
quences. The study population consisted of a group of thirteen well-defined RTT 
girls with extended clinical, molecular and neurophysiological assessments. Despite 
normal levels of total dietary energy and protein intakes, malnutrition was con-
firmed based on significantly low fat-free mass index (FFMI) values. Biochemical 
screening of multiple metabolic pathways showed significantly elevated plasma 
creatine concentrations and increased urinary creatine/creatinine ratio in five RTT 
girls. Four girls, 10 years and older, were forceful breathers, one 13-year-old girl had 
an undetermined cardiorespiratory phenotype. An isolated increase of the urinary 
creatine/creatinine ratio was seen in two girls, a 9-year-old forceful and a 4-year-old 
feeble breather. Given that the young girls are feeble breathers and the older girls 
are forceful breathers, it is impossible to determine whether the elevated creatine 
concentrations are due to increasing age or cardiorespiratory phenotype. Further-
more, MeCP2 deficiency may cause epigenetic aberrations affecting the expression 
of the creatine-transporter gene, which is located at Xq28. Further studies are re-
quired to confirm these findings and to provide greater insight into the pathogene-
sis of the abnormal creatine metabolism in RTT. 
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Introduction 
Rett syndrome (RTT; OMIM 312750) is a unique X-linked neurodevelopmental dis-
order. Affecting 1 in 10,000 females, RTT is a common genetic cause of severe intel-
lectual disability in females (Smeets & Schrander-Stumpel, 2005; Williamson & 
Christodoulou, 2006). In up to 95% of all classical cases, RTT is caused by a mutation 
in the methyl-CpG-binding protein 2 gene (MECP2) located on the long arm of the X 
chromosome (Xq28) (Amir et al., 1999; Williamson & Christodoulou, 2006). 
Despite their good appetite, the majority of the females with RTT meet the cri-
teria for moderate to severe malnutrition. However, not all RTT females present in 
this manner (Rice & Haas, 1988). The true prevalence of malnutrition in RTT is un-
known, and the pathological mechanism underlying is barely understood. Although 
feeding difficulties may play a role, other constitutional factors such as altered met-
abolic processes are suspected (Motil et al., 1998; Oddy et al., 2007; Reilly & Cass, 
2001). 
Irregular breathing is a common clinical feature of RTT, reflecting the immaturi-
ty of the brainstem in these females. The underlying pathophysiology involves a 
defective control mechanism of carbon dioxide exhalation, leading to chronic res-
piratory alkalosis or acidosis (Julu et al., 2008a; Julu et al., 2001; Smeets & Schrand-
er-Stumpel, 2005). This change in pH might cause disturbance of the metabolic 
equilibrium in RTT females, with potential consequences for their nutritional status. 
Hitherto, no systematic studies on altered metabolic processes as a cause of 
impaired nutritional status in RTT have been carried out. The objective of this study 
was to examine whether chronic respiratory acidosis or alkalosis leads to disturbed 
metabolic profiles and enzyme activities in multiple metabolic pathways. 
Patients and methods 
Ethical approval was obtained from the Medical Ethical Committee at the Maas-
tricht University Medical Centre, and all parents provided informed written consent. 
The study was registered at clinicaltrials.gov. 
Patient population 
The patient population consisted of a group of thirteen well-defined RTT girls with 
extended clinical, molecular and neurophysiological assessment. This assessment 
consisted of: 
1. Clinical examination comprising a full physical examination including measure-
ment of height, weight and Body Mass Index (BMI). In addition, clinical features 
were scored uniformly using the International Scoring System (ISS) (Kerr et al., 
2001). The ISS is used to determine clinical severity concerning 20 items (maxi-
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mum score being 40), grouped into five functional domains (growth and devel-
opment, musculoskeletal, movement, cortical and autonomic features). 
2. Mutation analysis of MECP2 by PCR, sequencing the coding regions and multi-
plex ligation-dependent probe amplification analysis (nomenclature according to 
the MECP2A isoform reference sequence AF158180, numbering starting at the A 
of the ATG translation initiation codon). 
3. Detailed neurophysiological assessment using the Neuroscope, a technique for 
continuous and real-time assessment of brainstem function to define the cardi-
orespiratory phenotype (Julu & Engerström, 2005). The different cardiorespira-
tory phenotypes (Apneustic, Feeble, and Forceful breathers) in RTT have been 
described in detail elsewhere (Julu et al., 2008a, b). 
Diagnosis of RTT was based on the consensus diagnostic criteria for RTT and con-
firmed by mutation finding in MECP2 (Hagberg et al., 2002). All girls were diagnosed 
as classical RTT. 
Study design 
The RTT girls were recruited at the Clinical Genetics outpatient clinic at the Maas-
tricht University Medical Centre, the Netherlands. All participants were clinically 
assessed by the same experienced clinician (Dr. E. Smeets). The nutritional status 
was assessed by a complete nutrition assessment and measurement of body com-
position. Blood and urine samples were collected for biochemical analysis and 
stored at -20°C until analysis after the appropriate workup. 
Nutritional status 
Dietary intake was assessed using a standardized format including two 3-day food 
records. Parents were instructed to record all foods and beverages consumed on 
three subsequent days, including one weekend day. The timing of the first 3-day 
record period was prior to the blood sampling, and the second period was recorded 
approximately 6 months later. The amount of liquid and the size of food portions 
offered and actually consumed at each meal were reported in household measures. 
Energy and nutrient intake was calculated using the Dutch food composition table 
(NeVo, version 06) and the software Komeet® (BaS Nutrition Software, Arnhem).  
In addition to the food records, a semistructured interview was administered to 
the parents to specify usual dietary intakes, eating abilities, and food preferences.  
Body composition was measured using the Deuterium dilution method accord-
ing to the Maastricht protocol (Westerterp et al., 1995). A random urine sample was 
used to determine the background isotope level before the administration of a D2O 
mixture. At least 6 h after administration of a D2O dose (per oz or through a PEG 
catheter), a urine sample was taken from the second voiding. Fat-free mass (FFM) 
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was then calculated from total body water (TBW) using the child-specific hydration 
factors published by Lohman (Lohman, 1989). Subsequently, FFM was divided by 
squared height to calculate the fat-free mass index (FFMI; kg/height(m)2). Malnutri-
tion was defined as an FFMI below the fifth percentile (or -2 SD) for age and gender 
(VanItallie et al., 1990; Schutz et al., 2002). 
Metabolic measurements 
Routine chemistry and hematology were carried out, as proposed by the Frösö Dec-
laration and included full blood count, total protein, albumin, protein electrophore-
sis, urea, creatinine, electrolytes such as Na+/K+/Ca2+/Cl-/PO4. Liver function tests 
were only done if specifically indicated (Julu et al., 2008b).  
In addition, the metabolic screening program as shown in Table 1 was carried 
out to identify markers pointing toward possible consequences of an altered carbon 
dioxide metabolism. In view of the specific breathing irregularities in combination 
with feeding problems, one would expect changes in the “intermediate metabo-
lism” including metabolism of glucose, glycogen, amino acids/proteins, and fatty 
acids. Short- and long-term changes due to, for example, a specific nutritional status 
are reflected in amino acid profiles in urine and plasma, acylcarnitine profiles in 
plasma (to also exclude a fatty acid oxidation defect or organic acidurias) and excre-
tion of metabolites (organic acids) in urine (organic acid excretion profile).  
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Table 1 General overview of selective metabolic screening including matrix and methodology 
Analysis Matrix Methodology 
Amino acid analysis Urine, plasma LC-MS/MS 
Organic acid analysis Urine, plasma GC-MS, silylated 
Purines and pyrimidines Urine, plasma LC-MS/MS 
Guanidinoacetate and creatine Urine, plasma LC-MS/MS 
Phenolic compounds Urine HPLC-fluorescence 
Acylcarnitine profiling Plasma MS/MS 
Very-long chain fatty acids Plasma LC-MS/MS 
Sialotransferrines Plasma Isoelectric focusing 
Methylmalonate Plasma LC-MS/MS 
Homocysteine Plasma LC-MS/MS 
Adenosine Deaminase activity Erythrocytes HPLC-UV 
Adenine Phosphoribosyltransferase activity Erythrocytes HPLC-UV 
Hypoxanthine Phosphoribosyltransferase activity Erythrocytes HPLC-UV 
Inosine triphosphatase activity Erythrocytes HPLC-UV 
Nucleotide profile Erythrocytes HPLC-UV 
α-Galactosidase A activity Leukocytes Fluorescence 
LC-MS/MS Liquid Chromatography with Tandem Mass Spectrometry, GC-MS Gas chromatography-mass 
spectrometry, HPLC High-performance liquid chromatography, MS/MS Tandem mass spectrometers, 
HPLC-UV High-Pressure Liquid Chromatography with UV Detector 
Statistical analysis 
Using SPSS version 15.0, frequency tables including percentages were obtained for 
the variables “MECP2-mutation”, “cardiorespiratory phenotype”, and “anthropome-
try data”. Concerning age, mean values and standard deviation were calculated. 
Regarding ISS scores, both frequency tables and mean scores were calculated. 
Results 
Patient characteristics 
Patient characteristics are presented in Table 2. 
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Table 2 The clinical characteristics of the RTT girls 
RTT 
girl 
Age 
(yr.month) 
Height  
(cm+p) 
Weight  
(kg+p) 
Head  
circumference 
(cm+p) 
BMI  
(kg/m2+p) 
ISS MECP2  
mutationa 
CRPh tcpCO2 
(mmHg) 
1 2.4 85 (p2) 11.3 (p10) 45 (p2) 15.6 (p25) 14 p.R255X FeB 43.3 
2 3.11 98 (p50) 16 (p25) 48.5 (p25) 16.7 (p50) 8 p.T158M FeB 48.2 
3 4.0 107 (p70) 14.5 (p10) 50.5 (p50) 12.7 (p2) 8 p.R294X FeB 52.3 
4 4.3 103 (p50) 20.5 (p98) 47 (p2) 19.3 (p98) 21 fs710dupG FeB 50.6 
5 5.3 112 (p50) 19 (p50) 49 (p25) 15.2 (p50) 20 p.R270X FeB 40.9 
6 6.2 113 (p25) 18 (p25) 49 (p25) 14.3 (p25) 9 p.R306C FoB 22.3 
7 9.8 120 (<p2) 20.5 (p2) 51 (p25) 14.2 (p10) 20 fs705delG FoB 15.5 
8 9.8 132 (p2) 26.4 (p10) 49.5 (p2) 15.2 (p25) 20 p.P152R FoB 25.8-42.0
9 10.11 127 (<p2) 24.5 (p2) 50.5 (p25) 15.2 (<p2) 26 p.R106W FoB 15.5 
10 13.3 148 (p2) 31.7 (p2) 50 (<p2) 14.5 (p2) 23 p.R294X FoB 10.5-22.5
11 13.11 148 (<p2) 54 (p75) 54 (p50) 24.7 (p98) 27 c.1158del55 Und 35.2 
12 19.3 171 (p50) 65 (p75) 52 (p3) 22.3 (p50) 24 p.R306C FoB 20.8 
13 20.3 150 (<p2) 43 (p2) 53 (p25) 19.1 (p2) 24 p.R168X FoB N.A. 
p percentile, ISS total ISS score, CRPh Cardiorespiratory phenotype, FeB Feeble breather, FoB Forceful 
breather, Und Undetermined, tcpCO2 transcutaneous pCO2 (reference values 38-44 mmHg), N.A. Not 
acquired a Nomenclature according to the MECP2A isoform reference sequence AF158180, numbering 
starting at the A of the ATG translation initiation codon 
Age 
The ages of RTT girls ranged from 2 years and 4 months to 20 years and 3 months 
(mean age 9 years and 5 months, sd=5 years and 11 months). 
Anthropometry 
Mean height, weight, BMI, and head circumference scores of RTT girls were below 
that of their age group. The height of 54% of the RTT girls was below the fifth per-
centile, of which 86% were 9 years or older. Regarding BMI, 31% of the girls were 
below the fifth percentile and two girls had a BMI over the 50th percentile. Regard-
ing age, low BMI was present in 75% of those 9 years and older. 
ISS score 
Mean ISS scores for the RTT girls was 18.8 (range: 8-27, sd=6.78). Severe RTT (score 
25-29) was present in two girls, mild to less severe RTT (score 10-24) in eight and 
very mild RTT (score below 10) in three girls. Severe RTT was only seen in girls 9 
years and older and very mild scores only in those younger than 9 years. Mean 
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score of the girls younger than 9 years was 13.3 (range: 8-21, sd=5.99), compared to 
23.4 (range: 20-27, sd=2.70) in those 9 years and older. 
Mutation analysis 
Both missense and nonsense mutations in MECP2 were each observed in five girls. 
Of these mutations, four were located in the methyl-CpG binding domain and six in 
the transcription repression domain. Two girls had a frameshift mutation and only 
one girl had a CTS deletion. In view of the variety in mutations, no differences con-
cerning other patient characteristics could be observed. 
Cardiorespiratory phenotype 
Of the 13 girls included in this study, five girls were feeble breathers, seven girls 
were forceful breathers, and one girl had an undetermined cardiorespiratory phe-
notype. Remarkably, all feeble breathers were below 5 years of age and all forceful 
breathers were 6 years and older. Furthermore, Table 2 shows the tcpCO2 values 
measured during the Neuroscope assessment. As one can see, overall feeble 
breathers show high tcpCO2 levels in contrast to forceful breathers who show low 
tcpCO2 levels. 
Nutritional status 
Results on dietary intakes and body composition are presented in Table 3 
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Table 3 Nutritional status of the RTT girls including age-specific and lifestyle adjusted recommended / 
reference values 
RTT girl Dietary energy  
(kcal/day) 
Protein 
(gm/kg/day) 
FFMI 
(kg/l2) 
1 1,179 (800) 3.0 (>0.9) 11.94 (unknown) 
2 1,222 (800) 2.4 (>0.9) 12.71 (unknown) 
3 1,920 (1,120) 4.5 (>0.9) N.A. 
4 1,150 (1,120) 2.3 (>0.9) 9.62 (unknown) 
5 1,189 (1,120) 2.1 (>0.9) 9.12 b (11.7-15.7) 
6 1,010 a (1,120) 1.3 (>0.9) 11.48 b (11.7-15.7) 
7 1,137 (1,120) 2.4 (>0.9) 11.60 b (11.7-15.7) 
8 1,222 (1,120) 1.9 (>0.9) 10.34 b (11.7-15.7) 
9 1,710 (1,680) 2.2 (>0.9) 12.05 b (11.7-15.7) 
10 1,828 (1,680) 1.6 (>0.9) 10.46 b (13.2-17.2) 
11 895 a (1,680) 1.2 (>0.9) 11.23 b (13.2-17.2) 
12 1,893 (1,680) 0.9 (>0.8) 12.29 b (13.8-17.6) 
13 1,630 a (1,680) 1.5 (>0.8) 12.18 b (13.8-17.6) 
FFMI Fat-free mass index, N.A. Not acquired 
a Low dietary energy compared to the recommended values 
 b FFMI value < 2 SD or p5 (Freedman et al., 2005; Schutz et al., 2002) 
 
Dietary intakes 
Dietary intakes were evaluated and compared to age-specific standards for an inac-
tive lifestyle, by which the normal values were adjusted to 80% of the recommend-
ed values for healthy girls. Overall, the total daily dietary energy was reasonably 
normal in the RTT girls, as the mean dietary intake was 117% of the adjusted rec-
ommended values. Almost 77% of the RTT girls met these adjusted recommended 
values. Only three girls had a dietary energy intake below these values, respectively, 
of 90%, 53%, and 97% of the recommended values. The RTT girl having a dietary 
energy intake of only 53% of the recommended values had a BMI at the 98th per-
centile and she was on a strict diet.Protein intake in all patients was above the age-
specific recommended values. 
 Prior to blood and urine sampling, no specific nutrients were consumed which 
could influence the metabolic investigations as has been described by Arias and 
colleagues (Arias et al., 2007). 
Body composition 
As one can see in Table 3, 9 RTT girls confirm the definition of malnutrition, defined 
as an FFMI below the fifth percentile (or -2 SD) for age and gender. Since reference 
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values for girls younger than 5 years of age are not available, one cannot confirm 
malnutrition in these younger girls. 
Metabolic investigations 
As shown in Table 4, significantly elevated plasma creatine concentrations and in-
creased urinary creatine/creatinine ratios were observed in five RTT girls. An isolat-
ed increase of the urinary creatine/creatinine ratio was seen in two girls. The creati-
nine plasma concentrations were relatively low in all RTT girls. The slightly elevated 
guanidinoacetate concentrations observed in three females are not clinically rele-
vant, since they do not meet the criteria of a guanidinoacetate methyltransferase 
deficiency (Stromberger et al., 2003). An elevated CK concentration was seen in a 
girl with normal creatine concentrations. Other metabolic investigations (Table 1) 
showed no abnormalities. 
 
Table 4 Creatine metabolism in RTT girls including age-specific reference values 
RTT girl Cr plasma  
(µmol/l) 
Cr/Crn urine 
(mmol/mol) 
Crn plasma 
(µmol/l) 
CK (U/L) GAA plasma 
(µmol/l) 
GAA/Crn urine 
(mmol/mol) 
1 75.7 (17-109) 490.6 (6-1,200) 29.7 b (35-62) 73 (<140) 1.1 (0.35-1.8) 116.2 (4-220) 
2 79.5 (17-109) 421.3 (6-1,200) 27.0 b (35-62) 79 (<140) 2.1 a (0.35-1.8) 102.3 (4-220) 
3 88.1 (17-109) N.A. 30.7 b (44-71) 77 (<140) 1.6 (0.35-1.8) N.A. 
4 81.0 (17-109) 828.8 a (17-720) 28.0 b (44-71) 49 (<140) 1.2 (0.35-1.8) 76.8 (4-220) 
5 83.5 (17-109) 28.6 (17-720) 34.4 b (44-71) 44 (<140) 1.4 (0.35-1.8) 26.8 (4-220) 
6 63.0 (17-109) 629.7 (17-720) 28.8 b (44-71) 285 a (<140) 1.2 (0.35-1.8) 56.7 (4-220) 
7 52.9 (17-109) 756.2 a (17-720) 43.6 b (44-80) 104 (<140) 1.4 (0.35-1.8) 73.2 (4-220) 
8 68.7 (17-109) 124.3 (17-720) 29.2 b (44-80) 66 (<140) 0.8 (0.35-1.8) 45.0 (4-220) 
9 70.4 a (6-50) 1,305.3 a (17-720) 31.7 b (53-88) 65 (<140) 1.6 (0.35-1.8) 72.7 (4-220) 
10 73.5 a (6-50) 448.0 a (11-240) 42.3 b (62-97) 64 (<140) 1.6 (0.35-1.8) 64.4 (4-220) 
11 101.5 a (6-50) 1,040.3 a (11-240) 40.3 b (62-97) 26 (<140) 1.4 (0.35-1.8) 59.2 (4-220) 
12 88.5 a (6-50) 403.7 a (11-240) 36.7 b (50-100) 53 (<140) 1.3 (1.0-3.8) 106.7 a (3-78) 
13 65.0 a (6-50) 538.3 a (11-240) 38.3 b (50-100) 19 (<140) 1.9 (1.0-3.8) 82.7 a (3-78) 
Cr Creatine, Crn Creatinine, CK Creatine kinase, GAA Guanidinoacetate, N.A. Not acquired 
a Elevated value 
b Low value of Creatinine 
 
Elevated creatine concentrations were only seen in those 9 years and older, except 
for one 4-year-old girl with an isolated increased urinary creatine/creatinine ratio. 
Mean age of the girls having an elevated plasma creatine was 14.54 years (range: 
9.6-20.3, sd=4.33), compared to 5.09 years (range: 2.3-9.7, sd=2.34) of the girls 
having a normal plasma creatine. Mean age of the girls having an increased urinary 
creatine/creatinine ratio was 13.07 years (range: 4.3-20.3, sd=2.34), compared to 
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5.47 years (range: 2.3-9.7, sd=2.75) in the normal urinary creatine/creatinine ratio 
group. 
Anthropometric characteristics between the two groups were roughly equal, 
except for height. Height was below the fifth percentile in 83% of the girls with 
elevated creatine concentrations, and greater than the 50th percentile in 57% of the 
girls with normal creatine concentrations. 
Furthermore, only the girls with an elevated creatine concentration in plasma 
and urine had a severe ISS score, and the girls with a normal creatine concentration 
in plasma and urine had a very mild ISS score. The mean score of the girls in the 
elevated plasma creatine group was 24.0 (range: 20-27, sd=2.45) versus 14.3 (range: 
8-21, sd=6.02) in the normal plasma creatine group. The mean score of the girls in 
the increased urinary creatine/creatinine ratio group was 23.6 (range: 20-27, 
sd=2.51) compared to 14.2 (range: 8-20, sd=5.76) in the normal urinary crea-
tine/creatinine ratio group. Except for ISS domain four (mental/ cortical function), in 
which the scores were equally distributed in both groups, girls with an elevated 
creatine showed high scores in all domains. 
In view of the variety in mutations, no differences concerning other patient 
characteristics could be observed.  
Concerning the cardiorespiratory phenotype, in the elevated creatine group, 
four girls were forceful breathers and one girl had an undetermined cardiorespira-
tory phenotype. The girls with an isolated increased urinary creatine/creatinine 
ratio were a forceful and a feeble breather. 
Finally, all RTT girls wherefore reference values of FFMI were available met the 
criteria for malnutrition. Therefore, a possible relationship between elevated crea-
tine concentrations and an impaired nutritional status could not be investigated. 
Discussion 
This study is the first attempt to correlate metabolic alterations as a possible expla-
nation of impaired nutritional status in RTT. Despite normal levels of total dietary 
energy and protein intakes, malnutrition was confirmed in all RTT girls wherefore 
reference values of FFMI were available. Although the loss of skeletal muscle mass 
could be partly due to physical inactivity, these low values are certainly an indica-
tion for impaired nutritional status in these RTT girls. 
Blood and urine samples were collected for biochemical screening of multiple 
metabolic pathways. We observed significantly elevated plasma creatine concentra-
tions and increased urinary creatine/creatinine ratios in half of the RTT girls. The 
creatinine plasma concentrations were relatively low, as one would expect in view 
of the low FFMI values. Nonetheless, the elevated creatine/creatinine ratios are 
most likely primarily due to the elevated creatine concentrations, considering the 
high plasma creatine concentrations at the same time. 
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Given that in this study the young girls were feeble breathers and the older girls 
were forceful breathers, it is impossible to determine whether the elevated creatine 
concentrations are age related or associated with the cardiorespiratory phenotype. 
This age distribution is likely coincidental since previous studies showed no signifi-
cant age difference between the different cardiorespiratory phenotypes (Julu & 
Engerström, 2005). At present, it is uncertain whether an altered carbon dioxide 
metabolism affects the creatine metabolism in females with RTT. 
It is difficult to explain why creatine concentrations should increase with age in 
the RTT cohort. According to the reference values for creatine, creatine concentra-
tions normally decrease with increasing age (Salomons et al., 2003). Furthermore, 
Horská and colleagues reported stable creatine concentrations with increasing age 
in RTT girls using proton magnetic resonance spectroscopy (Horská et al., 2009). 
Consequently, it seems highly unlikely that the altered creatine concentrations can 
be explained by age. 
Regarding the cardiorespiratory phenotype, two possible explanations can be 
given. First of all, as has been described by Julu and colleagues, a major difference in 
the cardiorespiratory phenotypes is the blood pH value (Julu et al., 2008a, b). Fe-
males with a forceful breathing type tend to be alkalotic due to excessive loss of CO2 
via respiration, in contrast to females with a feeble breathing pattern who tend to 
be acidotic. The pH differences between these phenotypes can be as much as 0.4-
0.5 pH-units (personal observation Dr. P.O.O. Julu). This pH difference may affect 
the creatine metabolism in RTT girls. Second, it can be speculated that the elevated 
creatine concentrations might be due to the increased energy expenditure as de-
scribed in forceful breathers (Julu et al., 2008b). Phospho-creatine (P-creatine) to-
gether with ATP makes up the phosphagen energy system. P-creatine contains the 
high-energy phosphate bond, which is 3-8 times as abundant as ATP. As soon as 
more ATP is needed, P-creatine transfers its high energy phosphate to ATP (Guyton 
& Hall 2000). Following this suggestion, it may be speculated that in forceful 
breathers, the elevated creatine concentrations are indirectly caused by higher P-
creatine needs. 
Furthermore, as the creatine-transporter gene (SLC6A8) is located adjacent to 
MECP2 at Xq28, MeCP2 deficiency may cause epigenetic aberrations affecting the 
expression of the SLC6A8. The clinical phenotypes of RTT and an X-linked creatine 
transporter deficiency overlap regarding mental retardation, epilepsy, and language 
delay (Salomons et al., 2001). However, few studies have examined the brain me-
tabolites of RTT females using proton magnetic resonance spectroscopy (Gökcay et 
al., 2002; Hashimoto et al., 1998; Horská et al., 2000, 2009; Khong et al., 2002; Pan 
et al., 1999). Overall, N-acetylaspartate/total creatine was significantly decreased 
compared with age-matched controls, primarily reflecting reduced N-acetyl-
aspartate levels. Even so, an 8% greater mean creatine concentration was previous-
ly found in the frontal white matter in the RTT group. This difference was not signifi-
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cantly different, because of a high variability in creatine levels in both RTT and con-
trol groups (Horská et al., 2000, 2009). Nevertheless, in case of a decreased expres-
sion of SLC6A8, less creatine would be present in the brain, making this diagnosis 
highly unlikely in our patients (Salomons et al., 2001). 
Clinically, the girls with an elevated creatine concentration differed from girls 
with a normal creatine concentration regarding height and ISS score. Girls with an 
elevated creatine concentration were substantially shorter and a more severe phe-
notype was observed. This severe phenotype reflected several functional domains, 
that is growth and development, musculoskeletal, movement, and autonomic fea-
tures. 
In summary, this is the first study to report abnormalities in creatine concentra-
tions in RTT girls. Hitherto, only Freilinger and colleagues performed metabolic 
screening including urinary creatine/creatinine ratio (Freilinger et al., 2007). They 
did not report any abnormalities in creatine/ creatinine ratios in 29 Rett females 
with a mean age of 13 years. Reference values were not defined. However, as can 
clearly be seen in that article, three females have a highly elevated crea-
tine/creatinine ratio. Furthermore, an MECP2 mutation was identified in 76% of the 
females, which is rather low compared to previously published data (Williamson & 
Christodoulou, 2006). Cardiorespiratory data were not available. So, the discrepancy 
may be because of difference in reference values or patient populations, as the 
diagnosis of RTT in the previous study was mainly based on clinical criteria alone 
and a possibly lower percentage of forceful breathers. The strength of our study 
was the use of a well-defined group of RTT girls. Only due to these strict inclusion 
criteria, our study is hampered by the small sample size, which does not allow us to 
understand the observed creatine abnormalities fully. At this moment, we are not 
able to confirm our hypothesis regarding metabolic alterations as a possible expla-
nation of impaired nutritional status in RTT, since impaired nutritional status was 
seen in all RTT girls wherefore reference values of FFMI were available. Different 
etiologies can explain the observed elevated creatine concentrations in the RTT 
girls. Except for creatine transporter defects, no other neurological disease ever 
showed elevated creatine values. Further studies concerning the creatine metabo-
lism in relation to the nutritional requirements and cardiorespiratory status or phe-
notype of RTT girls are important in order to provide appropriate and effective 
management. 
Conclusions 
Despite normal levels of total dietary energy and protein intakes, malnutrition was 
confirmed in all RTT girls wherefore reference values of FFMI were available. An 
important percentage of RTT girls showed creatine concentrations above the refer-
ence values. Currently, it is undetermined how the creatine metabolism is affected 
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in females with RTT, and how this may affect their nutritional status. Further studies 
are required to confirm these findings and to provide greater insight into the patho-
genesis of the abnormal creatine metabolism in RTT. 
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Abstract 
The aging process of people with intellectual disabilities has been a topic of interest 
in recent years. Good knowledge of the specific healthcare problems in adults with 
intellectual disabilities and anticipating on these problems are important issues in 
providing support and healthcare for these persons. Nevertheless little is known 
about the aging process of people with specific syndromes, like Rett syndrome. In 
association with the Dutch Rett syndrome parent association, 70 postal question-
naires were sent to the contact persons of the females aged at least 16 years with a 
clinical diagnosis of Rett syndrome. The questionnaire consisted of general ques-
tions, questions about living conditions, skills, physical and psychiatric morbidity. 
The response rate was 76% (n=53). In general adults with Rett syndrome seemed to 
be reasonably healthy, whereas neurological, respiratory and behavioral morbidity 
appeared to be of great influence. High care dependency was confirmed. In contrast 
with underweight, overweight showed to be an under-ascertained feature. The 
general disorder profile was confirmed, considering the increase with age regarding 
kyphosis and the better communication and autonomic dysfunction in the oldest 
age group compared to the younger age groups. Features of autonomic dysfunction 
deserve more medical attention, especially the interrelation between quality of 
sleep, respiration and behavior in Rett syndrome. Longitudinal studies including 
genotype-phenotype analyses are needed for insight in individual changes in sup-
port needs and health. 
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Introduction 
Thanks to better life circumstances and major advances in medical care and tech-
nology, the life expectancy of persons with childhood onset diseases and/or genetic 
syndromes has increased (Patja et al., 2000; Donckerwolcke & Van Zeben-Van der 
Aa, 2002; Maaskant et al., 2002; Fisher & Kettl, 2005). Consequently, the number of 
adults with intellectual disabilities (ID) has increased substantially during the last 
decades and will continue to increase in the next years (Janicki & Breitenbrach, 
2000; Bernard et al., 2002). Compared to persons without ID, age specific conditions 
occur more often and earlier in life (Maaskant et al., 1996; Van Schrojenstein Lant-
man-de Valk et al., 1997). Nevertheless little is known about aging in people with 
specific syndromes, except for Down syndrome (Roeden & Zitman, 1995; Torr & 
Davis, 2007; Jervis and Prinsloo, 2008). In this study we focus on Rett syndrome 
(RTT), a neurodevelopmental disorder affecting almost exclusively females. The 
prevalence is 1:10,000 girls at 11 years and therefore a common genetic cause of 
severe ID in females (Hagberg et al., 1983; Smeets & Schrander-Stumpel, 2005; 
Williamson & Christodoulou, 2006). In spite of the molecular confirmation of a 
MECP2 mutation, diagnosis of RTT remains mainly clinically based on internationally 
accepted criteria (Amir et al., 1999; Hagberg et al., 2002). RTT manifests particular 
symptoms at certain ages, including a wide variability in clinical evolution and sever-
ity (Smeets et al., 2003; Williamson & Christodoulou, 2006). Hagberg and Witt-
Engerström (1986) devised a staging system that divides the natural history of RTT 
into four stages: early stagnation, rapid regression, pseudo stabilization and late 
motor deterioration. The general RTT profile is that of a slowly continuing deteriora-
tion of gross motor performance over the years in contrast with a relatively better 
preserved cognitive ability to communicate, mainly with the eyes. An inactive, small 
and thin woman with trophic skin changes is the general long-term clinical disorder 
profile, suggesting a kind of ‘‘pre-aging’’ in RTT (Hagberg, 2002; Cass et al., 2003). 
The aim of the present study is to gain insight into age-related features in RTT. The 
research question is: what physical, behavioral and psychiatric conditions are pre-
sent in adults with RTT and which of these conditions are age-related? 
Materials and methods 
Prior to the start of this study, ethical approval was obtained from the Medical Ethi-
cal Committee at the academic hospital of Maastricht.  
Subjects 
Subjects were recruited through the Dutch RTT parent association. Questionnaires 
were developed and sent to 70 contact persons (mainly parents), of which 76% 
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were returned. In total, data were derived from 53 Dutch females aged 16 years and 
older with a clinical diagnosis of RTT, confirmed by experienced clinicians. The par-
ents answered in 47 cases, parents together with a professional career in 3 cases, a 
professional career in 1 case and a physician in 1 case. Those who completed the 
questionnaires are further referred to as ‘‘parents’’. 
Questionnaire 
The questionnaire consisted of four major subdivisions. The first part included ques-
tions about demographic characteristics, including height, weight and abdominal 
circumference. The second part comprised questions about living conditions and 
use of care facilities. In the third part the Observational Questionnaire Elderly Resi-
dents with Intellectual Disabilities (Observatielijst Ouderwordende Bewoners, OOB) 
was inserted. The OOB is an instrument that assesses functioning, behavior and care 
dependency; it has to be completed by a care-provider familiar with the client. The 
OOB has four subscales: (1) activities of daily living (ADL), (2) psychological function-
ing, (3) (inappropriate) reactions, and (4) physical functions and care dependence. 
The questionnaire was supplemented with questions addressing RTT specific fea-
tures. The range for the scale is 0 or 1-4: the higher the score the better the func-
tioning. The reliability and validity of the OOB has been demonstrated to be satis-
factory to good (Hoefnagel, 1989). Questions on the medical history, medication 
use, genetic diagnosis, physical and psychiatric morbidity were inserted in the 
fourth part of the questionnaire. Ultimately, the view of parents regarding signifi-
cant changes in skills and morbidity from the age of 10 years was rated on a 3-
points scale (no change, improvement, or decline). All data were processed anony-
mously. 
Response 
Table 1 shows the characteristics of the respondents. The mean age was 26.9 years. 
Among the 53 persons with clinical RTT, mutation analyses were performed in 70%, 
of which 84% were molecularly confirmed. Forty percent of the RTT persons had a 
normal weight, 49% were underweight and 11% were overweight. Seventeen con-
tact persons did not return the questionnaire. The mean ages of non-respondents 
and respondents were 25.7 and 26.9 years, respectively (p=0.17). There are no indi-
cations that the non-response was selective and affected the results. 
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Table 1 Characteristics of the respondents according to age, genotype and BMI 
 N % 
Age 
 16 - 20 years 
 20 - 30 years 
 30 + years 
Mean age: 26.9 years, range 16-53, sd=7.85 
 
11 
24 
18 
 
21% 
45% 
34% 
Genotype 
 Mutation analyses performed 
  MECP2 positive 
  MECP2 negative 
  Results unknown 
 Mutation analyses not performed  
 Unknown 
 
37 
31 
4 
2 
12 
4 
 
70% 
58% 
8% 
4% 
23% 
8% 
BMI category 
 < 18,5 (underweight) 
 18,5 - 25 (normal weight) 
 > 25 (overweight) 
 Unknown 
Mean BMI: 20.0, range 13.0-38.1, sd=4.51 
 
22 
18 
5 
8 
 
42% 
34% 
9% 
15% 
Data analyses 
Questionnaires were reviewed before data were correlated; in case of two answers 
the best answer was consistently chosen. SPSS version 14.0 was used for analyzing 
the data. Three age groups (16-20, 20-30, 30+) were to analyze possible age-related 
conditions. Prevalence rates were calculated for morbidity and mean scores were 
calculated for BMI and perceived health. Concerning skills and behavior, frequencies 
and mean scores were calculated. The following statistical tests were performed: 
Chi-square (for nominal and ordinal data) and Kendall’s tau-b (for ordinal data), 
independent t tests (means of two groups) or ANOVA (means of more than two 
groups). 
Results 
Living conditions and use of care facilities 
Approximately one third (36%) of the RTT persons lived full-time or part-time with 
their parents. About two thirds (71%) lived in residential facilities, of whom 13% still 
spent some (weekend) days a week with their parents. Three RTT persons (6%) lived 
in apartments with 24 h daily support. Significantly more young adults lived with 
their parents and older adults lived in residential facilities (Kendall’s tau-b: p<0.01 
respectively p<0.05). Analyses regarding age at entering residential facilities showed 
an ordinal relation with age (Kendall’s tau-b: p<0.01).  
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Most RTT persons (67%) spent their days in day care facilities. Respite care facilities 
were used by 12%, specifically and non-specifically for persons with ID (10% respec-
tively 2%). 
Health 
Health of the individuals was assessed on a 5-point scale ranging from very good (1) 
to very bad (5). In general, the respondents valued the health of the RTT persons as 
good (mean 2.15, range 1-4). Perceived health was not related to age (Kendall’s tau-
b: p=0.86) with mean scores in the different age groups of 2.0, 2.2, and 2.1. Further 
analyses showed a significant relation between health and apnea (Kendall’s tau-b: 
p<0.01), breath holding spells (Kendall’s tau-b: p<0.05), mood changes (Kendall’s 
tau-b: p<0.01), spasticity (Kendall’s tau-b: p<0.01) and joint deformities (Kendall’s 
tau-b: p<0.001). Care dependence and physical complaints had a negative relation 
with health (Kendall’s tau-b: p<0.01 and p<0.001). 
Weight status and eating behavior 
Discarding the missing values in some respondents, prevalence of underweight RTT 
persons was 49%; 40% had a normal weight and 11% were overweight. Comparing 
BMI and eating behavior a positive relation was shown (Kendall’s tau-b: p<0.01). No 
relation between BMI and perceived health or age was found (ANOVA: p=0.95 re-
spectively p=0.78). 
Communication 
Only one third of the RTT persons were at least sometimes able to express them-
selves by spoken language and/or signals, of which 13% through eye pinpointing 
behavior. Concerning this group, the communication was considerably better in the 
older age groups (Kendall’s tau-b: p=0.10). Changes in communication skills were 
experienced by parents: 10 parents considered improvement in their children’s 
communication from the age of 10 years, whereas 3 parents experienced a decline 
(Chi-square: p=0.01). 
Morbidity 
Table 2 shows the morbidity and behavioral problems of RTT persons per age group. 
Arranged by subject, explanatory remarks are made below. Skin problems, sleep 
abnormalities, respiratory problems and behavioral problems are considered as 
manifestations of autonomic dysfunction. To investigate potential relations be-
tween the different items further analyses were performed. 
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Table 2 Prevalence of morbidity in RTT persons per age-group and significance level 
Morbidity by age group 16-20  
(n=11)  
(%) 
20-30  
(n=24) 
(%) 
30+  
(n=18) 
(%) 
Total  
(n=53) 
(%) 
Kendall’s 
tau-b 
Chi-square 
Skin problems 
 Cold feet 
 Pressure sores and vesicles  
 Trophic skin and nail changes 
 
100% 
40% 
33% 
 
96% 
54% 
39% 
 
94% 
39% 
18% 
 
96% 
46% 
30% 
 
p=0.41 
p=0.73 
p=0.16 
 
p=0.56 
p=0.56 
p=0.05* 
Sleep abnormalities 
 Nightly unrest 
 Prolonged wakefulness and /  
  or early morning awakening 
 Sleepy during the day 
 
64% 
 
36% 
80% 
 
79% 
 
58% 
83% 
 
83% 
 
50% 
89% 
 
77% 
 
51% 
85% 
 
p=0.16 
 
p=0.54 
p=0.59 
 
p=0.16 
 
p=0.66 
p=0.59 
Respiratory problems 
 Apnea 
 Hyperventilation 
 Breath holding spells 
 Air swallowing 
 
44% 
30% 
80% 
40% 
 
46% 
42% 
83% 
44% 
 
23% 
39% 
56% 
39% 
 
38% 
39% 
73% 
41% 
 
p=0.13 
p=0.65 
p=0.24 
p=0.83 
 
p=0.01* 
p=0.76 
p=0.30 
p=0.96 
Behavioral problems 
 Nightly screaming 
 Mood changes 
 Agitation 
 Anxious impression 
 
33% 
67% 
22% 
50% 
 
46% 
61% 
65% 
79% 
 
33% 
72% 
56% 
62% 
 
39% 
66% 
54% 
68% 
 
p=0.56 
p=0.32 
p=0.27 
p=0.89 
 
p=0.96 
p=0.82 
p=0.25 
p=0.49 
Musculoskeletal 
 Scoliosis 
 Kyphosis 
 Spasticity 
 Joint deformities 
 
90% 
0% 
60% 
44% 
 
88% 
24% 
41% 
65% 
 
94% 
19% 
61% 
61% 
 
90% 
16% 
52% 
60% 
 
p=0.43 
p=0.05* 
p=0.51 
p=0.77 
 
p=0.41 
p=0.21 
p=0.37 
p=0.70 
Epilepsy 82% 62% 83% 74% p=0.93 p=0.51 
* p≤ 0.05 
 
Autonomic manifestations 
Skin problems. Cold feet were notified in 96% of the RTT persons, 50% with blue 
discoloration, and 50% without. Pressure sores and vesicles occurred in 46%. The 
prevalence of trophic skin and nail changes was 30%, whereas the occurrence was 
significantly lower in the oldest age group (18%, Chi-square: p=0.05). According to 
the parents, in 7 of their children’s a decline in skin problems was observed from 
the age of 10 years. 
Sleep abnormalities. Half of the RTT persons sometimes had nightly unrest, 
whereas 20% had nightly unrest at least once a week up to daily. The prevalence of 
nightly unrest was higher in the two older age groups, although these differences 
were awakening not statistically significant (64% to 79% to 83%, Kendall’s tau-b: 
p=0.16). Prolonged wakefulness and/or early morning awakening was more or less 
pronounced in 51%. Daytime sleeping was reported in 85%, ranging from some-
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times in 50% to constantly in 8%. No statistically significant relationships with age 
were found (Kendall’s tau-b: p>0.16).  
Respiratory problems. Apnea was reported in 38% of the RTT persons, ranging 
from 16% once a month up to 14% daily. The prevalence was significantly lower in 
the oldest age group (23%, Chi-square: p=0.01). Thirty-nine percent of the RTT per-
sons had hyperventilation and 73% had breath holding spells. Air swallowing was 
present in 41%. Except for apnea, the differences between the age groups and res-
piratory problems were not statistically significant.  
Behavioral problems. Nightly screaming was reported in 39%, two thirds less 
than once a week. Prevalence of mood changes was 66%, one third at least once a 
week. Abnormal agitation was more or less pronounced in 54%. Whereas the occur-
rence was lower in the younger age group, this was not significant (22%, Chi-square: 
p=0.25). Two thirds of the RTT persons showed anxiety, of which 4% was constantly 
agitated. No statistically significant relationships with age were found (Kendall’s tau-
b: p>0.27). 
Interrelationships 
Further analyses regarding autonomic manifestations showed a relation between 
behavioral problems and sleep abnormalities (Kendall’s tau-b: p<0.01-0.019), and 
respiratory problems and sleep abnormalities (Kendall’s tau-b: p<0.001-0.03). 
Musculoskeletal 
The prevalence of scoliosis in our study was 90%. Thirty-six percent had undergone 
surgery and 40% had not been operated. For the remaining 24%, scoliosis operation 
was not mentioned by parents in the medical history. 
The overall prevalence of kyphosis was 16%, whereas the occurrence was signif-
icantly higher in the older age groups (0% to 24% to 19% respectively, Kendall’s tau-
b: p=0.05). Analyses regarding osteoporosis and kyphosis showed 25% occurrence 
of osteoporosis in the kyphosis group in contrast to 0% occurrence in the remaining 
group (Chi-square: p<0.01). Hereby, the occurrence of osteoporosis was unknown 
with 50% of the kyphosis group and 60% of the remaining group. Ambulation and 
mobility were very limited in all age-groups, and no relationship with age was found 
(Kendall’s tau-b: p=0.72 respectively p=0.82). Anticonvulsive treatment was used by 
100% of the osteoporosis group, 75% of the kyphosis group and 70% of the remain-
ing group (Chi-square: p=0.66). Since our statistical power to investigate explicit 
anticonvulsive treatment was limited, we were not able to perform these analyses.  
The prevalence of spasticity was 52%, mainly affecting the arms and legs. Sixty 
percent of the RTT persons had joint deformities, mainly affecting the feet. 
Except for kyphosis, the differences between the age-groups and muskoskeletal 
morbidity were not statistically significant (Kendall’s tau-b: p>0.43). 
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Epilepsy 
A history of epilepsy was present in 74%, of whom 95% used anticonvulsive treat-
ment. The occurrence of epilepsy was significantly higher with combination therapy 
compared to monotherapy (Kendall’s tau-b: p<0.01). The differences in prevalence 
of epilepsy between the age-groups were not statistically significant (Kendal’s tau: 
p=0.93). 
Observational questionnaire elderly residents with ID 
In general RTT persons scored low on the subscale ‘‘ADL’’ (mean score: 1.15, 
sd=0.2), meaning they have limited ADL-skills. Regarding ‘‘psychological function-
ing’’ they also scored low (mean score: 1.63, sd=0.6), meaning limited abilities on 
this subject. Concerning ‘‘(inappropriate) reactions’’ they scored reasonable (mean 
score 2.9, sd=0.7), meaning occasionally appearance of these reactions. Regarding 
‘‘physical functions’’ they also scored reasonable (mean score 2.8, sd=0.5), meaning 
moderate physical limitations.  
No relationship with age was found (Table 3). Further analyses on item-level 
showed no relation regarding age and ambulation and mobility (Kendall’s tau-b: 
p=0.72 respectively p=0.82), which is in accordance with the view of the parents. In 
conclusion, care dependence was lower in the older age groups (Kendall’s tau-b: 
p=0.08).  
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Table 3 OOB-scores in relation to age 
OOB subscales 16-20 years 20-30 years 30+ years ANOVA 
Daily activity 
 Mean score 
 Range  
 sd 
 
1.11 
1.0-1.5 
0.20 
 
1.17 
1.0-1.5 
0.22 
 
1.15 
1.0-1.63 
0.23 
 
p=0.76 
Psychological functioning 
 Mean score 
 Range  
 sd 
 
1.52 
0.67-2.5 
0.47 
 
1.74 
0.9-3.5 
0.57 
 
1.55 
0.53-4.0 
0.77 
 
p=0.52 
(Inappropriate) reactions 
 Mean score 
 Range  
 sd 
 
3.12 
1.0-3.83 
0.83 
 
2.85 
1.5-3.83 
0.61 
 
3.00 
1.33-4.0 
0.72 
 
p=0.80 
Physical functioning 
 Mean score 
 Range  
 sd 
 
2.69 
1.0-3.38 
0.66 
 
2.84 
1.88-3.63 
0.45 
 
2.80 
2.13-3.71 
0.53 
 
p=0.51 
Genotype-phenotype analyses 
Genotype-phenotype analyses have not been performed, since our statistical power 
to investigate the effect of genotype was limited.  
Among the 53 persons with clinical RTT, mutation analyses was performed in 
70%, of which 84% were molecularly confirmed. As a result, we had 31 confirmed 
MECP2 mutations and 22 RTT persons with a negative or unknown mutation status. 
The mean ages of the molecularly confirmed RTT persons and those with a negative 
or unknown mutation status were respectively 27.1 and 26.6 years (p=0.82). There 
are no indications that the negative or unknown mutation status is due to selection 
bias and would affect the results. 
Discussion 
Anticipating on specific health problems in adults with ID is important in providing 
long-term healthcare for these persons (Schrander-Stumpel et al., 2007). Concern-
ing RTT, a cross-sectional study was performed. Owing to the high response rate of 
76%, we gathered data on 53 Dutch RTT individuals aged 16 years or older with a 
clinical diagnosis of RTT with a broad range of clinical symptoms. Our data represent 
almost exclusively the parental view. Since parents are closest to their children in 
everyday life, they have the opportunity to experience their lack or change of de-
velopment early on. The medical background of parents may be limited although.  
 In general the parents valued the health of the RTT persons as good, irrespec-
tive of age, whereas neurological, respiratory and behavioral morbidity appeared to 
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be of great influence. This is important for professionals in considering the signifi-
cant impact of these features on quality of life of the RTT person and her family.  
Although care dependency was lower in the older age groups, the required 
therapeutic services remained high. This is in accordance with the conception of a 
stable condition with high dependency needs at adult age (Smeets et al., 2003; 
Williamson & Christodoulou, 2006). Reported underweight in half of the subjects is 
in line with previous reports (Williamson & Christodoulou, 2006). Overweight on the 
contrary is an under-ascertained feature in RTT. Some RTT girls will have a tendency 
to become overweight if they are allowed to eat what they want (Smeets & 
Schrander-Stumpel, 2005). A positive relation was shown between eating behavior 
and BMI. Therefore, nutritional factors and energy expenditure play an important 
role in weight control and general health at adult age.  
Although speech is absent in most RTT persons, in our study non-verbal com-
munication was considerably better in the older age groups. This in accordance with 
the view of parents and previous observations that comprehension, contact behav-
ior and non-verbal communication improve with age (Hagberg, 2002; Williamson & 
Christodoulou, 2006). Given the importance of mutual understanding, active man-
agement of communication is required in RTT.  
Contrary to the better preserved communication abilities, gross motor perfor-
mance in RTT slowly but continuously declines over the years (Steffenburg et al., 
2001; Hagberg, 2002; Kerr, 2002; Williamson & Christodoulou, 2006). Nonetheless, 
we demonstrated no relationship between musculoskeletal problems and age, ex-
cept for kyphosis. Kyphosis is present in 16% of the respondents and the occurrence 
was significantly higher in the older age groups. Information about prevalence and 
age dependency for kyphosis in both RTT and the female Dutch population is ex-
tremely limited, making comparison impossible. In this study, analyses showed a 
significantly high occurrence of osteoporosis in the kyphosis group (25%) compared 
with the remaining RTT persons (0%). The occurrence of osteoporosis in the female 
Dutch population at the age of 20-24 years is 0.013% and at the age of 50-54 years 
0.74% (Poos & Gijsen, 2003). Besides, in three quarters of the RTT persons the oc-
currence of osteoporosis was unknown. Active management and future study re-
garding diagnostics of osteoporosis and kyphosis is therefore advisable. Scoliosis is 
seen in 90% of the subjects in our study. This is in accordance with the results of a 
study in the UK with a prevalence of 87% at the age of 25 years (Kerr et al., 2003). 
Scoliosis in RTT is typically noted between 8 and 11 years, whereas the progress 
usually occurs in early adolescence and close to the growth spurt (Keret et al., 1988; 
Percy, 2002). The RTT persons in our study are at least 16 years old; therefore the 
increase with age has already taken place. In our study scoliosis necessitated sur-
gery in 36%, which is in accordance with approximately 28% in the age-group 16-20 
years (Kerr et al., 2003). As scoliosis is a major clinical manifestation that has detri-
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mental effects on health and quality of life, medical attention is highly important 
(Ager et al., 2006).  
Regarding epilepsy, we found no relation with age. However, many paroxysmal 
events diagnosed in RTT as epileptic have been found to be of non-epileptic origin 
(Glaze et al., 1998; Smeets et al., 2006). Active management is of great importance, 
in particular on behalf of the high consumption of anti-epileptic drugs reported in 
our study.  
In line with previous reports, we noted a tendency towards improving autonom-
ic dysfunction in adult RTT (Ellaway & Christodoulou, 2001; Julu et al., 2001; Wil-
liamson & Christodoulou, 2006). Trophic skin and nail changes are significantly less 
prevalent in the older age group, which is in contrast with the view of parents who 
did not report any improvement. However, this is a cross-sectional study and the 
view of the parents changes with time. Regarding breathing dysfunction, apnea is 
significantly less prevalent in the older age group. The prevalence of autonomic 
dysfunction widely differs in the current literature; making comparisons with our 
results very difficult (Julu et al., 2001; Mount et al., 2001, 2002). Another important 
finding in this study is the positive relation between both behavioral and respiratory 
problems with sleep abnormalities, which is in line with previous reports. Autonom-
ic dysfunction reflects the immaturity of the brainstem in RTT resulting from the 
hyperactive sympathetic system with insufficient or absent parasympathetic control 
(Kerr & Julu, 1999; Julu et al., 2001; Smeets et al., 2006). Because of their role in 
overall health, respiratory and behavioral problems can be seen as the most dis-
tressing features in RTT. Therefore, their relationship to quality of sleep is an im-
portant target for future study. 
Another area that requires more attention in the future is genotype-phenotype 
analyses. Recent studies show a correlation of disease severity with mutation type 
and location (Cheadle et al., 2000; Christodoulou & Weaving, 2003; Charman et al., 
2005; Archer et al., 2007). Since our statistical power to investigate the effect of 
genotype was limited, we unfortunately were not able to perform these analyses. 
However, there was no indication that this would affect the results.  
Finally, since cross-sectional data are used, one has to realize there might be a 
selection towards survivors, with the most severely affected dying earlier. It is 
hoped that this information will lead to further longitudinal studies of the natural 
history of RTT. 
Conclusion 
Although the results in this report relate to cross-sectional data, the adult RTT group 
has a more or less stable condition. The general RTT profile is confirmed, consider-
ing the increase with age regarding kyphosis and the better communication and 
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autonomic dysfunction in the oldest age group compared to the younger age 
groups. 
Early intervention and preventive management in RTT requires an individualized 
approach at every age. It is aiming at maintaining or improving motor and commu-
nicative skills and trying to find treatment for respiratory health in order to improve 
the quality of life of the individuals and their families. In order to get a better under-
standing of the aging process and mortality in RTT, longitudinal studies including 
genotype-phenotype analyses are of great importance. 
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Aging in Rett syndrome: a longitudinal 
study 
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Abstract 
Little is known about the aging process of people with specific syndromes, like Rett 
syndrome (RTT). Recognition of the clinical and behavioral characteristics of the 
adult RTT is needed in order to improve future management of the RTT girl and 
counseling of parents. In association with the Dutch RTT parent association, a 5-year 
longitudinal study was carried out. The study population consisted of 53 adult 
women with a clinical diagnosis of RTT. Postal questionnaires were sent, including 
demographic features, skills, physical and psychiatric morbidity. At the time of the 
second measurement seven women had died. In 2012, 80% of the questionnaires 
(37/46) were returned. Mean age of the women was 31.4 years. Molecular confir-
mation was possible for 83% of the women for whom analyses were carried out. 
The adult RTT woman has a more or less stable condition. The general disorder 
profile is that of a slow on-going deterioration of gross motor functioning in contrast 
to a better preserved cognitive functioning, less autonomic and epileptic features 
and good general health. This is the first longitudinal cohort study about aging in 
RTT. Continuing longitudinal studies are needed to gain more insight into the aging 
process in RTT.  
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Introduction 
Owing to advances in medical care and technology, persons with childhood onset 
diseases and/or genetic syndromes are now living to advanced ages (Patja et al., 
2000; Maaskant et al., 2002; Fisher & Kettl, 2005; Tyler & Noritz, 2009; Haveman et 
al., 2010). Expectations are that their life expectancy will even continue to increase 
in the next years (Janicki & Breitenbach, 2000; Bernard et al., 2002; Tyler & Noritz, 
2009). Therefore, clinicians are increasingly challenged by the care for adults with 
specific genetic syndromes (Donckerwolcke & Van Zeben-Van der Aa, 2002; Tyler & 
Noritz, 2009; Vignoli et al., 2012). Still little is known about the aging process of 
people with specific syndromes, like Rett syndrome. 
Rett syndrome (RTT, OMIM 312750) is one of the most common causes of se-
vere intellectual disabilities (ID) in girls, with a prevalence of 1:10,000 to 1:15,000 
(Hagberg et al., 1983; Leonard et al., 1997; Bienvenu et al., 2006; Smeets et al., 
2012). In spite of the molecular confirmation of a MECP2 mutation, RTT remains a 
clinical diagnosis based on internationally accepted criteria (Amir et al., 1999; Neul 
et al., 2010). RTT is characterized by early neurological regression affecting motor, 
cognitive and communication skills, along with autonomic dysfunction and the de-
velopment of stereotypic hand movements (Rett, 1966; Hagberg et al., 1983, 
Smeets et al., 2012). The natural history of RTT is divided into four stages: early 
stagnation, rapid regression, pseudostabilization and late motor deterioration (Hag-
berg & Witt-Engerström, 1986). 
Studies on aging in RTT are scarce, counting a few cross-sectional studies and 
some longitudinal follow-up case studies (Jacobsen et al., 2001; Nielsen et al., 2001; 
Cass et al., 2003; Hagberg, 2005; Halbach et al., 2008; Lotan et al., 2010; Vignoli et 
al., 2012). The clinical condition of RTT women tends to stabilize over time, and 
prolonged survival has recently been showed (Freilinger et al., 2010; Kirby et al., 
2010). 
A longitudinal study was designed in order to gain better understanding of the 
aging process and mortality in RTT. Recognition of the clinical and behavioral char-
acteristics of the adults with RTT is needed, in order to improve future management 
and follow-up of the RTT girl and counseling of parents regarding prognosis, natural 
course of the disease, and life expectancy. 
Materials and methods 
Prior to the start of this study, ethical approval was obtained from the Medical Ethi-
cal Committee at the Maastricht University Medical Center.  
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Subjects 
In association with the Dutch RTT parent association, a 5-year longitudinal study 
was carried out including two measurements (2007 - 2012). The initial study popula-
tion consisted of 53 women above 16 years of age with a clinical diagnosis of RTT, 
confirmed by experienced clinicians. Results of the first measurement have already 
been published (Halbach et al., 2008). 
Since 2007, seven of these 53 RTT women, aged between 21 and 43 years 
(mean age: 26.7 years), had died. Exact cause of death was known for two women: 
pneumonia and status epilepticus. For the remaining five women cause of death 
was not registered, the possibility of sudden death was sometimes mentioned. 
Postal questionnaires were sent to the remaining 46 contact persons. 
Questionnaire 
The questionnaire consisted of four major subdivisions (Halbach et al., 2008). The 
first two parts included demographic features including living conditions (living at 
home or in residential facilities) and use of care facilities (day care or respite care 
facilities). In the third part the Observational Questionnaire Elderly Residents with 
Intellectual Disabilities (OOB) was inserted. This instrument assesses functioning, 
behavior and care dependency. It has four subscales: (1) activities of daily living 
(ADL), (2) psychological functioning, (3) (inappropriate) reactions, and (4) physical 
functions and care dependence. The range for the scale is 0 or 1 - 4: the higher the 
score, the better the functioning. The reliability and validity of the OOB has been 
showed to be satisfactory to good (Hoefnagel, 1989). Questions on the medical 
history (hospital admission and surgery), medication use (type and dose of medica-
tion including duration of use), genetic diagnosis (presence and specific type of 
MECP2 mutation), physical (e.g. epilepsy, scoliosis, breathing problems and osteo-
porosis) and psychiatric morbidity (e.g. mood changes, screaming spells and abnor-
mal agitation) were inserted in the fourth part of the questionnaire. Finally, the 
view of parents regarding significant changes in skills and morbidity from the age of 
10 years was recorded on a 3-point scale (no change, improvement or decline). The 
age of 10 years was selected because by this age most affected girls, even the atypi-
cal ones, have emerged from the regression stage (stage 2). Parents were asked to 
evaluate changes in each of the RTT features. Parents’ responses that had been 
provided in 2007 were compared with those provided in 2012, allowing changes 
over these 5 years to be appreciated. All data were processed anonymously. 
Response 
Eighty percent of the questionnaires sent were returned (n=37). The parents an-
swered in 30 cases, parents together with a professional carer/physician in six cases 
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and a professional carer in one case. Those who completed the questionnaires are 
further referred to as ‘parents’. Reasons for non-responding were mainly unknown 
address and lack of time of parents and/or professional carer, despite two remind-
ers. 
Table 1 shows the characteristics of the respondents in 2007 and 2012. The 
mean age in 2012 was 31.4 years (range: 21 - 46 years, sd=7.37). Eighty-three per-
cent of the women in whom mutation analyses were performed, diagnosis was 
molecularly confirmed. In four women mutation analyses were not performed, and 
in four women it was unknown whether analyses were performed. Forty-six percent 
of the RTT women in 2012 had a normal weight, 35% were underweight, 9% were 
overweight and in 11% BMI status was unknown. 
Those who died and those for whom the questionnaire was not completed did 
not differ significantly from the rest of the cohort, concerning age, general health, 
skills, physical and psychiatric morbidity. 
 
Table 1 Characteristics of the respondents in 2007 and 2012 according to age, genotype and BMI 
 2007, n (%) 2012, n (%) 
Age 
 16 - 20 years 
 20 - 30 years 
 30 + years 
 
11 (21%) 
24 (45%) 
18 (34%) 
Mean age: 26.9 years,  
range 16-53, sd=7.85 
 
11 (30%) 
15 (41%) 
11 (30%) 
Mean age: 31.4 years,  
range 21-46, sd=7.37 
Genotype 
 Mutation analyses performed 
 MECP2 positive 
 MECP2 negative 
 Unknown 
 Mutation analyses not performed  
 Unknown 
 
37 (70%) 
31 (84%) 
4 (11%) 
2 (5%) 
12 (23%) 
4 (8%) 
 
29 (78%) 
24 (83%) 
5 (17%) 
0 (0%) 
4 (11%) 
4 (11%) 
BMI category 
 < 18,5 (underweight) 
 18,5 - 25 (normal weight) 
 > 25 (overweight) 
 Unknown 
 
22 (42%) 
18 (34%) 
5 (9%) 
8 (15%) 
Mean BMI: 20.0,  
range 13.0-38.1, sd=4.51 
 
13 (35%) 
17 (46%) 
3 (8%) 
4 (11%) 
Mean BMI: 20.4,  
range 13.0-34.85, sd=4.78 
n=number of RTT women 
Data analyses 
SPSS version 18 was used for analyzing the data.  
The main aim was to compare data of 2007 and 2012 regarding several varia-
bles for the whole group (n=37). The variables were: demographic features includ-
C h a p t e r  6  
 100
ing living conditions and use of care facilities, data on functioning via OOB (total, 
subscales and individual item scores), physical and psychiatric morbidity and view of 
parents regarding changes in skills and morbidity. For ordinal data χ2 tests were 
used. In case data were on ratio level and normally distributed, the t-test for related 
groups was used. However, in case these data were not normally distributed, Wil-
coxon signed-rank test (nonparametric tests for related groups) was used. 
For each age group (16 - 19 years, 20 - 29 years and 30+ years), the scores for 
2007 and 2012 were compared. On the basis of the number of respondents per age-
groups, the nonparametric Kruskall - Wallis test (nonparametric tests for more than 
two unrelated groups) rather than a parametric test was used for analyzing the 
data. 
For all tests, a p-value of 0.05 or less was used for statistical significance. 
Results 
The ages given in this section are those of 2007. 
Living conditions and use of care facilities 
Approximately one-third (n=12) of the RTT women lived full time or part time with 
their parents. Eighty-two percent lived in residential facilities, of whom 14% still 
spent some (weekend) days a week with their parents. Two RTT women lived in 
apartments with 24 h daily support. Compared to 2007, eight RTT women now 
spent less time living with their parents and four women spent more time with their 
parents. More young women lived in residential facilities, in contrast to the oldest 
age group with no changes in living conditions (p=0.005). In the oldest age group 
only one woman still lived at home.  
Sixty percent of the RTT women spent their days in day care facilities. The use of 
these facilities increased in four women, of whom three were between 16 and 20 
years of age. Respite care facilities were used by three RTT women.  
Health 
General health of the individuals was assessed on a 5-point scale ranging from very 
good (1) to very bad (5). In general, the respondents reported the health of RTT 
women as good (mean: 2.24, range: 1 - 4, and sd=0.86). Health had improved the 
most in the oldest age group (p=0.007). Concerning physical complaints a significant 
improvement was shown in the total RTT population (p=0.03). 
During the last 5 years 10 women were hospitalized. Main reason was pneumo-
nia (three women), followed by seven different indications: respiratory distress, 
status epilepticus, rectal bleeding, PEG probe, bladder inspection, decline in walking 
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and refusal to eat and/or drink. Surgery was performed in five women; three wom-
en had an orthopedic surgery because of contractures, and two women had a den-
tal surgery for extraction of wisdom teeth. 
Weight status and eating behavior 
Discarding the missing values in some respondents, the prevalence of underweight 
RTT women was 39%, 52% had a normal weight and 9% were overweight. Com-
pared to 2007 the mean BMI decreased by only 0.21 points (p=0.70). Concerning 
the different age groups, BMI only slightly increased in the youngest age group 
(0.29) and decreased the most in the oldest age group (−0.93; p=0.44).  
The majority of the RTT women are oral feeders needing assistance, only four 
females used a G-tube. 
Communication 
Only 22% of the RTT women were at least sometimes able to express themselves by 
spoken language and/or signals. Since 2007, three women had improved their abil-
ity to express themselves and three had shown deterioration in self-expression. 
Improvement was especially seen in the oldest group (p=0.16). Parents reported a 
deterioration in two women and improvement in three women (p=0.17). 
Morbidity 
Table 2 shows the morbidity of the total RTT cohort in 2007 (n=53) and the longitu-
dinal data of 2007 and 2012 (n=37). Arranged by subject, explanatory remarks are 
made below. Skin problems, sleep abnormalities, respiratory problems, behavioral 
problems and drooling are considered as manifestations of autonomic dysfunction. 
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Table 2 Prevalence of morbidity of total RTT cohort in 2007a (n=53), 2007 (n=37) and 2012 (n=37) 
Morbidity 2007a 
(n=53) 
2007 
(n=37) 
2012 
(n=37) 
Skin problems 
 Cold feet 
 Trophic skin changes 
 
96% 
46% 
 
97% 
54% 
 
92% 
31% 
Sleep abnormalities 
 Nightly unrest 
 Prolonged wakefulness and /  
  or early morning awakening 
 Sleepy during the day 
 
77% 
51% 
 
85% 
 
81% 
56% 
 
81% 
 
78% 
54% 
 
87% 
Respiratory problems 
 Apnea during daytime 
 Apnea during night 
 Hyperventilation 
 Breath holding spells 
 Air swallowing 
 Bloating 
 
38% 
41% 
39% 
73% 
41% 
54% 
 
37% 
40% 
40% 
72% 
47% 
65% 
 
32% 
30% 
26% 
60% 
46% 
60% 
Behavioral problems 
 Nightly screaming 
 Mood changes 
 Abnormal agitation 
 Anxiety 
 
39% 
66% 
54% 
68% 
 
43% 
71% 
51% 
72% 
 
35% 
70% 
65% 
65% 
Drooling 80% 83% 65% 
Musculoskeletal 
 Scoliosis 
 Kyphosis 
 Spasticity 
 Joint deformities 
 
90% 
16% 
52% 
60% 
 
89% 
15% 
50% 
57% 
 
89% 
29% 
49% 
64% 
Epilepsy 74% 68% 76% 
a Halbach et al., 2008 
 
Autonomic manifestations 
Skin problems 
The prevalence of cold feet was nearly the same as in 2007, occurring in 92% of the 
RTT women. Trophic skin changes, including sores and vesicles occurred in 31%, 
whereas improvement was seen in 11 women and deterioration was seen in three 
women (p=0.03). 
Sleep abnormalities 
The prevalence of nightly unrest was nearly the same as in 2007, occurring in 78% of 
the RTT women. Prolonged wakefulness and/or early morning awakening was more 
or less pronounced in 54%, with a significant improvement in RTT women aged 
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between 16 and 20 years (p=0.04). Daytime sleeping was reported in 87%, which is 
in line with previous results in 2007. 
Respiratory problems 
Apnea during daytime was reported in 32% of the RTT women, whereas improve-
ment was mainly seen in women aged between 16 and 20 years (p=0.08). During 
night the prevalence was 30%, compared to 40% in 2007. Significant improvements 
were seen in the total RTT group, but especially in women aged between 20 and 30 
years (p=0.03 and p=0.04, respectively). Hyperventilation was reported in 26% of 
the women, significant improvement was seen for the total RTT group (p=0.02). This 
is in line with the view of parents, reporting mainly improvement. The prevalence of 
breath holding spells was 60%, compared to 72% in 2007. Improvement was seen in 
six women and deterioration in two women (p=0.03). Air swallowing was present in 
46% of the RTT women and bloating in 60%. Both for air swallowing and bloating, 
no significant changes were seen in the last 5 years. 
Behavioral problems 
Nightly screaming was reported in 35%, whereas improvement was mainly seen in 
the women aged between 16 and 20 years and deterioration in women aged 30 
years and older (p=0.05). Prevalence of mood changes was 70%, 13 women im-
proved and six women deteriorated (p=0.19). Abnormal agitation was more or less 
pronounced in 65%, whereas improvement was mainly seen in the women aged 
between 20 and 30 years and deterioration in women aged 30 years and older 
(p=0.06). Two thirds of the RTT women showed anxiety, whereas improvements 
were mainly seen in women aged 30 years and older (p=0.07). 
Remaining autonomic problems 
Drooling was reported in 65% of the women. Nine had improved and two had dete-
riorated (p=0.03). Improvement was especially seen in women aged 30 years and 
older (p=0.04). 
Musculoskeletal 
The prevalence of scoliosis was 89%, with no changes in the last 5 years. The overall 
prevalence of kyphosis had increased to 29% (p=0.06). Three women had deterio-
rated, all between 16 and 20 years, and one had improved (p=0.33). Ambulation 
and mobility were still very limited, whereas mobility mainly deteriorated in the last 
5 years (p=0.08). This is in line with the view of parents, who mainly report deterio-
ration of mobility (p=0.02). However, some elderly women improved regarding to 
ambulation and mobility. 
 The prevalence of rigidity was 49%, whereas improvement was reported in five 
of the seven women aged 30 years and older (p=0.008). Joint deformities were seen 
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in 64% of the RTT women, with improvement in three women and deterioration in 
five women (p=0.49). 
Epilepsy 
A history of epilepsy was present in 76% of the RTT women, of whom 54% was sei-
zure free for at least 3 months. Anticonvulsive treatment was used by 93% of the 
RTT females with a history of epilepsy, of whom 64% received combination therapy. 
Compared to 2007, improvement was reported in four women mainly aged 30 
years and older, deterioration was seen in five women mainly between 16 and 20 
years of age (p=0.17). Parents indicated stabilization and/or improvement of epilep-
sy in women aged between 20 and 30 years (p=0.01). 
Age related morbidity 
Both hypertension and diabetes were not reported in any of the RTT women. Oste-
oporosis was only reported in two women. 
Observational questionnaire elderly residents with ID 
ADL 
In general, RTT women scored low on the subscale ‘ADL’ (mean score: 1.14, 
sd=0.21), meaning they have limited ADL-skills. In the last 5 years no significant 
changes were seen in this subscale and/or the individual items.  
Psychological functioning 
Regarding ‘psychological functioning’ the scores were remarkably higher than in 
2007 (mean score: 1.85 vs 1.63), which was significant in the elderly RTT women 
(p=0.01). On item level three items showed significant differences compared to 
2007: memory, alertness and purposeful behavior. Memory improved in women 
aged 16 to 20 years (p=0.02). Alertness improved in the whole RTT group, especially 
women aged 30 years and older (both p=0.045). Purposeful behavior also improved 
in the whole RTT group (p=0.009). 
(Inappropriate) reactions 
Concerning ‘(inappropriate) reactions’ the RTT women still scored reasonable (mean 
score: 2.98, sd=0.59), meaning occasionally appearance of these reactions. Com-
pared to 2007, no significant changes were seen in this subscale, besides the sleep 
abnormalities as already described in the autonomic section. 
Physical functions 
Regarding ‘physical functions’ the women scored slightly better compared to 2007 
(mean score 2.98 vs 2.87), meaning moderate physical limitations. Improvement 
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was mainly seen in the elderly women (p=0.15). On item level, two items showed 
significant differences compared to 2007. First, physical complaints, as already de-
scribed in the health section. Second, constipation improved in the whole RTT 
group, especially women aged 20 years and older (p=0.01 and p=0.009).  
Care dependency 
Care dependence remained high, with a mean score of 1.86 (sd=0.35). No significant 
changes were seen in the last 5 years (p=0.66).  
Genotype-phenotype analyses 
Genotype-phenotype analyses have not been performed, as the statistical power to 
investigate the effect of genotype was limited. Among the 37 women with clinical 
RTT, mutation analyses were performed in 78%, of which 83% were molecularly 
confirmed. As a result, 24 RTT women had a confirmed MECP2 mutation and 13 RTT 
women had a negative or unknown mutation status. Besides, in the past results of 
mutation analyses were limited to a positive MECP2 mutation, no specific details 
were given. In this cohort only in seven RTT women a specific MECP2 mutation is 
known, respectively one p.R133C mutation, one p.D156E mutation, one p.R270X 
mutation, one p.R306C mutation, two large deletions and one CTS deletion. The 
mean perceived health of the molecularly confirmed RTT women and those with a 
negative or unknown mutation status were respectively 2.20 and 2.00 (p=0.48). 
There are no indications that the negative or unknown mutation status is due to 
selection bias and would affect the results.  
Discussion 
This is the first longitudinal cohort study on aging in RTT. It provides longitudinal 
data of a 5-year follow-up. A high response rate of 80% resulted in obtained data on 
37 Dutch RTT individuals aged 21 years or more, reporting a broad range of clinical 
symptoms. This is a reasonably large cohort for a relatively recently defined disor-
der, infrequently diagnosed in adults (Nielsen et al., 2001). Molecular confirmation 
was possible for 83% of the women for whom analyses were carried out. This is 
reasonable, as not all analyses had access to the Multiplex Ligation-dependent 
Probe Amplification (MLPA) of MECP2 required for the detection of large deletions 
(Erlandson et al., 2003). Mutation results were not available for eight women. In 
spite of the molecular confirmation of a MECP2 mutation, RTT remains a clinical 
diagnosis based on internationally accepted criteria (Amir et al., 1999; Neul et al., 
2010). Molecular confirmation is not always necessary or desirable in older people 
who exhibit the clearly defined clinical characteristics. 
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Our results indicate improvement in the general health of the adult with RTT, 
with a reduction in physical complaints. However there remains a high level of care 
dependency, as a result of many RTT women living in residential facilities. Hospitali-
zation in the adult RTT women is mainly due to pneumonia, also an important cause 
of death in RTT (Freilinger et al., 2010). Therefore pneumonia should clearly be 
considered when such a woman is unwell. In this study few operations had been 
performed, mainly for orthopedic or dental conditions, confirming the overall good 
health. 
We confirmed the previously reported high mortality in RTT as compared with 
the general population (Kerr et al., 1997). During the 5-years of follow-up seven 
women died at a mean age of 27 years. The exact cause of death was not registered 
in most cases. As previously shown, there was a high incidence of sudden death in 
RTT, which makes it difficult to compile the exact causes of death in RTT (Kerr et al., 
1997; Ellaway & Christodoulou, 2001; Byard, 2006). In the initial records we found 
no significant health differences between those in the cohort who survived and 
those who later died or for whom the second questionnaire was not returned. In 
the earlier literature, the clinical picture in adult RTT has been reported to stabilize 
over time, with a high level of dependency. It is characterized by severe neurological 
impairment with a decline in motor function. In contrast to the surprisingly well-
preserved cognitive functions, reduced seizure activity and improved autonomic 
function (Witt Engerström & Hagberg, 1990; Ellaway & Christodoulou, 2001; Hag-
berg, 2002; Cass et al., 2003; Hagberg, 2005; Halbach et al., 2008; Smeets et al., 
2012; Vignoli et al., 2012). 
In this study there was only slight deterioration in gross motor function, based 
mainly on the parental view (Hagberg, 2002; Kerr, 2002; Cass et al., 2003; Hagberg, 
2005; Williamson & Christodoulou, 2006; Vignoli et al., 2012). However some elder-
ly women actually improved on these aspects (Jacobsen et al., 2001; Cass et al., 
2003; Hagberg, 2005). Emphasizing that therapy in the adult RTT women is still of 
great importance, in which the need to be adjusted to the characteristics of RTT 
(Jacobsen et al., 2001). Musculoskeletal problems were relatively stable during the 
5-year follow-up. However the prevalence of kyphosis increased with age, as previ-
ously reported by us, although the data on that change did not reach significance 
(Halbach et al., 2008). It is note-worthy that kyphosis has not been so far researched 
in RTT and guidelines for its management are lacking. Our study found less increase 
in rigidity and contractures as compared to other reports for adults with RTT and we 
suggest that this observation merits further investigation (Witt Engerström & Hag-
berg, 1990; Ellaway & Christodoulou, 2001; Hagberg, 2002; Cass et al., 2003; Hag-
berg, 2005; Smeets et al., 2012; Vignoli et al., 2012). It is possible that in our study 
the favorable reports reflected the overall improvement in psychological function-
ing. Giving a global picture of a more comforting RTT woman, parents could report a 
decreased level of rigidity. 
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Improvement in psychological functioning was mainly based on an improved 
memory, alertness and purposeful behavior in the adult RTT women (Hagberg, 
2002; Hagberg, 2005). Improved communication was reported in those over 30 but 
this did not reach statistical significance (Fontanesi & Haas, 1988; Budden et al., 
1990; Hagberg, 2002; Cass et al., 2003; Hagberg, 2005; Williamson & Christodoulou, 
2006; Halbach et al., 2008; Smeets et al., 2012; Vignoli et al., 2012). Given the im-
portance of mutual understanding, it is clear that active intervention with provision 
of alternative communication is justified throughout life in RTT (Halbach et al., 
2012). 
Our study confirmed the previously reported decrease in epilepsy in the older 
person with RTT (Steffenburg et al., 2001; Hagberg, 2002; Cass et al., 2003; Hagberg, 
2005; Vignoli et al., 2012). Nevertheless, the prescription of anticonvulsant medica-
tion remained high, indicating a need for regular review. Also the autonomic prob-
lems appeared to improve in the adults (Engerström, 1990; Kerr & Julu, 1999; Ella-
way & Christodoulou, 2001; Julu et al., 2001; Cass et al., 2003; Williamson & Chris-
todoulou, 2006; Halbach et al., 2008). Arguing the potential survival effect, reported 
as a possible explanation in our previous study (Halbach et al., 2008). Improvement 
was seen in several areas of autonomic function: skin problems, sleep disturbances, 
respiratory irregularities and digestive difficulties. However, nightly screaming had 
increased in women aged over 30 years (Hagberg, 2002; Hagberg, 2005; Smeets et 
al., 2012). 
Age related morbidity appeared uncommon. Hypertension and diabetes were 
reported to be absent, in contrast to the Dutch age and sex matched prevalence of 
hypertension of 7.5 - 15% (www.rivm.nl). Osteoporosis was reported in only two 
RTT women in our study, contrasting with the reports from other studies (Haas et 
al., 1997; Budden & Gunness, 2003; Zysman et al., 2006). Under reporting due to 
absence of screening may be responsible for these unexpectedly low figures. 
Screening for these age related conditions may be advisable as a routine element in 
the care for adult RTT women. 
In conclusion, many of our findings confirm earlier reports. The general disorder 
profile of the adult RTT woman in this study is that of a slow on-going deterioration 
of gross motor functioning in contrast to a better preserved cognitive functioning, 
less autonomic and epileptic features and overall good general health. Clinical pro-
vision should include the maintenance of gross motor skills and communication, 
awareness of the risk of pneumonia, regular review of anticonvulsant medication 
and screening for such age related disorders as hypertension, diabetes, osteoporo-
sis and kyphosis. Differences in results with most published RTT studies could be 
explained by several reasons. First, this study analyzed changes longitudinally rather 
than in a single cross-sectional review at one time. Comparing results in the same 
individual excludes the possible survivor effect in cross sectional studies. However, 
this longitudinal study has only a follow-up period of 5 years. Extending the follow-
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up period will probably give better and more reliable results. At last, the data are 
almost exclusively based on the parental view. Especially in the fourth section of the 
questionnaire with the vision of parents specifically requested. Our model for inves-
tigating the views of parents regarding their aging daughters has not been formally 
tested. However we consider that, in spite of their lack of medical training, parents 
are likely to be the first to notice changes in their daughters because they are so 
close to them in everyday life. The clinical data provided in this study offer insight in 
the natural course and prognosis of RTT in adults. It holds potential for continuing 
longitudinal review and the development of guidelines for early intervention and 
life-long individualized multidisciplinary provision that can improve the quality of 
life and health for the RTT woman and her family. 
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General discussion  
Thirty years have passed since RTT was revealed to the world as a unique and puz-
zling disorder in girls (Hagberg et al., 1983). There has been hope of developing a 
targeted therapy, especially since its reversibility was demonstrated in mouse mod-
els (Guy et al., 2007). However for the present there is still no specific treatment 
that can arrest the disorder's evolution or rescue the loss of acquired abilities. 
Hence the need for clinicians of advice on the clinical management of these females 
and support for their families. 
The aim of this thesis is to contribute to improved clinical management of RTT. 
Various aspects of the syndrome were evaluated, including the role of the genotype 
in clinical management, the pathophysiology of the impaired nutritional status and 
the ageing process of the RTT women. In this general discussion, the results will be 
discussed in a broader perspective and methodological considerations and clinical 
challenges will be addressed. Directions for future research in RTT are given. 
Results in perspective 
What is the role of the genotype in clinical management of the RTT female? 
Since the discovery in 1999 that RTT is caused by mutations in MECP2, large retro-
spective genotype-phenotype correlation studies have been performed and yielded 
often conflicting results (Amir et al., 1999; Amir et al., 2000; Cheadle et al., 2000; 
Huppke et al., 2000; Auranen et al., 2001; Hoffbuhr et al., 2001; Monros et al., 2001; 
Nielsen et al., 2001; Yamashita et al., 2001; Hoffbuhr et al., 2002; Huppke et al., 
2002; Leonard et al., 2003; Smeets et al., 2003; Weaving et al., 2003; Schanen et al., 
2004; Colvin et al., 2004; Charman et al., 2005; Fukuda et al., 2005; Kerr & Prescott, 
2005; Leonard et al., 2005; Smeets et al., 2005; Bebbington et al., 2008; Neul et al., 
2008; Smeets et al., 2009; Bebbington et al., 2010; Temudo et al., 2011). The limited 
correlation might be due to several reasons, including the subjectivity among differ-
ent clinicians or researchers completing the scoring lists. In chapter 2, a study is 
described in which one experienced clinician compared the clinical observations 
with the specific MECP2 mutations identified in a series of 137 cases. This in con-
trast to parental reports or questionnaires as used in other studies, making data 
more reliable and useful for counselling. Although general genotype-phenotype 
relationships could be confirmed, individual clinical variation in RTT females with 
the same mutation was generally very wide. Prognosis is a very important issue for 
parents. It determines their attitudes to planning their own and the planning of 
provision for their daughters. But due to the clinical variability of single mutations, 
genotype-phenotype relationships have only limited value in advising parents of 
newly diagnosed RTT females regarding her future outcome. However, the clinical 
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data presented in this study are of great value for the guidance of these parents 
during regular review of their daughters. The scoring lists include all common fea-
tures in RTT and the range of scores for these individual items is helpful in advising 
the parents about the expected clinical evolution. It is concluded that the limited 
genotype-phenotype correlation is not due to the subjectivity of different clinicians 
or researchers who fill in the scoring lists. It is more likely to arise from other fac-
tors, including methodological differences, for example in classification of muta-
tions, assessment tools and structure of datasets (Ham et al., 2005; Grillo et al., 
2012). Other genetic and epigenetic mechanisms, including variations in X inactiva-
tion patterns, may also modify the clinical presentation and these require further 
investigation (Ogier & Katz, 2008; Takahashi et al., 2008; Xinhua et al., 2008; Mat-
jievic et al., 2009). In addition “jumping genes” may also contribute to the pheno-
type. These genes, also known as retrotransposons, were first discovered by 
McClintock in 1948, wherefore she earned her Nobel Prize in 1983. Such genes can 
insert copies of so-called transposable elements of themselves into other parts of 
the genetic code, making one neuron function differently from its neighbour. In the 
absence of MeCP2 increased numbers of retrotransposons in the neurons of both 
mice and humans were found (Muotri et al., 2010). This could be an explanation for 
the clinical variety in RTT, even within females with the same mutation. 
 
In our collaborative multicentre study described in chapter 3, the effect of the geno-
type on brainstem instability was evaluated. Autonomic features are a major reason 
for seeking medical attention in RTT and this study is the first to use objective and 
robust data of brainstem cardiorespiratory variables in the study of genotype-
phenotype correlation in RTT. Baseline brainstem functions were severely affected 
in all RTT females investigated, reflecting the important impact of brainstem dys-
function on clinical severity in RTT as described in previous studies (Julu et al., 1997; 
Julu et al., 2001; Julu & Witt Engerström, 2005; Julu et al., 2012). These autonomic 
disturbances were not restricted to nor influenced by one specific group or single 
recurrent mutation. Although objective data were used, no constant relationship 
was found with the genotype. 
 
On the basis of the above-described studies, we concluded that the role of the gen-
otype in clinical management of RTT females is limited. The clinical variability within 
a specific genetic mutation or mutation group makes genotype-phenotype correla-
tions impossible. Autonomic dysfunction (dysautonomia) was present in all RTT 
females and no relation with the genotype could be found. Therefore we concluded 
that, from the clinical point of view, the cardiorespiratory phenotype is more im-
portant for clinical management than the genetic mutation. Neurophysiological 
assessment is recommended early after diagnosis or promptly after the onset of 
brainstem autonomic symptoms. This is advisable in order to plan an effective man-
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agement strategy for RTT females, since each of the three distinguishable cardi-
orespiratory phenotypes requires a different management strategy (Julu, 2001; Julu 
et al., 2005; Julu et al., 2008; Julu et al., 2012). Of course mutation in MECP2 should 
be determined on clinical suspicion of RTT in an infant girl with developmental de-
lay. Such early diagnosis is important in order to avoid prolonged uncertainty for the 
parents, to allow genetic counselling for the family and so that clinical management 
strategies may be initiated at the earliest possible age. 
Malnutrition in RTT: could altered metabolic processes be a cause? 
Although malnutrition is a prevalent problem in RTT females, the pathophysiology is 
still unknown and probably complex. In chapter 4, we investigated whether acid-
base imbalance due to the breathing irregularities causes disturbances in the meta-
bolic equilibrium, so contributing to malnutrition. Despite normal levels of total 
dietary energy and protein intake, all RTT females had significantly low fat-free mass 
index (FFMI) values. Although the loss of skeletal muscle mass may be partly due to 
physical inactivity, these low values were certainly an indication for impaired nutri-
tional status in these RTT females. A systematic metabolic screening was performed 
and showed significantly elevated creatine concentrations in plasma and/or urine in 
half of the RTT females. Different aetiologies might explain these creatine abnor-
malities, including age, cardiorespiratory phenotype and epigenetic influences af-
fecting the creatine transporter gene SLC6A8. The relevance of these creatine ab-
normalities to malnutrition remained unclear. Further research is continuing and 
described in appendix 1. 
In this follow-up study, the functionality of the creatine transporter has been 
investigated in fibroblasts under different CO2 circumstances. Firstly, previous find-
ings were confirmed in 12 of the 13 females. In three of the females elevated crea-
tine values were found in at least one body fluid on each occasion. However, the 
respective body fluid in which the increased values were found was different on 
each occasion. Here it is important to realize that these measurements are snap-
shots. One female had normal creatine concentrations in both plasma and urine in 
2009, however elevated creatine concentrations in plasma in 2010. This can be 
explained by change of reference values of creatine concentrations in plasma at the 
age of 10 years. In 2009 this female was 9 years and 8 months old, so reference 
values of the younger age group were applied and values were within the normal 
range. Secondly, intracellular creatine concentrations were measured in the fibro-
blasts cultured in the presence of 5% CO2 and in CO2-independent medium and 
atmospheric CO2 pressure in the RTT population and three controls. In the controls 
practically equal intracellular creatine concentrations were found under both 
growth conditions studied. However, in the total RTT population intracellular crea-
tine concentrations were significantly elevated in the fibroblasts when cultured at 
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5% CO2 compared to the CO2-independent medium in the RTT females and both 
culture media in controls. Only slight differences were seen in the different sub-
groups of RTT females, with higher intracellular creatine concentrations in fibro-
blasts of the forceful breathers and females with elevated creatine concentrations 
in plasma and/or urine. There is an overlap, since in particular forceful breathers 
have increased levels of creatine concentrations in plasma and/or urine. Thirdly, 
measurements were performed in a muscle biopsy of a 15-year-old forceful breath-
er with elevated creatine concentrations in plasma and urine. Significantly low con-
centrations of creatine, creatine phosphate and ATP were found. Concluding, the 
fibroblasts data strongly suggest that there is no primary creatine transporter de-
fect. Though there may very well be an alteration in the creatine transport regula-
tion. Given the differences in intracellular creatine concentrations in the fibroblasts 
of both culture media, CO2 seems to influence the creatine metabolism and/or 
transport in RTT females. pH dependency of the equilibrium of the alteration of 
creatine to form creatinine has previously been described (Wyss & Kaddurah-Daouk, 
2000). Creatine formation is favoured at high pH, which is in line with our observa-
tions of high creatine concentrations in plasma and/or urine of the forceful breath-
ers. Furthermore, low creatine, creatine phosphate and ATP concentrations were 
seen in the myocytes of one RTT female. A possible explanation could be increased 
energy requirement, which cannot be fulfilled in this RTT female. However, this 
might also be an expression of an abnormality in creatine transport regulation, lead-
ing to difficulty in transport of creatine into the myocyte. Another possible factor 
affecting intracellular concentrations of creatine might be an alternation in the 
composition of the plasma membrane. During the metabolic measurements it was 
noticed that the erythrocytes were very difficult to lyse. In Duchenne Muscular 
Dystrophy patients, increased plasma membrane fragility and subsequent leakage 
of cytosolic components are described, leading to low muscle concentrations of 
creatine, creatine phosphate and ATP in contrast to high serum creatine (Wyss & 
Kaddurah-Daouk, 2000). Finally, MeCP2 binds to the promoter region of the gene 
encoding guanidinoacetate methyltransferase (GAMT), involved in the creatine 
biosynthesis (Chahrour et al., 2008). However, a decreased expression of GAMT will 
impair the ability of the guanidinoacetate methyltransferase enzyme to participate 
in the creatine synthesis and lower creatine concentrations would be expected. 
Further research using classical transporter studies with labelled creatine will be 
needed to provide greater insight into the pathogenesis of the abnormal creatine 
metabolism and/or transport of different cell types, and its possible association with 
malnutrition in RTT. 
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What is the phenotype of adult RTT women? 
Due to the prolonged survival of RTT females, clinicians are increasingly challenged 
by the provision of care for adults with RTT (Donckerwolcke & Van Zeben-Van der 
Aa, 2002; Tyler & Noritz, 2009; Freilinger et al., 2010; Kirby et al., 2010; Vignoli et 
al., 2012). However, little is known about the ageing process in RTT. To gain insight 
into the age-related features in RTT, in chapter 5 a cross-sectional questionnaire 
study was carried out. Data were gathered on 53 Dutch RTT individuals aged 16 
years or older with a clinical diagnosis of RTT. The adult RTT group had a more or 
less stable condition. The general RTT disorder profile indicated deterioration in 
gross motor function in contrast to surprisingly better preserved cognitive function-
ing and reduced autonomic dysfunction. However, since cross- sectional data were 
used, it was considered that there might be a selection bias with the most severely 
affected dying earlier. Therefore, in chapter 6 a longitudinal ageing study was con-
ducted. The same population was contacted on a second occasion after five years. 
Many of the findings of this study confirmed earlier reports of ageing in RTT. On the 
second questionnaire, the adult RTT women were reported to have better general 
health, with reduction in physical complaints. However a higher mortality rate as 
compared with the general population was confirmed (Kerr et al., 1997). In RTT a 
high incidence of sudden death has been reported, to which cardiorespiratory mor-
bidity is suspected to contribute (Kerr et al., 1997; Ellaway & Christodoulou, 2001; 
Byard, 2006). In our cross-sectional study neurological, respiratory and behavioural 
morbidity appeared to have a major influence on the general health of the RTT 
females. However analysing the initial records of the first ageing study, we did not 
find any health differences between those in the cohort who survived and those 
who died during the five years between questionnaires. The general disorder profile 
of the adult RTT women is that of a slow on-going impairment of motor function, in 
contrast to a relatively better preserved ability to communicate, mainly through the 
characteristic eye-pinpointing and visual interactive behaviour. The diminishing 
autonomic features and lesser to absence of epileptic seizures contribute to an 
overall good general health. 
In order to maximise the clinical outcome of adult RTT women, clinical man-
agement must be directed towards maintaining motor function and skills. Learning 
ability persists to older ages (Piazza et al., 1993; Jacobsen et al., 2001; Nielsen et al., 
2001; Cass et al., 2003; Hagberg, 2005). Continuation of physical therapy at later 
ages is of great importance to maintain motor function and to prevent orthopaedic 
malformations. Given the importance of mutual understanding, it is clear that active 
intervention with provision of alternative and supportive communication is justified 
throughout life in RTT. Special medical attention is needed for the prevention and 
diagnosis of pneumonia, since pneumonia was the main reason for hospital admis-
sion and also an important cause of death in RTT. Therefore the possibility of pneu-
monia should be considered when a RTT woman is unwell. Age-related morbidities 
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such as hypertension, diabetes type II and osteoporosis were rarely reported, in 
contrast to previous reports, in which osteoporosis was prevalent in RTT (Haas et 
al., 1997; Budden & Gunness, 2003; Zysman et al., 2006). Under reporting due to 
absence of screening is likely to be responsible for our unexpectedly low figures. 
Therefore, we advise screening for these age related conditions as a routine ele-
ment in the care for adult RTT women. Kyphosis is a common age-related orthopae-
dic malformation in RTT. Surprisingly, little is known about the clinical management 
of kyphosis. Given the increasing prevalence of kyphosis with age, future research is 
therefore needed. Reports of epileptic seizures reduced with increasing age. Never-
theless, the prescription of anticonvulsant medication remained high. Reduction of 
in antiepileptic drugs should be seriously considered when a RTT female is seizure 
free for 2 years. 
In conclusion, the clinical data provided in our ageing studies give more insight 
into the natural course and prognosis of RTT in adult women. Overall, clinical severi-
ty evolves over time and not always for the worse. Although the follow-up period in 
our cohort of RTT woman thus far is relatively short, the findings are interesting and 
consistent with previous research. Extending the follow-up period will give better 
and more stable results. These studies hold great potential for continuing longitudi-
nal review that will enable the development of guidelines for early intervention and 
a life-long individualised multidisciplinary approach. This can contribute to the qual-
ity of life and health of RTT women. The success of this approach needs to be as-
sessed in future studies. 
Methodological considerations 
Collaborations 
The majority of our studies have been performed in close association with the RTT 
parent associations and RTT parental support foundation. Close collaboration be-
tween physicians and parents is of great importance in clinical research and ensures 
that the needs of the RTT females and their families are met. It contributes to 
awareness, improved knowledge and the development of appropriate information 
for families and health professionals. The high response rates in the questionnaire 
studies confirm the success of this collaboration. As well as parental involvement, 
engagement in international collaborative networking is crucial to effective research 
in rare disorders. Sharing expertise and creating databases with sufficient numbers 
of patients improves the methodological quality of research and leads to better 
understanding of the syndrome. All this is essential in order to facilitate future de-
velopment of evidence-based management strategies and therapeutic intervention. 
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Material and methods 
In the genotype-phenotype studies, the internationally accepted clinical scoring 
system was used (Kerr et al., 2001). This scoring list was modified in our collabora-
tive multicentre study. Two adjustments were made: adding an item concerning 
gastro-intestinal and bladder problems and moving the oro-motor disturbances 
from the movement into the autonomic domain. Gastro-intestinal and bladder 
problems are in fact very prevalent in RTT females (Giesbers et al., 2012). Previous 
studies have shown that the oro-motor difficulties are brainstem related in RTT (Julu 
& Witt Engerström, 2005). This modified version of the clinical scoring system is 
more complete and adapted to the pathophysiology of RTT and therefore recom-
mended for use in future studies. 
 
Grouping of mutations was primarily based on the domain in the MECP2 gene in 
which the mutation was localised. Recurrent mutations were analysed separately. 
This method is commonly used in genotype-phenotype studies to date, but it only 
partly accounts for the biological effect of a mutation on the MeCP2 protein. There-
fore type and location should be combined as described in the collaborative multi-
centre study. This method is therefore recommended in future genotype-phenotype 
studies. 
 
Data in the ageing studies were based on questionnaires mainly completed by par-
ents. Although the medical background of parents may be limited, they are the 
closest to their daughters in everyday life and are the most able to notice changes in 
development. One of the disadvantages of using questionnaires, is the occurrence 
of recall bias. However, especially in exploratory research, the use of questionnaires 
is a good method for collection of a large amount of information. For follow-up 
studies it will be preferable to use clinical measurements in order to increase 
knowledge about ageing in RTT, and to facilitate the development of guidelines for 
early intervention and evidence-based management strategies. 
Clinical challenges 
As RTT is a rare disorder, most clinicians gain experience with only small patient 
series. RTT is a complex and puzzling disorder presenting some unique clinical mani-
festations. It therefore requires specific knowledge and specific intervention for 
proper evaluation and adequate management. In 2011, the Maastricht University 
Medical Centre established a RTT Expertise Centre, pursuing and advocating an 
individualised multidisciplinary team approach. Since parents become great experts 
concerning their own child’s history, behaviour and needs, they are critical mem-
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bers of this team. For more information on the RTT Expertise Centre and autonomic 
assessment in particular please refer to appendix 2 in this thesis. 
 
It is hoped that most paediatricians are now familiar with the presentation of classi-
cal RTT. However, in clinical practice RTT is frequently still diagnosed at a late stage, 
although it is one of the leading monogenetic causes of severe intellectual disability 
in females. Differential diagnoses such as Angelman syndrome, with a lower preva-
lence of 1:20,000 (Steffenburg et al., 1996), are often excluded at a much earlier 
age. Given the importance of early diagnosis, clinicians need to consider RTT in any 
infant girl with a developmental delay. RTT is under-diagnosed in elderly women, for 
whom diagnostic alertness may be reduced. At older ages the clinical characteristics 
become less obvious and are readily overlooked, especially when the information 
about early infancy and childhood is limited (Nielsen et al., 2001). 
Conclusions and future perspectives 
In this thesis, information is presented for clinicians and families regarding assess-
ment and clinical management of RTT females. The role of the genotype in clinical 
management, the pathophysiology of malnutrition and the phenotype of adult RTT 
women are considered. This information contributes to advice on the clinical man-
agement of RTT females and to the development of guidelines for early intervention 
and evidence-based management strategies. The deviant brain and brainstem de-
velopment with defective and immature functioning leads to a cascade of clinical 
features. Particularly striking is the prominent role of the cardiorespiratory pheno-
type in this syndrome. The breathing irregularities are very distressing to the RTT 
females and their families. They are a prominent reason for seeking medical advice 
and they may contribute to sudden death. The clinical relevance of the cardiorespir-
atory phenotype in RTT is confirmed in this study. Neurophysiological assessment is 
therefore recommended early in stage three, in order to plan better and effective 
clinical management strategies. The clinical management of the brainstem auto-
nomic dysfunction in RTT is a major challenge for the clinician. The multi-organ 
involvement requires multi-disciplinary and cross-professional collaboration to in-
clude paediatrician, respiratory physician, neurologist, anaesthetist, cardiologist, 
orthopaedic surgeon, endocrinologist, physiotherapist, speech therapist, nutritionist 
and nurse. Further advances in understanding the cardiorespiratory pathophysiolo-
gy in RTT will be the key to an appropriate and effective clinical management. 
 
The ultimate goal of basic research is to understand the disorder and so to design 
effective new therapeutic avenues. Although much has been learned about RTT 
since its first description, the pathogenesis of this unique disorder is still not fully 
understood despite the identification of the mutations in MECP2 in the vast majori-
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ty of the RTT females. In many ways RTT remains a mystery, with no clear correla-
tions between the gene mutation and abnormal biological markers (like creatine in 
our study), neuropathology and neurophysiology leading to its unique clinical 
presentation (Kerr & Witt Engerström, 2001; Hagberg et al., 2002; Bienvenu & 
Chelly, 2006; Chahrour & Zoghbi, 2007, Matsuishi et al., 2011). Optimism is justified 
regarding possible therapies, especially since the work of Guy and colleagues, that 
in the RTT mice the neurological regression may be reversed, in part or in whole 
(Guy et al., 2007). Lack of understanding its pathogenesis is the major reason for 
lack of an effective therapy in RTT. Therefore besides concentrating on clinical man-
agement, future research will need to focus further on understanding the molecular 
pathways in RTT, including the identification of further target genes and their inter-
action with MECP2 and CDKL5. Such research may provide alternative strategies to 
targeting MeCP2 deficiency directly through gene therapy. Gene therapy is particu-
larly problematic because MeCP2 levels are tightly regulated and over-expression as 
seen in patients with a MECP2 duplication appears to be even more deleterious 
than loss of expression. Hopefully the target gene approach will identify specific 
therapeutic targets, leading to improvement in the health and quality of life of the 
RTT females. It may also yield insights into normal brain development and function 
and into mechanism involved in other neurodevelopmental disorders. Another 
approach in basic science would consist of achieving read through in case of non-
sense mutations in MECP2. Pharmacological agents such as aminoglycoside antibiot-
ics may enable read through of these mutations, possibly resulting in the production 
of a full-length functional protein with virtually preserved activity. Recent research 
appears promising, but still is inconclusive (Brendel et al., 2009; Popescu et al., 
2010; Vecsler et al., 2011; Brendel et al., 2011). In basic research, animal models 
provide important opportunities to examine the pathophysiological mechanisms 
involved in various aspects of the syndrome and to evaluate potential therapeutic 
approaches. They will contribute to the understanding of MECP2 function and the 
pathobiology of RTT. 
 
In conclusion, treatment of RTT will be a lifelong challenge for clinicians and re-
searchers all over the world. Until a breakthrough in genetic therapy, clinicians will 
have to rely on conservative medical treatments and preventive management strat-
egies based on clinical evidence. Understanding of the cardiorespiratory neurophys-
iology in RTT is one of the important goals for research, resulting in an effective 
treatment that can improve quality of life and long term survival. 
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Altered carbon dioxide metabolism and 
creatine abnormalities in Rett syndrome: 
a continuing study 
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Introduction 
The pathophysiology of malnutrition in RTT is largely unknown. Besides feeding 
difficulties, other constitutional factors such as altered metabolic processes are 
suspected (Motil et al., 1998; Reilly & Cass, 2001; Oddy et al., 2007; Motil et al., 
2009; Platte et al., 2011; Motil et al., 2012). In preliminary research performed by 
our research group (Halbach et al., 2012), it was investigated whether acid-base 
imbalance due to the breathing irregularities causes metabolic disturbances, as a 
possible explanation for the impaired nutritional status. The systematic metabolic 
screening that was carried out revealed elevated creatine concentrations in plasma 
and/or urine in half of the RTT females. Since various etiologies might explain these 
results, further studies were indicated. 
Patients and Methods 
Ethical approval was obtained from the Medical Ethical Committee at the Maas-
tricht University Medical Centre, and all parents provided informed written consent. 
The study was registered at clinicaltrials.gov. 
Patient population 
In this follow-up study the same population was contacted as in preliminary re-
search (Halbach et al., 2012), consisting of 13 well-defined RTT females who had 
extended clinical, molecular and neurophysiological assessments. All parents of the 
RTT females agreed to participation. 
Study design 
The aim of this study was to confirm previous findings and to examine the function 
of the creatine transporter in RTT females in different CO2 circumstances. First, for 
confirmation of the previous study findings, blood and urine samples were collected 
for creatine measurements. Secondly, a skin biopsy was collected for functional 
studies of the creatine transporter. In one RTT female there was the opportunity to 
access a muscle biopsy allowing for creatine measurements to be made. 
Metabolic measurements 
Cell culture and creatine uptake 
Skin fibroblast cultures were established from skin biopsies and were routinely 
maintained in AminoMax II culture medium at 37 °C and 5% CO2 in a humidified 
atmosphere. For creatine uptake experiments, fibroblasts were harvested by trypsi-
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nation, and seeded in 6-well plate wells and allowed to adhere overnight. Medium 
was then refreshed and experiments were started once cultures reached 70-90%. In 
an alternative procedure, cells were cultured for two passages in CO2-independent 
medium at 37 °C in a humidified atmosphere, without extra CO2 (atmospheric CO2 
pressure). 
Creatine uptake studies were performed by replacing the medium with a crea-
tine enriched medium, containing 0-1100 µm creatine. The concentration used for 
the panel of cell lines was 500 µm creatine. After 24h of incubation, the cells were 
harvested by trypsination, washed in saline and then disrupted by sonication in 
water. The supernatant obtained after centrifugation, was used for the determina-
tion of creatine and protein content. Creatine was measured on a UPLC-MS/MS 
system using a stable isotope labeled internal creatine standard for quantification. 
 
In addition to the RTT population, measurements were performed in the same 
manner for three healthy female controls. 
Creatine measurements in muscle biopsy 
For loss of muscle mass and suspected mitochondrial disorder, a muscle biopsy was 
taken on clinical grounds in RTT female number 10. It was obtained during scoliosis 
surgery in 2011 from the middle region of the vastus lateralis muscle through the 
fascia by the percutaneous needle biopsy technique described by Bergström (1975), 
using a modified needle (Maastricht Instruments). A small incision was made in skin 
and fascia after which the biopsy needle was introduced in the muscle. Vacuum was 
applied to the needle and, with the needle kept in situ, several small muscle sam-
ples (total ± 50-80 mg) were taken. Spectrophotometric determination of creatine, 
creatine phosphate (PCr) and ATP was performed (Harris et al., 1974). 
Results 
Table 1 shows the patients' characteristics and creatine concentrations in plasma, 
urine and fibroblasts. Age of the females relates to the age in 2009. Of the 13 fe-
males, nine females showed equal results of creatine concentrations in plasma and 
urine, interpreted as normal and/or elevated. One female had elevated creatine 
concentrations in plasma in 2009 and in urine in 2010. Two females had elevated 
creatine concentrations in both plasma and urine in 2009. However in 2010, crea-
tine concentrations were elevated in plasma only. One female had normal creatine 
concentrations in both plasma and urine in 2009, and elevated creatine concentra-
tions in plasma in 2010.  
  
A p p e n d i x  1  
 128
Table 1 Patient characteristics and creatine concentrations in plasma, urine and fibroblasts including age-
specific reference values of 13 RTT females 
RTT 
female 
Age 2009 
(yr.months) 
CRPh Cr P 
2009 
Cr U 
2009 
Cr P 
2010 
Cr U 
2010 
Cr 
Total 
Cr F 
5% CO2 
Cr F 
0% CO2 
1 2.4 FeB 75.7 
(17-109) 
490.6 
(6-1200) 
61.6 
(17-109) 
650.6 
(6-1200) 
N 19.1 15.03 
2 3.11 FeB 79.5 
(17-109) 
421.3 
(6-1200) 
82.6 
(17-109) 
694.8 
(17-720) 
N 18.5 13.3 
3 4.0 FeB 88.1 
(17-109) 
Und 86.6 
(17-109) 
Und N 20.9 15.93 
4 4.3 FeB 81.0 
(17-109) 
828.8* 
(17-720) 
75.2 
(17-109) 
1456.6* 
(17-720) 
E 21.57 7.87 
5 5.3 FeB 83.5 
(17-109) 
28.6 
(17-720) 
47.3 
(17-109) 
26.0 
(17-720) 
N 18.47 16.3 
6 6.2 FoB 63.0 
(17-109) 
629.7 
(17-720) 
95.8 
(17-109) 
512.5 
(17-720) 
N 25 13.97 
7 9.8 FoB 52.9 
(17-109) 
756.2* 
(17-720) 
56.4* 
(6-50) 
508.4 
(17-720) 
E 23.77 13.47 
8 9.8 FoB 68.7 
(17-109) 
124.3 
(17-720) 
77.9* 
(6-50) 
98.7 
(17-720) 
E 16.87 10.97 
9 10.11 FoB 70.4* 
(6-50) 
1,305.3* 
(17-720) 
55.3* 
(6-50) 
932.1* 
(11-240) 
E 25.73 19.07 
10 13.3 FoB 73.5* 
(6-50) 
448.0* 
(11-240) 
71.4* 
(6-50) 
308.0* 
(11-240) 
E 20.97 10.77 
11 13.11 Und 101.5* 
(6-50) 
1040.3* 
(11-240) 
81.0* 
(6-50) 
1041.8* 
(11-240) 
E 24.2 16.93 
12 19.3 FoB 88.5* 
(6-50) 
403.7* 
(11-240) 
54.7* 
(6-50) 
117.0 
(11-240) 
E 28.57 12.83 
13 20.3 FoB 65.0* 
(6-50) 
538.3* 
(11-240) 
64.3* 
(6-50) 
211.5 
(11-240) 
E 15.57 17.03 
CRPh Cardiorespiratory phenotype, FeB Feeble breather, FoB Forceful breather, Und Undetermined, Cr 
Creatine, P Plasma, U Urine, Cr F Intracellular creatine in fibroblasts in nmol creatine/mg protein, N 
normal creatine concentrations, E Elevated creatine concentrations, * Elevated value. 
 
Intracellular creatine concentrations were measured in fibroblasts cultured in the 
presence of 5% CO2 and in CO2-independent medium and atmospheric CO2 pres-
sure. In Table 2 the mean intracellular creatine concentrations measured under the 
described conditions are presented for the RTT population and controls, and for 
different subgroups of the RTT population selected according to cardiorespiratory 
phenotype and creatine concentrations in plasma and urine. As already stated in 
our previous study (Halbach et al., 2012), the mean age of the forceful breathers 
was significantly higher than the mean age of the feeble breathers (14.1 vs. 5.4 
years). The mean age of the RTT population was somewhat lower than the controls, 
10.8 years and 12.7 years respectively. The intracellular creatine concentrations of 
the controls were almost identical under both growth conditions studied. In the RTT 
population, when cultured at 5% CO2 intracellular creatine concentrations were 
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significantly higher than in controls (mean creatine concentration 21.48 compared 
to 13.04). At atmospheric CO2 intracellular creatine concentrations were almost 
identical in the RTT population and controls (14.11 compared to 14.15). With re-
spect to subgroups, at 5% CO2 intracellular creatine concentrations were higher in 
the forceful breathers (22.35) compared to the feeble breathers (19.71). Females 
with elevated creatine concentrations in plasma and/or urine also had higher crea-
tine concentrations in fibroblasts at 5% CO2 compared to females with normal crea-
tine concentrations in plasma and/or urine (22.16 vs. 20.39). At atmospheric CO2 
intracellular creatine concentrations were practically identical in all subgroups, with 
the exception of two RTT females. The lowest intracellular creatine concentration of 
7.87 was measured in a 5-year-old feeble breather with elevated creatine concen-
trations in urine. The highest intracellular creatine concentration of 16.93 was 
measured in a 15-year-old RTT female with an undetermined cardiorespiratory 
phenotype and elevated creatine concentrations in plasma and urine. 
 
Table 2 Mean age and creatine concentrations in fibroblasts (nmol creatine/mg protein) under conditions 
of 5% CO2 medium and CO2-independent medium in controls and the total and subgroups of the RTT 
populations 
Group (n) Mean 
age 2010 
Mean Cr 
5% CO2 
 
0% CO2 
Controls (n=3) 12.67 13.04 14.15 
Rett females Total group (n=13) 10.81 21.48 14.11 
Forceful breathers Total group (n=7) 14.06 22.35 14.02 
 Forceful breathers normal creatine concentrations (n=1) 7.25 25 13.97 
 Forceful breathers elevated creatine concentrations (n=6) 15.19 21.91 14.03 
Feeble breathers Total group (n=5) 5.37 19.71 13.69 
 Feeble breathers normal creatine concentrations (n=4) 5.33 19.24 15.14 
 Feeble breathers elevated creatine concentrations (n=1) 5.50 21.57 7.87 
Undetermined CRPh with elevated creatine 
concentrations (n=1) 
15.25 24.2 16.93 
Normal creatine concentrations (n=5) 5.72 20.39 14.91 
Elevated creatine concentrations (n=8) 13.99 22.16 13.62 
n Number of persons, Cr Creatine. 
 
Measurements in the muscle biopsy showed low concentrations of creatine in the 
RTT female (28.4 umol/g muscle) as compared with healthy controls (57.95 +/- 
11.18 umol/g). Also both PCr and ATP were lower in RTT tissue as compared with 
healthy controls (respectively 16.5 versus 45.28 +/- 26.32 umol/g and 7.20 versus 
21.00 +/- 5.15 umol/g). 
 
Research at our metabolic lab aimed at the functionality of the creatine transporter 
will be continued. 
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RTT Expertise Centre 
The RTT Expertise Centre was founded in September 2011 at the Maastricht Univer-
sity Medical Centre (MUMC+). This clinical research centre offers highly specialised 
multidisciplinary medical care, including autonomic assessment of brainstem func-
tions and serves as a centre of excellence in the Netherlands. In view of the im-
portant role of autonomic dysfunction in this thesis, we discuss here in some detail 
the autonomic assessment procedure as performed at the RTT Expertise Centre. 
Autonomic assessment background 
The neurophysiological technique used at the RTT Expertise Centre assesses brain-
stem function in real-time, continuously and synchronously. These functions are 
coupled with a time-locked 21 channel electroencephalogram (EEG) and video mon-
itoring of behaviour in order to help to differentiate seizures from RTT specific 
breathing disturbances. The cardiovascular and respiratory vital signs originating 
from and regulated by the brainstem are quantified and recorded synchronously for 
the study of both temporal and causal relationships. 
 
The cardiovascular signs quantified and recorded are: 
• Cardiac Vagal Tone (CVT) 
CVT is a measure of parasympathetic stimulation to the heart via the vagus 
nerve, i.e. it represents the cardiac index of parasympathetic activity. In ven-
tricular systole an increase in blood pressure results in baroreceptor stretching, 
causing increased baroreceptor discharge to the nucleus of the tractus solitarius 
(NTS). This stimulus initiates reflex vagal nerve discharge leading to reduction in 
the rate of spontaneous depolarisation of the sino-atrial node, thus prolonging 
the RR interval. CVT can therefore be calculated from the R-R intervals in the 
ECG, because it is a form of R-R interval variability (Hamilton et al., 2003). 
• Cardiac Sensitivity to Baroreflex (CSB) 
The baroreflex mechanism has been recognized as a key part of cardiovascular 
regulation. CSB is defined as the change in R-R interval per unit change in systolic 
blood pressure (ms/mmHg; Julu et al., 1996). It represents the feedback effect of 
blood pressure on heart rate. Its measurement therefore requires synchronous 
recording of both ECG and the beat- to-beat blood pressure waveform. 
• Arterial blood pressure (BP) 
• Heart rate (HR) 
 
The respiratory vital signs quantified and recorded are: 
• Breathing rate and pattern of breathing 
• Transcutaneous partial pressures of oxygen (tcpO2) and carbon dioxide (tcpCO2) 
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• Oxygen saturation using plethysmography 
Autonomic assessment in practice 
The RTT Expertise Centre’s autonomic assessment is performed at the Paediatric 
Intensive Care Unit (PICU). RTT females are admitted to the hospital for three days. 
On the second day, extensive autonomic assessment is performed. All procedures 
are non-invasive and painless. During these measurements, the female is comforta-
bly relaxed in a hospital bed for the afternoon and throughout the following night. 
Because of the restrictive effect of these measurements, the beat-to-beat BP meas-
urements are recorded only for up to two hours. All other parameters are recorded 
throughout the afternoon and night. BP waveforms are detected and recorded by a 
finger cuff, which are quantified and calibrated by the Nexfin (® Bmeye, Nether-
lands) resulting in calculated beat-to-beat systolic, mean and diastolic BP values. 
The ECG is measured to quantify HR, CVT and CSB. Two stretch-sensitive DC-
recording belts around the patient’s chest and abdomen record the frequency and 
amplitude of thoracic and abdominal breathing. Also mouth and nose respiration is 
monitored by a thermocouple and a capnograph to measure end-tidal CO2. 
Transcutaneous tcpO2 and tcpCO2 are quantified every second by an Intelliview 
MP50 monitor (® Philips, The Netherlands). The EEG is recorded by a 21-channel 
EEG combined with time-locked video monitoring of behaviour. 
Defining cardiorespiratory phenotype 
Breathing irregularities are a common feature in RTT. Moreover breathing 
dysrhythmia was seen in nearly all RTT females who underwent autonomic assess-
ment. Julu and Witt-Engerström (2005) have defined three different cardiorespira-
tory phenotypes in RTT. Research into the severe cardiorespiratory problems expe-
rienced by RTT females, is performed by the European Scientific Rett Research As-
sociation (ESRRA; www.esrra.eu). A strategy for clinical management of the cardi-
orespiratory problems has been published in the Lancet (Julu et al., 2008) and the 
most recent publication involves treating hypoxia in a feeble breather (Julu et al., 
2012). 
In the characterisation of the breathing patterns, both frequency and amplitude 
are important. A normal breathing movement is a ramp inspiratory expansion of the 
chest terminated abruptly and immediately followed by a double phased expiratory 
reduction in the chest volume (Figure 1). This shape reflects the normal function of 
the brainstem respiratory neurons. Normal breathing rhythm in RTT is below 35 
breaths/minute. To determine whether a given breath effort is sufficient to venti-
late a person, transcutaneous partial pressures of the respiratory gases are meas-
ured, including tcpO2 and tcpCO2. 
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Figure 1 Normal breathing movement (Julu, 2001) 
 
A total of 13 abnormal awake breathing rhythms have been described, with a subdi-
vision into three cardiorespiratory phenotypes representing nine of these abnormal 
breathing rhythms. An additional four breathing rhythms are Valsalva breathing, 
Biot’s breathing, Cheyne-Stokes breathing and atypical breathing. The latest types 
of breathing may be seen in all the cardiorespiratory phenotypes and do not appear 
to belong to one specific cardiorespiratory phenotype. To define the cardiorespira-
tory phenotype of the RTT female, the percentage of time spent in each rhythm of 
breathing is calculated. The majority of the females show almost all of abnormal 
breathing rhythm but one rhythm usually predominates and the cardiorespiratory 
phenotype diagnosis for that individual is made according to the predominant 
breathing rhythm. 
Forceful breathers 
Breathing rhythms belonging to this cardiorespiratory phenotype are: deep breath-
ing, tachypnoea and hyperventilation. Due to these breathing rhythms, forceful 
breathers tend to have fixed low levels of pCO2, i.e. chronic respiratory alkalosis. 
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Figure 2 Abnormal breathing patterns belonging to the forceful cardi-
orespiratory phenotype (Julu, 2001) 
Feeble breathers 
Breathing rhythms belonging to this cardiorespiratory phenotype are: central ap-
noea and shallow and rapid shallow breathing. Due to long-term inadequate ventila-
tion, feeble breathers tend to have fixed higher levels of pCO2, i.e. chronic respirato-
ry acidosis. 
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Figure 3 Abnormal breathing patterns belonging to the feeble cardi-
orespiratory phenotype (Julu, 2001) 
Apneustic breathers 
Breathing rhythms belonging to this cardiorespiratory phenotype are: protracted 
inspiration, breath holds and regular breath holds. Due to the delayed and inade-
quate expirations, apneustic breathers accumulate carbon dioxide and therefore 
tend to have fixed higher levels of pCO2. 
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Figure 4 Abnormal breathing patterns belonging to the apneustic
cardiorespiratory phenotype (Julu, 2001) 
 
For more detailed information please refer to www.esrra.eu. 
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Rett syndrome (RTT) is a severe, clinically defined neurodevelopmental disorder, 
affecting predominantly females. With an incidence of 1/10,000 to 1/15,000, RTT is 
recognized as a prominent genetic cause of severe intellectual disabilities in fe-
males. RTT is characterized by an apparently normal early development, followed by 
loss of intellectual functioning, communicative abilities and motor skills. The re-
placement of purposeful hand use by stereotypic hand movements, gait abnormali-
ties, growth retardation, seizures and autonomic dysfunction become evident. The 
natural history of RTT is separated into four distinct stages: early stagnation, rapid 
regression, pseudo-stabilization and late motor deterioration. Mutations in MECP2 
are detectable in up to 95% of classical RTT cases. Despite molecular genetics, RTT 
remains a clinical diagnosis. RTT is phenotypically complex with a wide variability in 
clinical evolution and severity and no clear genotype to phenotype relationships. 
Beside the classical form of RTT, several atypical variants have been recognised. 
Clinical management is essentially symptomatic and supportive, as at present there 
is no cure for the disorder. 
 
In chapter 1 RTT is described historically and clinically, including the staging system 
and diagnostic criteria, followed by genetic background and clinical management. 
The aim of this thesis is presented with an outline of the individual chapters. 
 
The first part of this thesis considers the role of the genotype in clinical manage-
ment. Up until now, genotype-phenotype studies have shown conflicting results. 
Among the many factors which could play a role, in chapter 2 it was excluded that 
these limited correlations between genotype and phenotype could be due to the 
subjectivity among clinicians and researchers completing the scoring lists. Even 
within one mutation or mutation group, clinical severity was very variable, providing 
limited prognostic assistance in counselling young parents. In chapter 3 the results 
of a collaborative multicentre genotype-phenotype study are presented. In this 
study, the influence of genotype on autonomic functions was investigated. Auto-
nomic dysfunction was shown to be present in all females, but there was no fixed 
relationship between the genotype and the autonomic variables studied. It was 
concluded that, whereas the exact genotype has limited relevance, clinical neuro-
physiological assessment is important for clinical management. 
 
The second part of this thesis addresses the little understood pathophysiology of 
impaired nutritional status in RTT. In chapter 4 the possible role of altered metabol-
ic processes was investigated. In half of the RTT females, systematic metabolic 
screening showed significantly elevated creatine concentrations in plasma and/or 
urine, for which there were considered to be several possible explanations. Further 
research on the function of the creatine transporter is ongoing, and is described in 
appendix 1. Early results confirmed elevation of creatine concentrations in plasma 
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and/or urine. Investigations performed in the fibroblasts of RTT females strongly 
suggested that there was no primary creatine transporter defect, however there 
remained the possibility of an abnormality of the creatine transport regulation. It 
was suggested that creatine metabolism or transport in RTT may be influenced by 
CO2 levels in plasma, because within the RTT population, a difference was found 
between the creatine concentrations in 5% CO2 medium and a CO2-independent 
medium. Significantly low concentrations of creatine, creatine phosphate and ATP 
measured in the myocytes of a RTT female could be due to increased energy re-
quirements or to an abnormality in the creatine transport regulation. Alterations in 
the plasma membrane were also considered a possible factor. It was concluded that 
further research is required to clarify the state of creatine metabolism and transport 
in RTT and possible associations with malnutrition. 
 
The third part of this thesis addresses the ageing process in RTT. Life expectancy of 
RTT females has improved substantially in the last decades, thereby increasingly 
challenging clinicians regarding the care of adult RTT women. However, little is 
known about the ageing process in RTT. Chapter 5 deals with a cross-sectional study 
that confirmed the recognised general disorder profile in RTT, including increasing 
incidence of kyphosis with better communication and autonomic functions. Chapter 
6 reports a longitudinal study carried out in order to exclude a possible 'survivor' 
effect (whereby only the most fit survive). This study demonstrated a slow on-going 
deterioration of gross motor functioning, contrasting with better preserved cogni-
tive functioning, reduced autonomic and epileptic features and improved general 
health. These findings justified recommendations for clinical management of RTT 
women, including continuing motor and communicative therapies, risk-awareness 
for pneumonia and the need for regular review of anti-epileptic medication and 
screening. 
 
Chapter 7 summarises the most important findings and considers these from a 
broader perspective, including methodological matters, clinical challenges and rec-
ommendations for future research. Appendix 2 describes the autonomic assess-
ment as performed at the RTT Expertise Centre of the Maastricht University Medical 
Centre. 
  

 143 
 
Samenvatting 
 
 
  
S a m e n v a t t i n g  
 144
Rett syndroom (RTT) is een ernstige, klinisch gediagnostiseerde ontwikkelingsstoor-
nis, welke bijna uitsluitend bij meisjes voorkomt. Met een incidentie van 1 op 
10.000 tot 15.000, is RTT één van de belangrijkste genetische oorzaken van ernstige 
verstandelijke beperkingen bij meisjes. RTT wordt gekarakteriseerd door een ogen-
schijnlijk normale vroege ontwikkeling, gevolgd door verlies van cognitieve, com-
municatieve en motorische functies. In der tijd ontstaan handstereotypen waardoor 
geen gerichte handfunctie meer mogelijk is, een afwijkend looppatroon, groeiach-
terstand, epilepsie en autonome dysfunctie. Vier stadia worden onderscheiden in 
het ontstaan en de ontwikkeling van RTT: vroege stagnatiefase, snelle destructiefa-
se, pseudo-stationaire fase en late deterioratiefase. Mutaties in het MECP2 gen 
worden in tot wel 95% van de meisjes met klassiek RTT gevonden. Ondanks deze 
moleculaire bevestiging, blijft RTT een klinische diagnose. RTT is een complexe aan-
doening met een grote variabiliteit in klinische evolutie en ernst, waarbij geen evi-
dente relaties worden gezien tussen het genotype en fenotype. Naast de klassieke 
vorm van RTT, zijn er ook enkele atypische varianten beschreven. Klinisch manage-
ment bij RTT is voornamelijk symptomatisch en ondersteunend, aangezien genezing 
vooralsnog niet mogelijk is. 
 
In hoofdstuk 1 wordt een toelichting op RTT gegeven, waarbij wordt ingegaan op de 
geschiedenis, de diagnosestelling, de genetische achtergrond van en het klinisch 
management bij RTT. De vraagstellingen behorende bij dit proefschrift worden na-
der toegelicht, gevolgd door een overzicht van de verschillende hoofdstukken. 
 
Het eerste gedeelte van dit proefschrift richt zich op de rol van het genotype in 
klinisch management. Vooralsnog laten genotype-fenotype studies tegenstrijdige 
resultaten zien. Als één van de mogelijke factoren voor de beperkt gevonden geno-
type-fenotype relaties, werd in hoofdstuk 2 de subjectiviteit onder clinici en onder-
zoekers bij het invullen van de vragenlijsten als mogelijk rol hierin geëxcludeerd. 
Binnen elke mutatie of mutatiegroep varieerde de ernst tussen de meisjes zodanig 
dat het moeilijk is om op basis van de mutatie informatie over de prognose te ge-
ven. In hoofdstuk 3 worden de resultaten van een multicenter genotype-fenotype 
studie naar de invloed van het genotype op de autonome functies besproken. Bij 
alle RTT meisjes was sprake van autonome dysfunctie, waarbij geen relatie werd 
gevonden tussen het genotype en de onderzochte autonome variabelen. Geconclu-
deerd werd dat de rol van het genotype in klinisch management beperkt is, echter 
het belang van klinisch neurofysiologisch onderzoek werd benadrukt. 
 
Het tweede gedeelte van dit proefschrift richt zich op de pathofysiologie van onder-
voeding bij RTT, welke grotendeels onbekend is. In hoofdstuk 4 wordt de mogelijke 
rol van veranderde metabole processen beschreven. De systematisch uitgevoerde 
metabole screening liet significant verhoogde creatine concentraties in plasma 
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en/of urine bij de helft van de RTT meisjes zien. Deze creatine afwijkingen waren 
echter niet eenduidig te verklaren. Verder onderzoek is gaande naar de functionali-
teit van de creatine transporter en is beschreven in appendix 1. De eerste resulta-
ten bevestigden de verhoogde creatine concentraties in plasma en/of urine. Fibro-
blastenonderzoek toonde geen primair defect in de creatine transporter aan, echter 
mogelijk is er sprake van een afwijking in de regulatie van het creatine transport. 
Gezien de verschillen bij de RTT populatie in creatine concentraties tussen het CO2 
5% medium en het CO2-onafhankelijke medium, lijkt het creatinemetabolisme of 
transport bij RTT beïnvloed te worden door CO2. De significant verlaagde concentra-
ties van creatine, creatinefosfaat en ATP gemeten in myocyten van een RTT meisje 
kunnen mogelijk verklaard worden door een toegenomen energiebehoefte danwel 
de reeds genoemde afwijkingen in de creatine transportregulatie. Een andere mo-
gelijk verklarende factor is celmembraanveranderingen. Verder onderzoek ter ver-
heldering van het creatinemetabolisme en transport, en het mogelijke verband met 
ondervoeding bij RTT is gewenst. 
 
Het derde gedeelte van dit proefschrift richt zich op het verouderingsproces bij RTT. 
De levensverwachting van RTT vrouwen is de afgelopen decennia dermate gestegen 
dat clinici toenemend geconfronteerd worden met de zorg voor volwassenen met 
RTT. Over het verouderingsproces bij RTT is weinig bekend. In hoofdstuk 5 wordt 
een cross-sectioneel verouderingsonderzoek beschreven. Het in de literatuur be-
schreven ontwikkelingsprofiel bij RTT werd bevestigd, gezien de toenemende inci-
dentie van kyfose en de verbeterende communicatieve en autonome functies. Ter 
uitsluiting van een mogelijke overlevingsbias (waarbij de gezondste personen ofwel 
minst aangedane personen overleven), is in hoofdstuk 6 een longitudinale studie 
verricht. Het algemene ontwikkelingsprofiel van de RTT vrouwen in deze studie 
werd gekarakteriseerd door een langzame verslechtering van grove motoriek, in 
tegenstelling tot betere cognitieve functies, minder autonome problemen en epi-
lepsie en een goede algemene gezondheid. Aanbevelingen met betrekking tot kli-
nisch management werden gegeven, zoals het continueren van motorische en 
communicatieve therapieën, het bedacht zijn op de aanwezigheid van een longont-
steking, frequente evaluatie van anti-epileptica en reguliere screeningsadviezen. 
 
In hoofdstuk 7 worden de belangrijkste bevindingen samengevat en in een bredere 
context geplaatst. Daarbij is speciale aandacht voor methodologische overwegin-
gen, klinische uitdagingen en aanbevelingen voor toekomstig onderzoek bij RTT. In 
appendix 2 wordt een nadere toelichting gegeven op het autonome onderzoek 
zoals uitgevoerd in het RTT Expertise Centrum van het Maastricht Universitair Me-
disch Centrum. 
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“Het aantal life-events heeft het aantal publicaties tijdens dit promotieonderzoek 
overstegen”. Een citaat van mijn promotor prof. dr. L.M.G. Curfs, wat een goed 
beeld geeft van de afgelopen 4,5 jaar. Het is dan ook niet verwonderlijk dat ik op 
deze plek velen van jullie wil bedanken. 
 
Omdat ik niet weet waar ik moet beginnen ga ik dit zoveel mogelijk op chronolo-
gische volgorde afwerken, in de hoop dat ik niemand vergeet. Mijn eerste ervaring 
met het Rett syndroom is geweest tijdens een lezing van dr. E.E.J. Smeets in 2003. Ik 
ontmoette hier Margo van Otterdijk, een prachtig jong blond Rett meisje die met 
haar blauwe sprekende ogen een onuitwisbare indruk heeft achtergelaten. Ik wil 
haar en haar familie dan ook in het bijzonder bedanken voor de aanwezigheid bij 
deze lezing. De verhalen en gevoelens welke jullie die dag, maar later ook in jullie 
uitgegeven boek met mij gedeeld hebben, heeft mijn interesse in het Rett syndroom 
gewekt. Ik hoop dan ook dat ouders deze lezing blijven vergezellen om ook toekom-
stige artsen in het Rett syndroom op te leiden en hopelijk ook te interesseren. Het 
gedichtje aan het begin van dit promotieboekje, is door de ouders van Margo des-
tijds uitgedeeld en mijn blijvende herinnering aan deze bijzondere ontmoeting. 
Daarnaast gaat mijn grote dank natuurlijk ook uit naar dr. E.E.J. Smeets, mijn co-
promotor. Beste Eric, vanaf het begin heb ik een enorme bewondering gehad voor 
jouw enthousiasme voor het Rett syndroom. Ouders noemen jou dan ook niet voor 
niks een pRETTige dokter. Ondanks jouw drukke leven, is jouw motivatie voor het 
syndroom blijven bestaan en de droom voor een Rett expertise centrum werkelijk-
heid geworden. Jouw enthousiasme is aanstekelijk en is een grote steun geweest 
gedurende mijn promotietraject.  
 
In 2007 heb ik onder leiding van prof. dr. L.M.G. Curfs, prof. dr. C.T.R.M. Schrander-
Stumpel en uiteraard dr. E.E.J. Smeets mijn GEZP-stage bij de klinische genetica 
gelopen. Beste Paul, mijn promotor, ik wil je bij deze bedanken voor je vertrouwen 
in mij, niet alleen tijdens deze WESP-stage, maar ook in 2008 toen je me als promo-
vendus Rett Syndroom aanstelde. Jouw flexibele houding ten opzichte van thuis-
werken hebben een positieve invloed gehad op de afronding van dit promotietra-
ject, maar ook zeker op het in balans houden van werk en privé. Mijn oprechte dank 
hiervoor. Beste Connie, jouw werk binnen de MR is bewonderenswaardig. Het is 
dan ook terecht dat je in de top 3 van experts wordt ingedeeld door je collega’s. Ik 
heb het dan ook een eer gevonden om met je samen te werken en ben trots dat je 
deel uitmaakt van de corona tijdens mijn verdediging.  
 
Na afronding van mijn studie begon ik als ANIOS kindergeneeskunde in het voorma-
lig Maaslandziekenhuis te Sittard. Een onvergetelijke periode met een geweldige 
team aan kinderartsen, verpleegkundigen, polidames en mede arts-assistenten. Ik 
wil jullie allemaal bedanken voor de fijne begeleiding en samenwerking welke iede-
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re pas beginnende arts-assistent zich zou wensen. In het bijzonder wil ik drs. J. Hey-
nens en drs. K. Oberndorff bedanken. Beste Jan, als mijn begeleider bleef je betrok-
ken en ben je ook de kinderarts van Anouk geweest. Ik kon altijd bij je terecht en 
heb 100% vertrouwen in jouw goede zorgen voor mij en mijn jongste dochter 
Anouk. Nu hopen dat we ons alleen nog maar buiten het ziekenhuis tegenkomen. 
Beste Karin, onze gezamenlijke interesse voor de genetica schepte een band en als 
we elkaar op de woensdagbesprekingen weer zagen, was het altijd gezellig om bij te 
kletsen. Ik hoop dat we contact zullen houden in de toekomst en jullie nog eens 
gezellig op “kraambezoek” komen. Maar ook mijn ex-collega’s, in het bijzonder 
Jelleke, Jeanine, Agnes en Tanja wil ik bedanken. Na onze Sittard-tijd hebben we 
nog altijd contact gehouden en gaan we dan ook elke 2-3 maanden gezellig bij el-
kaar eten of bijvoorbeeld naar de 90’s-party. Het is altijd gezellig en ik ben trots op 
onze vriendschap. 
 
1 september 2008 begon ik aan mijn promotietraject, waarbij ik een kamer in de 
“kelder” deelde met dr. M. Sinnema. Een betere collega ofwel partner in crime zoals 
je ons in jouw proefschrift noemde kon ik me niet wensen. Lieve Margje, eigenlijk al 
vanaf mijn WESP-stage tot mijn laatste dag bij de genetica heb je voor mij klaar 
gestaan. Je was mijn grote voorbeeld, jouw hulp bij METC-protocollen, artikelen 
indienen, promotieboekje schrijven is zo belangrijk geweest. We hebben veel mee-
gemaakt in de kelder, maar gelukkig is het nu tijd voor de positieve life-events: de 
geboorte van jullie dochter en jullie huwelijk staat voor de deur. Het is je zo gegund! 
Ik vond het bijzonder om je paranimf te zijn en nu draaien we de rollen om, wat ben 
ik trots dat jij achter mij zal staan op deze bijzondere dag. Maar naast Margje, zorg-
de ook Wilma, Wies, Judith en later ook Ingeborg voor de fijne sfeer in de kelder. De 
praatjes bij de waterkoker en lunches op het terras van het NH-hotel waren een 
heerlijke afwisseling van het onderzoekswerk, dankjewel hiervoor. Als laatste was ik 
ook maar één deur verwijderd van prof. dr. J. Geraedts. Beste Joep, dank voor de 
deur die altijd heeft opengestaan en de steun die ik heb mogen ervaren. Jouw werk 
voor de genetica is onbeschrijfelijk en zal door niemand vergeten worden. Maar nu 
kun je lekker van je welverdiende pensioen en kleinkinderen genieten. 
 
Nadat Margje in opleiding ging tot klinisch geneticus en 2 verdiepingen naar boven 
“promoveerde”, kreeg ik 2 nieuwe collega’s: Elke Mersy en Inge Smeets. Dames, 
ook jullie waren geweldige collega’s. We hebben veel zorgen, maar ook mooie mo-
menten gedeeld. Ik kijk nu al uit naar jullie promotieboekjes, dat zullen prachtwer-
ken worden. Elke, wij waren aanwezig bij jouw bruiloft en zullen dadelijk ook je 
dochter komen bewonderen. Ik heb een enorme waardering voor jouw doorzet-
tingsvermogen, gedrevenheid en werklust. Lieve Inge, ik ben erg blij dat we elkaar 
hebben kunnen steunen bij de moeilijkere perioden in ons leven. Weet dat ik ook in 
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de toekomst altijd bereikbaar zal blijven, de vriendschap die we hebben opgebouwd 
is mij erg waardevol. 
 
Maar naast mijn directe collega’s, wil ik ook alle andere collega’s van de polikliniek 
klinische genetica bedanken. De stafleden, de A(N)IOS, genetisch consulenten, poli-
dames en secretariaat. Enkele hiervan zou ik graag in het bijzonder willen bedanken. 
Allereerst Suzanne, Kim, Felicia, Cynthia en Els, ik heb me altijd als een collega bij 
jullie gevoeld, dank hiervoor. Maar ook de genetisch consulenten, met in het bij-
zonder Sera en Joyce. Dames, dank voor jullie betrokkenheid, zowel op persoonlijk 
vlak als met betrekking tot mijn onderzoek. Jullie hebben allebei prachtige dochters, 
waar jullie terecht apetrots op zijn. Ik hoop dat we contact kunnen blijven houden. 
Maar ook Maud Seuren, wat heb ik een bewondering voor jouw keuze om voor de 
liefde te kiezen en naar Spanje te vertrekken. Je was een geweldige collega en ik mis 
onze woensdaglunches nog steeds. Ik wens jou, Rubén en jullie toekomstige twee-
ling alle goeds toe. Verder wil ik ook de polidames bedanken, in het bijzonder Sabri-
na en Tiny die de onderzoekspoli’s en Rett expertise poli’s mogelijk hebben gemaakt 
en altijd probeerde onderzoekskamer 3 voor ons vrij te houden. 
 
Maar naast de collega’s van de polikliniek, wil ik ook graag nog collega’s van de 
andere units bedanken. Allereerst het lab EMZ, aangezien een groot deel van mijn 
promotieboekje zonder hun niet mogelijk zou zijn geweest. De stafleden dr. J. Bier-
au, dr. J. Bakker en dr. I Körver-Keularts, hartelijk dank voor jullie medewerking aan 
de onderzoeken, de expertise die jullie met mij hebben willen delen en het uiteinde-
lijke resultaat waarbij hopelijk een puzzelstukje binnen Rett syndroom op zijn plaats 
gaat vallen. Beste Irene, jou wil ik nog in het bijzonder bedanken voor onze weke-
lijkse woensdaglunches die ook na vertrek van Maud naar Spanje zijn doorgegaan. 
Onze band ontstond al gelijk toen ik je vroeg of jouw vader mijn scheikundeleraar 
van de middelbare school zou kunnen zijn. Inmiddels kunnen we alles met elkaar 
bespreken en hebben we een bijzondere vriendschap opgebouwd. Maar naast mijn 
dank aan de stafleden, gaat er natuurlijk een grote dank uit naar de analisten op het 
lab met in het bijzonder Dennis, die alle bepalingen voor mijn onderzoek hebben 
uitgevoerd. Ook al kwam ik nog in de namiddag met bloed of urinesamples aanzet-
ten, jullie gingen altijd enthousiast aan de slag. Dank voor het vele werk wat jullie 
hebben uitgevoerd. En Janine, bedankt voor onze gezellige treinritten samen met 
Tamara. De 45 minuten durende reis van Landgraaf naar Maastricht Randwyck vlo-
gen om als we bijpraatten over zwangerschappen, baby’s, verhuizingen etc. Ik wens 
je een prachtige en vooral gezond tweede kindje toe in jullie mooie nieuwe huis. 
Maar ook dr. Salomons, collega EMZ in Amsterdam wil ik bedanken voor de bijdrage 
aan het tweede deel van het metabole onderzoek. Zelfs ’s avonds om 22:00 was je 
nog beschikbaar voor een telefonische brainstormsessie. Daarnaast wil ik ook de 
groep van prof. dr. van Loon, Department of Movement Sciences bedanken voor 
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hun bijdrage aan dit vervolgonderzoek. Tenslotte heeft ook Clinical Genomics bijge-
dragen aan mijn promotieonderzoek en dan in het bijzonder drs. K. van Roozendaal. 
Beste Kees, dank voor je altijd inspirerende besprekingen en de tijd die je altijd voor 
me nam als ik weer eens aan je deur kwam kloppen. 
 
Maar naast de afdeling Klinische Genetica, heb ik ook samengewerkt met vele ande-
re afdelingen. Als eerste wil ik hier dr. Maaskant bedanken. Beste Marian, eerst de 
onderzoeksvraag bepalen voordat je aan de slag gaat met de statistische analyses, is 
de belangrijkste les die je iedere student bijbrengt. Het lijkt zo’n vanzelfsprekend-
heid, maar in de praktijk verlies je vaak door alle data toch uit het oog welke vraag 
je nu eigenlijk wilde beantwoorden. Jouw feedback op de artikelen was altijd van 
grote waarde, voor vragen was je altijd beschikbaar en was niks je teveel. Daarnaast 
bewonder ik ook je olifantengeheugen, je kent niet alleen mijn verjaardag, maar ook 
die van drs. drs. Beckers en mijn dochters uit je hoofd. Je altijd attente kaartjes zal ik 
niet snel vergeten. 
 De andere collega’s welke ik wil bedanken, zijn werkzaam binnen het Rett ex-
pertise centrum. Allereerst de PICU (pediatric intensive care unit van het MUMC+). 
Wat een geweldig team aan mensen, die altijd mee willen denken en zoveel Rett 
gezinnen zich thuis hebben laten voelen. In het bijzonder wil ik dr. van Waarden-
burg, Hay Baggen, Judith Brands en Hilde Wielders bedanken. Beste Dick, jouw be-
trokkenheid bij het Rett expertise centrum is van grote waarde. Maar ook persoon-
lijk ben je betrokken geweest en zal ik je attente bezoekje tijdens mijn eigen zieken-
huisopname niet vergeten. Ik heb onze samenwerking altijd als zeer prettig ervaren. 
Beste Hay, wat ben je een ongelofelijk enthousiaste en bekwame nurse practitioner. 
Vanaf het begin van de Rett opnames heb je met ons meegedacht, een grote bijdra-
ge geleverd aan het ontwikkelen van het rebreathingsmasker en zo ontzettend veel 
gezinnen hiermee begeleid. Zelfs als je vrij had, was je nog per telefoon of mail 
beschikbaar. Beste Judith en Hilde, casemanagers van het CASK, ik ben er zeker van 
dat de praktische zaken van het Rett expertisecentrum in goede handen zijn bij 
jullie. Dank voor jullie inzet en betrokkenheid.  
Maar ook de afdeling KNF (klinische neurofysiologie) wil ik ontzettend bedan-
ken voor hun samenwerking. De polidames voor de hulp bij het opstarten van de 
Rett PC, zodat ik de analyses vanuit mijn eigen werkplek kon uitvoeren. Maar ook 
zeker dr. van Kranen-Mastenbroek, dr. Reulen, Kevin van Schaijk en de laboranten. 
Beste Vivianne, als ik de EEG-registraties zag was ik altijd blij dat jij die taak op je 
nam. Ik weet hoe ongelofelijk moeilijk deze registraties te beoordelen zijn. Ik wil je 
dan ook bedanken voor de goede samenwerking (middels notes in de registratie) in 
de analyse van de autonome registratie, waarbij we vervolgens met het hele team 
de belangrijke antwoorden op de vragen van Rett ouders konden geven. Beste Jos, 
dankzij jou is de “Rolls Roys” versie van de Neuroscope werkelijkheid geworden. 
Jouw inzet is van grote waarde geweest om de metingen binnen het Rett expertise 
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centrum mogelijk te maken. Beste Kevin, jij stond altijd paraat om mijn ICT-
problemen bij de analyses op te lossen en hebt gezorgd voor mijn webex zodat ik de 
analyses zowel vanuit mijn werkplek als thuis kon verrichten. En last but not least de 
laboranten, dank voor jullie betrokkenheid voor de Rett meisjes en vrouwen en het 
engelengeduld dat jullie kunnen opbrengen tijdens het aansluiten van de “Rolls 
Roys” Neuroscope. 
Tenslotte drs. H. Trines. Beste Hanneke, als personal assistant van prof. dr. 
L.M.G. Curfs, verzet ook jij enorm veel werk voor het Rett expertisecentrum. Maar 
ook voor mijn promotieonderzoek heb je altijd klaar gestaan, en zonder jou waren 
alle formele taken rondom de promotie niet gelukt. 
 
Bij de verschillende onderzoeken heb ik ook hulp mogen ontvangen van verschillen-
de studenten. Noortje, Petra en Catherine, dank voor jullie inzet voor de verschil-
lende onderzoekslijnen. Ik heb het ontzettend leuk gevonden jullie te begeleiden en 
vooral ook samen te werken. Ik hoop dat jullie allemaal een mooie carrière tege-
moet gaan. Daarnaast wil ik ook hier Emma bedanken. Emma, jij was tijdens mijn 
promotieonderzoek betrokken bij het ondervoedingsproject. Ik heb bewondering 
voor jouw onderzoeksinzicht en organisatorisch vermogen, want begeleiding was bij 
jou haast niet nodig. Ook in de grote stad Amsterdam zijn ze al onder de indruk van 
je werk. Ook voor jou een prachtige carrière en hopelijk blijven we contact houden. 
 
Naast alle Nederlandse collega’s, zou ik ook graag een aantal buitenlandse collega’s 
bedanken en wel mijn ESRRA (European Scientific Rett Research Association) colle-
ga’s. Dear Peter, Ingegerd, Bengt, Stig, Flora, Stephania, Giorgio and Shane. From 
the very first moment it felt I belonged to a big family. So many experts with one 
shared passion: Rett syndrome. It was an honour to work with all of you. Your work 
for RTT is amazing, just keep on doing this wonderful work. But also dr. A. Kerr, the 
Rett expert of the United Kingdom. Dear Alison, thank you very much for your use-
ful comments and for checking my English writing. 
 
Maar naast al mijn collega’s, zijn er 13 meiden en hun families die ik enorm dank-
baar ben: Annika, Celeste, Evi, Fenna, Fenne, Floortje, Jade, Kelly, Lieke, Margo, 
Nathalie, Terre en Willemijn. Jullie enthousiaste deelname aan mijn onderzoek heb-
ben een grote indruk op mij gemaakt. Jullie zijn zo’n bijzondere meiden, waar jullie 
familie terecht heel trots op is. Ik zal jullie nooit vergeten. Beste Annika, jij hebt zelf 
nog een extra bijdrage geleverd en wel de prachtige omslag van dit proefschrift. Een 
Rett meisje dat schildert, hoe bijzonder!  
 
Maar op deze plek zou ik ook graag de Nederlandse en Belgische Rett vereniging 
bedanken voor hun enthousiaste bijdrage aan het onderzoek. En in het bijzonder 
Stichting Terre, zonder jullie was dit promotie onderzoek en het Rett expertisecen-
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trum niet mogelijk geweest. Bedankt voor het vertrouwen dat jullie in mij hebben 
gehad. Ik ben er vast van overtuigd dat jullie net zo trots op dit boekje zijn als ik. 
Hopelijk zullen er nog vele promotieboekjes Rett syndroom volgen. Jullie inzet voor 
de “Rett wereld” is bewonderenswaardig. 
 
En nu is het tijd om alle mensen buiten het werk te bedanken. 
Lieve vrienden, jullie hebben altijd gezorgd voor de gezonde afwisseling tussen 
werk en privé. In de moeilijke tijden hebben jullie voor ons klaar gestaan, maar wat 
hebben we ook veel gelachen. Naast de mensen die ik in voorafgaande tekst reeds 
heb genoemd, wil ik nu ook Rik en Katrin, Maud en Mark, Ellen en Raymond, Debby 
en Kevin, Ben en Daniëlla, Bianca en Jeroen, Rianne, Roger en Jessica bedanken! 
Door de specifieke betrokkenheid in mijn promotietraject, wil ik Rik en Ellen in het 
bijzonder bedanken. Bij jullie was mijn promotietraject altijd een vast onderwerp 
van gesprek. Door jullie eigen onderzoek/promotie ervaringen, konden jullie je goed 
inleven in mijn situatie en was jullie advies van zeer grote waarde. Dankjewel, jullie 
waren mijn perfecte uitlaatklep. Ik hoop dat onze vriendschap nog lang moge be-
staan. 
Lieve familie, jullie zijn altijd betrokken geweest, al vragen jullie je soms af of ik 
pas klaar ben met studeren als ik met pensioen ga. Als ik op congres ging en een 
presentatie gaf in Parijs, New Orleans of een andere wereldstad, viel jullie mond 
open van bewondering. Tijdens je promotiettraject lijkt dat op een gegeven mo-
ment de normaalste zaak van de wereld, maar door jullie reactie wist ik dat ik in-
derdaad met iets bijzonders bezig was. Maar weet ook dat dit onderdeel is van mijn 
vak en ik jullie werk net zoveel waardeer. Het gaat er niet om wat we in het leven 
doen, maar wie we zijn. Lieve papa en mama, jullie altijd aanwezige steun en hulp is 
onbeschrijfelijk. Het gevoel altijd bij jullie terecht te kunnen is zo belangrijk voor mij 
in het leven. Ik ben er trots dat jullie mijn ouders zijn en hoop ooit voor Esmée en 
Anouk net zo’n goede ouder te worden. Jenna en Roy, zusje en schoonbroer, on-
danks dat we ongeveer dag en nacht van elkaar verschillen staan we altijd voor 
elkaar klaar. Ik ben blij dat we zo’n goede en sterke band hebben en wat is het mooi 
onze kinderen samen te zien opgroeien. Jenna, ik ben dan ook super trots dat jij op 
deze bijzondere dag mijn paranimf wil zijn. Lieve oma, helaas ben je niet meer bij 
ons, maar wat zou je trots zijn geweest. Ik kan me nog goed herinneren dat je me 
vol lof vertelde dat je mijn naam op de radio had gehoord. Je schreef “Rett syn-
droom” op een briefje, zodat je iedereen kon vertellen wat ik deed. Maar ook tij-
dens onze bezoekjes bij de oncoloog, liet je weten dat je kleindochter arts was en 
goed op je lette. Oma, ik zal je nooit vergeten en weet dat je ook tijdens de verdedi-
ging dicht bij me zal zijn. 
 
En als laatste de meest bijzondere mensen in mijn leven, die waarschijnlijk net als 
mij enorm blij zijn dat deze mijlpaal gehaald is. Frank, wat ben ik trots dat jij mijn 
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man bent en de papa van onze meisjes. Samen kunnen wij de wereld aan, je maakt 
me echt gelukkig. Esmée en Anouk, mijn prachtige dochters, mijn grote trots, zodra 
jullie “mama” roepen als ik van het werk thuis kom, valt alles van mij af en GENIET ik 
alleen nog maar. Samen met papa zijn jullie de liefde van mijn leven, ik hou zo ont-
zettend veel van jullie drie! 
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Nicky S.J. Beckers-Halbach werd op 14 september 1983 geboren te Heerlen. Haar 
VWO examen behaalde zij in 2001 aan het Eijckhagencollege te Landgraaf. Zij stu-
deerde Geneeskunde aan de Universiteit Maastricht, waar in 2005 het doctoraal-
examen cum-laude werd afgelegd. Tijdens deze studie heeft zij deelgenomen aan 
het keuzeonderwijs “aangeboren en erfelijke afwijkingen bij kinderen” en was haar 
wetenschapsstage gericht op veroudering bij Rett syndroom, hetgeen tot haar eer-
ste publicatie leidde. In juni 2007 behaalde zij haar artsexamen. 
Van juni 2007 tot september 2008 was zij werkzaam als ANIOS Kindergenees-
kunde in het voormalig Maaslandziekenhuis te Sittard. Aansluitend werkte zij tot en 
met januari 2013 aan haar promotieonderzoek, onder leiding van prof. dr. L.M.G. 
Curfs en dr. E.E.J. Smeets. Zij presenteerde haar onderzoeksresultaten op nationale 
en internationale congressen, waaronder het NVK, IASSID, Europese en Wereld Rett 
congressen. Inmiddels is zij (mede-)auteur van verscheidene medische publicaties 
over het Rett Syndroom en lid van de internationale research groep ESRRA (Europe-
an Scientific Rett Research Association).  
Op 11 oktober 2012 is zij getrouwd met Frank Beckers. Zij hebben twee doch-
ters, Esmée (3) en Anouk (2). 
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